

CITATION REPORT

List of articles citing

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

DOI: 10.1126/science.3798106
Science, 1987, 235, 177-82.

Source: <https://exaly.com/paper-pdf/19131315/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|------|---|------|-----------|
| 2243 | Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotyping. 2005 , 19-30 | | |
| 2242 | The taxonomic status of <i>Serratia Plymuthica</i> (Lehmann and Neumann) Bergey et al. and of <i>Serratia indica</i> (Eisenberg) Bergey et al.. 1960 , 10, 247-254 | | 2 |
| 2241 | REVIEWS OF BOOKS. 1983 , 64, 98-99 | | |
| 2240 | Proto-oncogenes and human cancers. 1987 , 317, 955-7 | | 101 |
| 2239 | Transformation by oncogenes encoding protein kinases induces the metastatic phenotype. <i>Science</i> , 1987 , 238, 202-5 | 33.3 | 123 |
| 2238 | Oncology. 1987 , 258, 2261 | | |
| 2237 | A novel putative tyrosine kinase receptor encoded by the eph gene. <i>Science</i> , 1987 , 238, 1717-20 | 33.3 | 368 |
| 2236 | Cellular oncogenes in neoplasia. 1987 , 40, 1055-63 | | 20 |
| 2235 | Abstracts of papers presented at the 11th Annual Meeting of the United Kingdom Environmental Mutagen Society held at Bath University, 7 th April, 1987. 1987 , 2, 297-312 | | |
| 2234 | Evaluation of epidermal growth factor receptors in bladder tumours. 1987 , 56, 533-7 | | 150 |
| 2233 | Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. <i>Science</i> , 1987 , 238, 185-8 | 33.3 | 284 |
| 2232 | Influence of blood group type on the natural history of superficial bladder cancer. 1987 , 138, 758-9 | | 14 |
| 2231 | Stage- and tissue-specific expression of the neu oncogene in rat development. 1987 , 84, 8498-501 | | 138 |
| 2230 | Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.. 1987 , 6, 605-610 | | 427 |
| 2229 | Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea. 1987 , 84, 6317-21 | | 93 |
| 2228 | Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. 1987 , 84, 7159-63 | | 538 |
| 2227 | Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. 1987 , 7, 2019-23 | | 306 |

| | | |
|------|---|---------|
| 2226 | Identification and biochemical characterization of p70TRK, product of the human TRK oncogene. 1987 , 84, 6707-11 | 49 |
| 2225 | Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. 1987 , 84, 9243-7 | 234 |
| 2224 | Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. 1987 , 1, 1398-402 | 496 |
| 2223 | Oncogenes: their role in neoplasia. 1987 , 30, 1-10 | 4 |
| 2222 | Receptor- and signal transductionrelated proto-oncogenes in breast cancer. 1987 , 8, 372-375 | 3 |
| 2221 | A variant t(X;15)(p11;q22) translocation in acute promyelocytic leukemia. 1987 , 29, 65-74 | 6 |
| 2220 | Do oncogenes determine clinical features in chronic myeloid leukaemia?. 1987 , 1, 1402-5 | 45 |
| 2219 | The estrogen-regulated 52K-cathepsin-D in breast cancer: from biology to clinical applications. 1987 , 14, 377-84 | 10 |
| 2218 | Gene Amplification in Malignancy. 1987 , 329, 839-840 | |
| 2217 | Immunohistochemical localization of c-erbB-2 in human breast carcinomas. 1987 , 1, 383-91 | 37 |
| 2216 | erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. <i>Science</i> , 1987 , 237, 178-82 | 333 890 |
| 2215 | Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation. 1987 , 7, 2597-601 | 77 |
| 2214 | Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. 1987 , 51, 1063-70 | 602 |
| 2213 | Adjuvant Tamoxifen in Early Breast Cancer. 1987 , 330, 191-192 | |
| 2212 | Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. 1987 , 2, 69-72 | 330 |
| 2211 | The role of oncogenes in chemical carcinogenesis. 1987 , 75, 81-6 | 36 |
| 2210 | Cellular and molecular mechanisms of multistep carcinogenesis: relevance to carcinogen risk assessment. 1987 , 76, 65-70 | 57 |
| 2209 | Proto-oncogene structure and breast cancer prognosis. 1987 , 5, 993-5 | 3 |

| | | |
|------|--|-----|
| 2208 | Prognostic factors for recurrence and survival in human breast cancer. 1987 , 10, 5-9 | 132 |
| 2207 | Loss of heterozygosity and the origin of meningioma. 1987 , 77, 349-51 | 58 |
| 2206 | Amplification of the epidermal growth factor receptor gene in the BT20 breast carcinoma cell line. 1987 , 40, 189-91 | 27 |
| 2205 | Expression of the c-erbB-2 protein in normal and transformed cells. 1987 , 40, 246-54 | 201 |
| 2204 | Targeted expression of the ras and myc oncogenes in transgenic mice. 1987 , 3, 306-308 | 20 |
| 2203 | Subversion of growth regulatory pathways in malignant transformation. 1987 , 907, 219-44 | 28 |
| 2202 | Gene transfer into the nervous system. 1987 , 1, 339-71 | 22 |
| 2201 | Receptor systems in tissues of the nervous system. 1987 , 100, 153-84 | 5 |
| 2200 | In vitro and in vivo regulation of liver epithelial cells carrying a metallothionein-rasT24 fusion gene. 1988 , 1, 89-95 | 15 |
| 2199 | Amplification of the EGF receptor and c-myc genes in human esophageal cancers. 1988 , 42, 502-5 | 128 |
| 2198 | Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors. 1988 , 42, 774-9 | 18 |
| 2197 | Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status. 1988 , 12, 23-30 | 23 |
| 2196 | EGF binding is quantitatively related to growth in node-positive breast cancer. 1988 , 12, 45-9 | 16 |
| 2195 | Gene products which play a role in cancer invasion and metastasis. 1988 , 11, 113-24 | 52 |
| 2194 | Differential organ tissue adhesion, invasion, and growth properties of metastatic rat mammary adenocarcinoma cells. 1988 , 12, 167-76 | 40 |
| 2193 | Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. 1988 , 12, 191-204 | 119 |
| 2192 | Resistance of tumor cells to tumor necrosis factor. 1988 , 8, 333-41 | 42 |
| 2191 | Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. 1988 , 7, 143-88 | 441 |

| | | |
|------|--|-----|
| 2190 | Adjuvant chemotherapy for breast cancer. 1988 , 4, 250-5 | 3 |
| 2189 | Relationships between oestrogen receptor, epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer. 1988 , 155, 143-50 | 35 |
| 2188 | Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. 1988 , 13, 263-72 | 30 |
| 2187 | Dysregulation of growth factor-receptor system in cellular transformation. 1988 , 79, 885-901 | 7 |
| 2186 | No correlation between L-myc restriction fragment length polymorphism and malignancy of human colorectal cancers. 1988 , 79, 674-6 | 24 |
| 2185 | Structure and expression of oncogenes in surgical specimens of human breast carcinomas. 1988 , 57, 464-8 | 23 |
| 2184 | Recessive mechanisms of malignancy. 1988 , 58, 115-21 | 40 |
| 2183 | An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. 1988 , 58, 448-52 | 194 |
| 2182 | c-erbB-2 expression in benign and malignant breast disease. 1988 , 58, 453-7 | 175 |
| 2181 | In situ hybridisation and S1 mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer. 1988 , 58, 715-22 | 11 |
| 2180 | Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. 1988 , 57, 358-63 | 104 |
| 2179 | The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy. 1988 , 14, 3-10 | 169 |
| 2178 | Does adjuvant radiotherapy have a role in the postmastectomy management of patients with operable breast cancer--revisited. 1988 , 15, 519-35 | 14 |
| 2177 | news about c-erb-B-2 and HER2. 1988 , 4, 247-8 | 5 |
| 2176 | Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. 1988 , 948, 175-224 | 149 |
| 2175 | The fms oncogene. 1988 , 948, 225-43 | 12 |
| 2174 | The ras gene family and human carcinogenesis. 1988 , 195, 255-71 | 603 |
| 2173 | Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. 1988 , 42, 842-5 | 108 |

| | | | |
|------|---|------|------|
| 2172 | Sequence-specific ¹ H NMR assignments and identification of slowly exchanging amide protons in murine epidermal growth factor. 1988 , 27, 2235-43 | | 30 |
| 2171 | Flow cytometry in the clinical laboratory. 1988 , 171, 125-73 | | 18 |
| 2170 | Activation of c-Ki-ras coexists with c-myc amplification in cells from a nude mouse tumor induced by the human breast carcinoma cell line SW 613-S. 1988 , 233, 268-72 | | 3 |
| 2169 | Mechanisms by which genes encoding growth factors and growth factor receptors contribute to malignant transformation. 1988 , 551, 320-35; discussion 336 | | 15 |
| 2168 | Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. 1988 , 27, 1-19 | | 138 |
| 2167 | Mutation as a cause of genetic disease. 1988 , 319, 325-40 | | 5 |
| 2166 | Growth factor receptor tyrosine kinases. 1988 , 57, 443-78 | | 1688 |
| 2165 | Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. 1988 , 54, 105-15 | | 996 |
| 2164 | The clinical biology of hormone-responsive breast cancer. 1988 , 15, 33-51 | | 14 |
| 2163 | Genetic variability of proto-oncogenes for breast cancer risk and prognosis. 1988 , 70, 951-9 | | 16 |
| 2162 | Cell and environment interactions in tumor microregions: the multicell spheroid model. <i>Science</i> , 1988 , 240, 177-84 | 33-3 | 1493 |
| 2161 | Cellular and molecular aspects of neoplastic progression in the mammary gland. 1988 , 24, 15-20 | | 25 |
| 2160 | Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. 1988 , 24, 1529-30 | | 2 |
| 2159 | [Specific expression of human pS2 gene in breast cancer]. 1988 , 70, 961-8 | | 8 |
| 2158 | Nuclear oncogene amplification or rearrangement is not involved in human colorectal malignancies. 1988 , 24, 1321-8 | | 14 |
| 2157 | Molecular basis of the substitutive expression of MYC genes in small cell lung cancer. 1988 , 4, 128-130 | | 1 |
| 2156 | Physiological implications of estrogen receptor modulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. 1988 , 42, 5-14 | | 62 |
| 2155 | Hormone receptors and cancer. 1988 , 24, 509-11 | | 1 |

| | | |
|------|--|----------|
| 2154 | The role of growth factors and growth factor receptors in neoplastic cell transformation. 1988 , 4, 135-154 | 3 |
| 2153 | Functional aspects of cellular and transforming oncogenes and their relationship to heart disease. 1988 , 18, 293-303 | |
| 2152 | Structure, function, regulation and clinical significance of the 52K pro-cathepsin D secreted by breast cancer cells. 1988 , 70, 943-9 | 53 |
| 2151 | Amplification of c-erbB-2 and aggressive human breast tumors?. <i>Science</i> , 1988 , 240, 1795-8 | 33.3 219 |
| 2150 | The clinical biology of breast cancer. 1988 , 39, 453-64 | 7 |
| 2149 | Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. 1988 , 2, 1486-95 | 77 |
| 2148 | Breast Cancer: Cellular and Molecular Biology. 1988 , | 4 |
| 2147 | Amplification of the epidermal growth factor receptor gene in biopsy specimens from human intracranial tumours. 1988 , 2, 217-25 | 30 |
| 2146 | DNA probes in diagnostic pathology. 1988 , 90, 340-4 | 17 |
| 2145 | The importance of the induction of gene expression and differentiation by cytotoxic chemotherapy. 1988 , 6, 747-53 | 6 |
| 2144 | Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. 1988 , 26, 97-152 | 48 |
| 2143 | Oncogenes and breast cancer. 1988 , 319, 1281-2 | 7 |
| 2142 | In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors?. <i>Science</i> , 1988 , 240, 1796-8 | 33.3 35 |
| 2141 | Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. 1988 , 319, 1239-45 | 748 |
| 2140 | The preneoplastic state in mouse mammary tumorigenesis. 1988 , 9, 1113-9 | 41 |
| 2139 | Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules. 1988 , 85, 4804-8 | 110 |
| 2138 | c-kit protein, a transmembrane kinase: identification in tissues and characterization. 1988 , 8, 4896-903 | 133 |
| 2137 | Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. 1988 , 8, 5570-4 | 173 |

| | | |
|------|---|-----|
| 2136 | neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation. 1988 , 85, 8057-61 | 15 |
| 2135 | Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts. 1988 , 85, 1477-81 | 119 |
| 2134 | v-myc alters the response of a cloned mouse mammary epithelial cell line to lactogenic hormones. 1988 , 2, 133-42 | 27 |
| 2133 | Implications of growth kinetic concepts for cancer chemoprevention. 1988 , 6, 625-8 | 1 |
| 2132 | Production and characterization of monoclonal antibodies to the c-erbB-2 proto-oncogene protein using a synthetic peptide immunogen. 1988 , 16, 675-7 | 2 |
| 2131 | Oncogenes and tumor suppressor genes. 1988 , 27, 427-37 | 28 |
| 2130 | Simultaneous estimation of epidermal growth factor receptors and steroid receptors in a series of 136 resectable primary breast tumors. 1988 , 9, 200-11 | 28 |
| 2129 | Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer. 1988 , 296, 59-66 | 50 |
| 2128 | Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. 1988 , 140, 1580-6 | 46 |
| 2127 | Epidermal growth factor receptor status of histological sub-types of breast cancer. 1988 , 58, 458-60 | 63 |
| 2126 | Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. 1988 , 85, 5102-6 | 104 |
| 2125 | Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. 1988 , 85, 5389-93 | 76 |
| 2124 | Analysis of gene amplification in human tumor cell lines. 1988 , 85, 6846-50 | 35 |
| 2123 | Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph. 1988 , 8, 3770-6 | 56 |
| 2122 | Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. 1988 , 8, 3969-73 | 168 |
| 2121 | EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.. 1988 , 7, 995-1001 | 151 |
| 2120 | The relationship of clinical classification to ras p21 expression in human non-small cell lung cancer. 1988 , 45, 396-400 | 9 |
| 2119 | Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.. 1988 , 7, 2043-2052 | 234 |

| | | |
|------|---|-----|
| 2118 | Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. 1988 , 108, 14-20 | 90 |
| 2117 | Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. 1988 , 6, 1071-2 | 33 |
| 2116 | Lymphomas--current progress and future directions. 1989 , 32, 513-25 | 0 |
| 2115 | The clinical usefulness of oestrogen-receptor and other markers of hormone dependence. 1989 , 95, 145-150 | 1 |
| 2114 | Oestrogen-induced pro-cathepsin D in breast cancer: from biology to clinical applications. 1989 , 95, 107-118 | |
| 2113 | Current controversies in the role of antioestrogens in the treatment of carcinoma of the breast. 1989 , 95, 221-229 | |
| 2112 | Biology of Large Bowel Cancer. 1989 , 3, 19-34 | 13 |
| 2111 | Breast cancer and a proto-oncogene. 1989 , 299, 1061-2 | 31 |
| 2110 | HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor.. 1989 , 8, 167-173 | 102 |
| 2109 | Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth factor and insulin receptors.. 1989 , 8, 2943-2954 | 63 |
| 2108 | Genomic Alterations in Human Breast Cancer: A Review. 1989 , 75, 311-320 | 9 |
| 2107 | Long-Term Survival and Prognostic Factors for 2170 Breast Cancer Patients Treated at Two Cancer Centers: (Milan and Houston). 1989 , 75, 123-131 | 8 |
| 2106 | A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.. 1989 , 8, 159-166 | 58 |
| 2105 | An overview of tumor biology. 1989 , 7, 247-65 | 3 |
| 2104 | Drug Resistance in Cancer Therapy. 1989 , | 4 |
| 2103 | Allelic Loss in Colorectal Carcinoma. 1989 , 261, 3099 | 214 |
| 2102 | Rapid dot blot quantitation of viral DNA and amplified genes in less than 1,000 human cells. 1989 , 8, 361-7 | 7 |
| 2101 | Does Candida have a role in oral epithelial neoplasia?. 1989 , 27, 277-294 | 49 |

| | | |
|------|---|-----|
| 2100 | p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. 1989 , 9, 1165-72 | 596 |
| 2099 | Human medullary thyroid carcinoma. Initial characterization and in vitro differentiation of two new cell lines. 1989 , 115, 478-83 | 13 |
| 2098 | Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. 1989 , 28, 561-6 | 42 |
| 2097 | Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA. 1989 , 9, 4903-13 | 90 |
| 2096 | Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. 1989 , 321, 636-41 | 111 |
| 2095 | Oncogenes and neuro-oncology. 1989 , 3, 3-11 | 5 |
| 2094 | The role of oncogenes and onco-suppressor genes in carcinogenesis. 1989 , 1, 70-74 | |
| 2093 | The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer. 1989 , 246, 121-5 | 35 |
| 2092 | Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein. 1989 , 8, 749-56 | 25 |
| 2091 | c-erbB-2 oncoprotein expression in malignant and nonmalignant breast tissue. 1989 , 158, 137-40 | 10 |
| 2090 | Genetic alterations in primary breast cancer. 1989 , 13, 191-203 | 38 |
| 2089 | Heritability of breast cancer and its role in pre-menopausal cases. 1989 , 14, 39-41 | 1 |
| 2088 | Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. 1989 , 14, 329-36 | 41 |
| 2087 | Current status of tumor markers in large bowel cancer. 1989 , 13, 52-9 | 15 |
| 2086 | Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. 1989 , 416, 65-73 | 38 |
| 2085 | [Cell cycle specific expression of the HER-2/NEU oncogene in breast cancer cell lines]. 1989 , 245, 656-8 | 0 |
| 2084 | [Oncogene organization and expression in breast cancer exemplified by proto-oncogene c-erb B2]. 1989 , 245, 658-60 | |
| 2083 | Oncogenes, growth, and the cell cycle: an overview. 1989 , 22, 405-24 | 11 |

| | | |
|------|---|-----|
| 2082 | Co-operation between viral oncogenes in avian erythroid and myeloid leukaemia. 1989 , 19, 491-502 | 22 |
| 2081 | A newly established metastatic breast tumor cell line with integrated amplified copies of ERBB2 and double minute chromosomes. 1989 , 1, 48-58 | 31 |
| 2080 | Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. 1989 , 43, 201-8 | 166 |
| 2079 | The significance of oncogene amplification in primary breast cancer. 1989 , 43, 270-2 | 82 |
| 2078 | Amplification of c-ras-Ki oncogene in human ovarian tumours. 1989 , 43, 428-30 | 45 |
| 2077 | Relative tumorigenicities of hybrid cells with and without HSR-bearing chromosomes from a human melanoma cell line. 1989 , 44, 360-6 | 2 |
| 2076 | Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance. 1989 , 44, 802-5 | 32 |
| 2075 | Trisomy of chromosome 9q: specific chromosome change associated with tumorigenicity during the process of X-ray-induced neoplastic transformation in golden hamster embryo cells. 1989 , 44, 1057-61 | 8 |
| 2074 | Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay. 1989 , 39, 153-66 | 56 |
| 2073 | Overexpression of the c-erbB-2 protein in human breast tumor cell lines. 1989 , 39, 167-73 | 92 |
| 2072 | Inhibition of epidermal growth factor/transforming growth factor-alpha-stimulated cell growth by a synthetic peptide. 1989 , 141, 420-30 | 37 |
| 2071 | Breast cancer risk: a review of definitions and assessments of risk. 1989 , 41, 42-6 | 5 |
| 2070 | Patterns of proto-oncogene expression in human glioma cell lines. 1989 , 24, 97-106 | 37 |
| 2069 | Spontaneous progression of hyperplastic outgrowths of the D1 lineage to mammary tumors: expression of mouse mammary tumor virus and cellular proto-oncogenes. 1989 , 1, 229-38 | 12 |
| 2068 | Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas. 1989 , 63, 2008-13 | 15 |
| 2067 | Locally advanced breast cancer current status and future directions. 1989 , 16, 775-84 | 17 |
| 2066 | Epidermal growth factor receptor in adenocarcinoma of the kidney. 1989 , 17, 251-4 | 11 |
| 2065 | Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP. 1989 , 15, 115-22 | 42 |

| | | |
|------|---|-----|
| 2064 | Prognostic factors in breast cancer. 1989 , 5, 102-10 | 83 |
| 2063 | The role of tumor markers in the early detection of cancer. 1989 , 5, 186-93 | 2 |
| 2062 | Oncogenes and onco-suppressor genes: their involvement in cancer. 1989 , 157, 1-10 | 60 |
| 2061 | An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. 1989 , 158, 97-105 | 47 |
| 2060 | c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. 1989 , 159, 107-11 | 93 |
| 2059 | Localization of H-ras mRNA in oral squamous cell carcinomas. 1989 , 18, 74-8 | 22 |
| 2058 | Association of elevated expression of the c-erbB-2 protein with spread of breast cancer. 1989 , 80, 1192-8 | 34 |
| 2057 | A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product. 1989 , 80, 10-4 | 43 |
| 2056 | The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. 1989 , 15, 351-62 | 97 |
| 2055 | An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple. 1989 , 15, 505-14 | 71 |
| 2054 | Immunohistochemical detection of the c-erbB-2 proto-oncogene product in normal, benign and malignant cartilage tissues. 1989 , 15, 71-6 | 18 |
| 2053 | Cellular protooncogenes are infrequently amplified in untreated non-small cell lung cancer. 1989 , 59, 76-80 | 32 |
| 2052 | Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?. 1989 , 59, 910-4 | 23 |
| 2051 | Pattern of expression of c-erbB-2 oncoprotein in human fetuses. 1989 , 60, 64-9 | 55 |
| 2050 | An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. 1989 , 60, 426-9 | 82 |
| 2049 | c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. 1989 , 60, 505-10 | 60 |
| 2048 | The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up. 1989 , 60, 693-700 | 111 |
| 2047 | Distribution of neu (c-erbB-2) protein in human skin. 1989 , 92, 786-90 | 44 |

| | | |
|------|--|------|
| 2046 | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. <i>Science</i> , 1989 , 244, 707-133,3 | 5801 |
| 2045 | Menstrual influence on surgical cure of breast cancer. 1989 , 2, 949-52 | 137 |
| 2044 | Structural basis for epidermal growth factor receptor function. 1989 , 1, 23-32 | 34 |
| 2043 | At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. 1989 , 5, 554-60 | 182 |
| 2042 | Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?. 1989 , 43, 641-9 | 9 |
| 2041 | Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. 1989 , 57, 931-6 | 356 |
| 2040 | Priorities in experimental therapeutics--a surfeit of riches. 1989 , 25, 1263-9 | 1 |
| 2039 | Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. 1989 , 25, 1233-40 | 35 |
| 2038 | Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. 1989 , 58, 287-92 | 296 |
| 2037 | Tumor grade as a prognostic factor in primary breast cancer. 1989 , 25, 403-9 | 37 |
| 2036 | Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. 1989 , 4, 362-6 | 149 |
| 2035 | Cell kinetics as a prognostic indicator in node-negative breast cancer. 1989 , 25, 1165-71 | 71 |
| 2034 | ras p21 expression in ovine pulmonary carcinoma. 1989 , 23, 279-91 | 1 |
| 2033 | Solid tumor cytogenetics. Progress since 1979. 1989 , 40, 3-12 | 27 |
| 2032 | Double minutes in two primary adenocarcinomas of the prostate. 1989 , 39, 191-4 | 27 |
| 2031 | Oestrogen and progesterone receptors and their relationship to histological grades of epithelial tumours of the magnum region of the oviduct of the domestic fowl. 1989 , 100, 275-86 | 12 |
| 2030 | Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. 1989 , 34, 123-31 | 125 |
| 2029 | Ras gene activation and epidermal growth factor receptor expression in human colon cancer. 1989 , 47, 418-22 | 11 |

| | | |
|------|--|-----|
| 2028 | Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer. 1989 , 184, 207-17 | 46 |
| 2027 | Transformation of mouse mammary epithelial cells with the Ha-ras but not with the neu oncogene results in a gene dosage-dependent increase in transforming growth factor-alpha production. 1989 , 250, 474-8 | 17 |
| 2026 | Oncogenes, growth factors, and signal transduction. 1989 , 321, 1383-91 | 276 |
| 2025 | Multiple tandem 18-kb sequences clustered in the region of the acute promyelocytic leukemia breakpoint on chromosome 17. 1989 , 4, 152-61 | 7 |
| 2024 | The pathologist and the clinical oncologist: a new effective partnership in assessing tumor prognosis. 1989 , 25, 585-98 | 8 |
| 2023 | Tumor markers in human biopsy material. 1989 , 28, 743-62 | 7 |
| 2022 | Receptor downregulation and DNA synthesis are modulated by EGF and TPA in cells expressing an EGFR/neu chimera. 1989 , 1, 323-34 | 6 |
| 2021 | Sequence-specific ¹ H-NMR assignments and identification of two small antiparallel beta-sheets in the solution structure of recombinant human transforming growth factor alpha. 1989 , 86, 1519-23 | 36 |
| 2020 | Genes and Chromosomes in Cancer. 1989 , 14, 216-220 | |
| 2019 | Genetic diagnosis. Implications for medical practice. 1989 , 5, 579-600 | 4 |
| 2018 | Early breast cancer. A review. 1989 , 28, 123-34 | 3 |
| 2017 | Mechanism of activation of the human trk oncogene. 1989 , 9, 15-23 | 45 |
| 2016 | Homologous plasmid recombination is elevated in immortally transformed cells. 1989 , 9, 4009-17 | 49 |
| 2015 | Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis. 1989 , 86, 9441-5 | 202 |
| 2014 | Loss of heterozygosity on chromosome 1q in human breast cancer. 1989 , 86, 7204-7 | 102 |
| 2013 | Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. 1989 , 86, 3179-83 | 97 |
| 2012 | Coamplification of human acetylcholinesterase and butyrylcholinesterase genes in blood cells: correlation with various leukemias and abnormal megakaryocytopoiesis. 1989 , 86, 4715-9 | 81 |
| 2011 | Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. 1989 , 86, 2545-8 | 42 |

| | | |
|------|--|----|
| 2010 | Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. 1989 , 142, 146-9 | 34 |
| 2009 | Chapter 13. New Approaches to Antitumor Therapy. 1989 , 24, 121-128 | 5 |
| 2008 | Differentiation and growth in the human breast parenchyma. 1989 , 17, 589-591 | 9 |
| 2007 | Gall bladder lithotripsy. 1989 , 299, 1060-1 | 2 |
| 2006 | Role of blood groups as prognostic factors in primary breast cancer. 1990 , 47, 308-12 | 21 |
| 2005 | Has adjuvant treatment of breast cancer had an unfair trial?. 1990 , 301, 1317-9 | 5 |
| 2004 | The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. 1990 , 10, 2749-56 | 68 |
| 2003 | Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage. 1990 , 87, 691-5 | 29 |
| 2002 | Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. 1990 , 10, 3247-52 | 81 |
| 2001 | Molecules, cancer, and the surgeon. A review of molecular biology and its implications for surgical oncology. 1990 , 212, 3-13 | 8 |
| 2000 | Molecular probes in neuro-oncology: a review. 1990 , 8, 425-38 | 5 |
| 1999 | Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. 1990 , 87, 2569-73 | 98 |
| 1998 | Multiple cis- and trans-acting elements involved in regulation of the neu gene. 1990 , 10, 6306-15 | 53 |
| 1997 | Oncogene amplification and expression. Importance of methodologic considerations. 1990 , 94, 240-1 | 12 |
| 1996 | Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. 1990 , 94, 681-6 | 67 |
| 1995 | Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. 1990 , 94, 125-36 | 52 |
| 1994 | Prognostic indicators in invasive breast cancer. 1990 , 70, 989-1004 | 27 |
| 1993 | Techniques and results of aspiration cytology for diagnosis of benign and malignant diseases of the breast. 1990 , 70, 801-13 | 20 |

| | | |
|------|---|----|
| 1992 | Selection of therapy for stage III breast cancer. 1990 , 70, 1061-80 | 20 |
| 1991 | Adjuvant chemotherapy of breast cancer. 1990 , 70, 1081-102 | 6 |
| 1990 | Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature. 1990 , 29, 931-4 | 20 |
| 1989 | Oncogenes and tumor growth factors in breast cancer. A minireview. 1990 , 29, 331-4 | 12 |
| 1988 | Epidermal growth factor receptor gene analysis in renal cell carcinoma. 1990 , 143, 191-3 | 27 |
| 1987 | The Epidermal Growth Factor. 1990 , 11, 229-261 | 64 |
| 1986 | Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. 1990 , 62, 585-90 | 53 |
| 1985 | Activation of cancer cell proteases and cytotoxicity by EGF and PDGF growth factors. 1990 , 300, 9-15 | 13 |
| 1984 | Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. 1990 , 81, 327-32 | 74 |
| 1983 | Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. 1990 , 81, 454-62 | 66 |
| 1982 | In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. 1990 , 81, 489-94 | 77 |
| 1981 | c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters. 1990 , 81, 620-4 | 19 |
| 1980 | A tyrosine-specific protein kinase inhibitor, alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide, blocks the phosphorylation of tyrosine kinase substrate in intact cells. 1990 , 81, 645-52 | 17 |
| 1979 | c-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study. 1990 , 17, 243-7 | 63 |
| 1978 | Alterations of oncogenes in metastatic tumours of human gastric carcinomas. 1990 , 62, 226-30 | 57 |
| 1977 | Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. 1990 , 62, 398-404 | 47 |
| 1976 | Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. 1990 , 62, 430-5 | 49 |
| 1975 | C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. 1990 , 61, 39-45 | 64 |

| | | |
|------|--|-----|
| 1974 | Immunohistochemical analysis of c-erbB-2 oncogene product and epidermal growth factor receptor expression in human urinary bladder carcinomas. 1990 , 40, 322-6 | 3 |
| 1973 | c-erbB2 expression in correlation to other biological parameters of breast cancer. 1990 , 116, 15-20 | 58 |
| 1972 | Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines. 1990 , 116, 29-37 | 12 |
| 1971 | Application of molecular cytogenetic techniques to the evaluation of renal parenchymal tumors. 1990 , 116, 318-23 | 33 |
| 1970 | Nobel Lecture. Retroviruses and oncogenes II. 1990 , 10, 473-91 | 16 |
| 1969 | Mutational activation of the c-K-ras gene in human pancreatic carcinoma. 1990 , 4, 151-69 | 46 |
| 1968 | A monoclonal antibody that inhibits the action of GM-CSF on normal but not leukaemic progenitors. 1990 , 14, 637-44 | 5 |
| 1967 | Protein tyrosine kinases in human breast cancer: kinetic properties and evidence for the presence of two forms of native enzyme. 1990 , 17, 99-107 | 13 |
| 1966 | Autocrine and paracrine growth regulation of breast cancer: clinical implications. 1990 , 15, 3-11 | 78 |
| 1965 | Tissue polypeptide antigen in tumor cytosol: a new prognostic indicator in primary breast cancer. 1990 , 17, 15-21 | 12 |
| 1964 | Comparison of deoxyribonucleic acid ploidy and nuclear expressed p62 c-myc oncogene in the prognosis of colorectal cancer. 1990 , 14, 545-50; discussion 551 | 9 |
| 1963 | Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis. 1990 , 161, 7-14 | 123 |
| 1962 | NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. 1990 , 161, 15-25 | 100 |
| 1961 | The c-erb B-2 proto-oncogene in human pancreatic cancer. 1990 , 161, 195-200 | 164 |
| 1960 | c-erbB-2 oncogene expression in ovarian cancer. 1990 , 162, 231-7 | 83 |
| 1959 | Chromosomal abnormalities in human breast cancer. 1990 , 9, 35-43 | 31 |
| 1958 | The current state of oncogenes and cancer: experimental approaches for analyzing oncogenetic events in human cancer. 1990 , 9, 63-80 | 18 |
| 1957 | Studies of human breast cancer metastasis using nude mice. 1990 , 8, 285-97 | 66 |

1956 Retroviren und Onkogene II (Nobel-Vortrag). **1990**, 102, 765-773

1955 Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. **1990**, 1, 289-300 133

1954 Proto-oncogene amplification and homogeneously staining regions in human breast carcinomas. **1990**, 2, 18-26 42

1953 The 11q13 amplicon of a mammary carcinoma cell line. **1990**, 2, 171-81 19

1952 Flow cytometric quantification of human chromosome specific repetitive DNA sequences by single and bicolor fluorescent in situ hybridization to lymphocyte interphase nuclei. **1990**, 11, 153-64 33

1951 Analysis of c-erbB-2 protein expression in conjunction with DNA content using multiparameter flow cytometry. **1990**, 11, 522-32 11

1950 The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. **1990**, 45, 55-8 68

1949 Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. **1990**, 45, 320-4 41

1948 Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. **1990**, 45, 457-61 198

1947 Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. **1990**, 45, 1018-21 65

1946 Mutations in human breast cancer cells: dominantly-acting oncogenes and tumor suppressor genes suggest strategies for targeted interference. **1990**, 5, 40-6 8

1945 Molecular lesions in breast cancer. **1990**, 5, 47-50 10

1944 The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. **1990**, 5, 55-61 102

1943 Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase. **1990**, 42, 123-33 11

1942 Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?. **1990**, 44, 189-98 56

1941 Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. **1990**, 3, 254-7 93

1940 Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. **1990**, 3, 350-62 86

1939 c-erbB-2 oncoprotein expression in primary human tumors. **1990**, 65, 88-92 124

| | | |
|------|--|-----|
| 1938 | Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. 1990 , 65, 265-71 | 150 |
| 1937 | Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry. 1990 , 65, 1545-51 | 31 |
| 1936 | Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. 1990 , 65, 1794-800 | 129 |
| 1935 | DNA alterations at proto-oncogene loci and their clinical significance in operable non-small cell lung cancer. 1990 , 66, 733-9 | 15 |
| 1934 | The biology of metastatic breast cancer. 1990 , 66, 1313-20 | 19 |
| 1933 | The role of the pathologist in breast cancer management. 1990 , 66, 1363-72 | 17 |
| 1932 | Molecular phenotype of a pediatric small round cell tumor. 1990 , 66, 1534-8 | 2 |
| 1931 | Heterogenous amplification of myc family oncogenes in small cell lung carcinoma. 1990 , 66, 2053-8 | 34 |
| 1930 | Epidermal growth factor in breast cancer. 1990 , 22, 939-45 | 16 |
| 1929 | Immunohistochemical Expression of c-erbB-2 in Human Breast Cancer by Monoclonal Antibody: Correlation with Lymph Node and Er Status. 1990 , 76, 461-464 | 8 |
| 1928 | Neu (c-erbB-2), a tumor marker in carcinoma of the female breast. 1990 , 58, 297-303 | 18 |
| 1927 | Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659---Glu659).. 1990 , 9, 181-190 | 63 |
| 1926 | Biochemical markers as prognostic indices in breast cancer. 1990 , 36, 188-191 | 17 |
| 1925 | Brain Tumor Epidemiology, Growth, and Invasion. 1990 , 1, 1-18 | 54 |
| 1924 | The Application of Monoclonal Antibodies in the Cytologic Evaluation of Tumors. 1990 , 10, 77-103 | 1 |
| 1923 | The int-2 gene product acts as an epithelial growth factor in transgenic mice.. 1990 , 9, 907-913 | 189 |
| 1922 | Oncogenes and anti-oncogenes in tumorigenesis. 1990 , 30, 445-54 | 5 |
| 1921 | Breast cancer: oncogenes and suppressor genes. 1990 , 1, 242-3 | 3 |

| | | | |
|------|---|------|-----|
| 1920 | c-erbB-2 protein expression in node negative breast cancer. 1990 , 1, 263-8 | | 27 |
| 1919 | A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. 1990 , 3, 245-8 | | 130 |
| 1918 | Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo. 1990 , 82, 1815-21 | | 44 |
| 1917 | EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. <i>Science</i> , 1990 , 248, 79-83 | 33-3 | 133 |
| 1916 | Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. <i>Science</i> , 1990 , 249, 1552-5 | 33-3 | 266 |
| 1915 | Related fibroblast growth factor receptor genes exist in the human genome. 1990 , 87, 8180-4 | | 111 |
| 1914 | Molecular biology and respiratory disease. 4. Cancer genes. 1990 , 45, 409-13 | | |
| 1913 | Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function. 1990 , 87, 8660-4 | | 62 |
| 1912 | Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells. 1990 , 10, 4027-34 | | 112 |
| 1911 | Ultrastructural localization of c-erbB-2 gene product in transitional cell carcinoma of the urinary tract. 1990 , 14, 399-405 | | 8 |
| 1910 | Improved detection of metastases to lymph nodes and estrogen receptor determination. 1990 , 125, 179-82 | | 16 |
| 1909 | Oncogene amplification in squamous cell carcinoma of the head and neck. 1990 , 116, 1394-8 | | 70 |
| 1908 | The c-erbB-2 protein. 1990 , 14, iii-iv | | 1 |
| 1907 | Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. 1990 , 87, 4499-503 | | 131 |
| 1906 | Growth factors and oncogenes in human solid tumors: clinical aspects. 1990 , 44, 25-34 | | 4 |
| 1905 | Mechanisms of growth regulation of human breast cancer. 1990 , 4, 51-66 | | 3 |
| 1904 | Insulin and epidermal growth factor stimulate phosphorylation of p185HER-2 in the breast carcinoma cell line, BT474. 1990 , 69, 111-9 | | 13 |
| 1903 | New developments in the molecular biology of breast cancer. 1990 , 26, 509-10 | | 7 |

1902 Specific relationships in neoplastic disease. **1990**, 31, 277-81

1901 Co-expression of N-ras p21 and C-erbB-2 (neu) oncogene products by common ALL antigen-positive aggressive diffuse lymphoma. **1990**, 336, 825-6 2

1900 Polypoid melanoma: a virulent variant of nodular melanoma. Report of three cases and literature review. **1990**, 23, 880-4 26

1899 Structure, function and transforming potential of the epidermal growth factor receptor. **1990**, 70, 205-16 59

1898 Growth factors and oncogenes in breast cancer. **1990**, 2, 1-13 21

1897 Expression of c-erbB-2 protein detected in adenocarcinoma arising from parotid pleomorphic adenoma. **1990**, 17, 115-20 5

1896 In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit. **1990**, 4, 11-23 25

1895 Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. **1990**, 26, 437-41 71

1894 Cellular ras protooncogene expression in human mammary explant cultures. A potential marker for chemical carcinogenesis. **1990**, 586, 230-7 9

1893 neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. **1990**, 21, 750-8 62

1892 Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. **1990**, 21, 1164-7 145

1891 ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. **1990**, 132, 73-80 32

1890 Oncogene alterations in endometrial carcinoma. **1990**, 38, 364-6 52

1889 Chromosome abnormalities in human epithelial ovarian malignancies. **1990**, 38, 473-7 38

1888 Role of human papillomavirus in the pathogenesis of genital tract warts and cancer. **1990**, 37, 151-64 92

1887 Double minute chromosomes and a homogeneously staining chromosome region in C3H10T1/2 murine cells transformed "in vitro" by proton radiation. **1990**, 49, 75-86 5

1886 Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. **1990**, 53, 213-22 15

1885 Cancer Invasion and Metastases. **1990**, 263, 1123 75

| | | |
|------|---|------|
| 1884 | HER-2 oncogene amplification and overall survival of breast carcinoma patients. 1990 , 26, 946-9 | 15 |
| 1883 | QUANTITATIVE VARIATIONS OF NUCLEAR DNA DURING PLANT DEVELOPMENT: A CRITICAL ANALYSIS. 1990 , 65, 185-225 | 49 |
| 1882 | Oncogenic proteins new targets for chemotherapeutic agents against cancer. 1990 , 4, 401-22 | 1 |
| 1881 | Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. 1990 , 39, 163-6 | 45 |
| 1880 | Expression of genes coding for pS2, c-erbB2, estrogen receptor and the H23 breast tumor-associated antigen. A comparative analysis in breast cancer. 1990 , 265, 46-50 | 48 |
| 1879 | The cellular myb oncogene is amplified, rearranged and activated in human glioblastoma cell lines. 1990 , 52, 57-62 | 30 |
| 1878 | Molecular oncogenetics of metastasis. 1990 , 11, 243-324 | 22 |
| 1877 | Receptor-like oncogenes: functional analysis through novel experimental approaches. 1990 , 27, 1319-24 | 8 |
| 1876 | Genetic and cellular basis of multistep carcinogenesis. 1990 , 46, 469-86 | 72 |
| 1875 | E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. 1991 , 113, 173-85 | 1328 |
| 1874 | Effect of protease inhibitors on DNA amplification in SV40-transformed Chinese hamster embryo cells. 1991 , 56, 103-8 | 6 |
| 1873 | Growth factors and oncogenes. 1991 , 5, 655-69 | |
| 1872 | Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognosis. 1991 , 27, 411-6 | 31 |
| 1871 | Monoclonal antibodies for radioimmunosintigraphy of breast cancer. 1991 , 18, 437-43 | 1 |
| 1870 | Precise gene dosage determination by polymerase chain reaction: theory, methodology, and statistical approach. 1991 , 5, 307-17 | 48 |
| 1869 | The importance of the specific Z-DNA structure and polyamines in carcinogenesis: fact or fiction. 1991 , 35, 353-7 | 3 |
| 1868 | Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. 1991 , 165, 640-6 | 58 |
| 1867 | Origin of the high constitutive level of progesterone receptor in T47-D breast cancer cells. 1991 , 75, 157-62 | 23 |

| | | |
|------|---|----------|
| 1866 | Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. 1991 , 164, 15-21 | 229 |
| 1865 | Co-operation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. 1991 , 40, 239-45 | 36 |
| 1864 | Adjuvant systemic therapy of stage I and II breast cancer. 1991 , 7, 175-86 | 2 |
| 1863 | Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. 1991 , 27, 1372-5 | 142 |
| 1862 | Chromosome aberrations and cancer. <i>Science</i> , 1991 , 254, 1153-60 | 33-3 495 |
| 1861 | Biochemical analysis of the ligand for the neu oncogenic receptor. 1991 , 30, 3543-50 | 68 |
| 1860 | Transactivation of the TPA-responsive element by the oncogenic C-erbB-2 protein is partly mediated by protein kinase C. 1991 , 178, 724-32 | 8 |
| 1859 | Recurrent homogeneously staining regions in 8p1 in breast cancer and lack of amplification of POLB, LHRH, and PLAT genes. 1991 , 52, 27-35 | 27 |
| 1858 | Preferential involvement of 11q23-24 and 11p15 in breast cancer. 1991 , 51, 183-8 | 32 |
| 1857 | Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. 1991 , 42, 256-64 | 40 |
| 1856 | Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. 1991 , 27, 977-80 | 69 |
| 1855 | The effect of surgical timing within the fertility cycle on breast cancer outcome. 1991 , 618, 277-91 | 13 |
| 1854 | A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology?. 1991 , 27, 1574-83 | 46 |
| 1853 | A retrospective analysis of breast cancer based on outcome differences. 1991 , 22, 475-80 | 12 |
| 1852 | Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. 1991 , 22, 254-8 | 79 |
| 1851 | Oestrogen and progesterone receptors in primary breast cancer: a population study. 1991 , 27, 491-5 | 4 |
| 1850 | Les facteurs pronostiques biologiques dans le cancer du sein. 1991 , 6, 23-28 | |
| 1849 | Mécanisme d'action des hormones, des facteurs de croissance et de leurs récepteurs dans les tissus tumoraux. Exemple des tumeurs mammaires. 1991 , 6, 11-18 | |

| | | |
|------|---|-----|
| 1848 | Aggressive Diffuse Lymphoma Coexpressing NRAS p21 and C-erbB-2 (neu) Oncogene Products, and CALL A (CD 10). 1991 , 4, 419-22 | |
| 1847 | Molecular and Clinical Advances in Anticancer Drug Resistance. 1991 , | 2 |
| 1846 | Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.. 1991 , 10, 2077-2086 | 90 |
| 1845 | Hypothermia: dead or alive?. 1991 , 302, 3-4 | 6 |
| 1844 | Proto-oncogene activation in rodent and human tumors. 1991 , 283, 235-43 | 5 |
| 1843 | Anwendung der Polymerase-Kettenreaktion (PCR) als Zusatzdiagnostik in der Gynko-Onkologie. 1991 , 31, 378-379 | |
| 1842 | Molecular determinants of metastatic transformation. 1991 , 93, 91-5 | 6 |
| 1841 | Recent advances in the treatment of breast cancer. 1991 , 301, 337-52 | 3 |
| 1840 | c-erbB-2 oncogene as a prognostic marker in breast cancer. 1991 , 63, 328-32 | 136 |
| 1839 | DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. 1991 , 146, 1398-401 | 35 |
| 1838 | Expression of c-erbB-2 gene product in urinary bladder cancer. 1991 , 145, 423-7 | 103 |
| 1837 | The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. 1991 , 63, 444-6 | 119 |
| 1836 | Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. 1991 , 64, 780-4 | 25 |
| 1835 | Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. 1991 , 63, 237-41 | 77 |
| 1834 | The long term prognostic significance of c-erbB-2 in primary breast cancer. 1991 , 63, 447-50 | 193 |
| 1833 | Cloning, expression, and biological effects of erbB-2/neu gene in mammalian cells. 1991 , 198, 272-7 | 6 |
| 1832 | Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. 1991 , 11, 1745-50 | 84 |
| 1831 | Identification and characterization of a novel enhancer for the rat neu promoter. 1991 , 11, 1875-82 | 26 |

| | | |
|------|--|-----|
| 1830 | A novel, plasmid-based system for studying gene rearrangements in mammalian cells. 1991 , 11, 3915-24 | 6 |
| 1829 | Two additional protein-tyrosine kinases expressed in human lung: fourth member of the fibroblast growth factor receptor family and an intracellular protein-tyrosine kinase. 1991 , 88, 10411-5 | 23 |
| 1828 | Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. 1991 , 88, 10435-9 | 173 |
| 1827 | The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. 1991 , 11, 833-42 | 116 |
| 1826 | Expression of haptoglobin-related protein in primary and metastatic breast cancers. A longitudinal study of 48 fatal tumors. 1991 , 96, 238-42 | 17 |
| 1825 | Expression of c-erbB-2 in human pancreatic adenocarcinomas. 1991 , 59, 46-52 | 59 |
| 1824 | Primary medical treatment in breast cancer. 1991 , 302, 2-3 | 3 |
| 1823 | Axillary dissection in primary breast cancer. 1991 , 302, 360-1 | 29 |
| 1822 | Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. 1991 , 88, 8691-5 | 180 |
| 1821 | Characterization of a neu/c-erbB-2 protein-specific activating factor. 1991 , 88, 8582-6 | 65 |
| 1820 | c-erbB-2 oncoprotein expression in primary and advanced breast cancer. 1991 , 63, 439-43 | 202 |
| 1819 | c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. 1991 , 63, 434-8 | 285 |
| 1818 | Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma. 1991 , 165, 137-45 | 26 |
| 1817 | Immunohistochemical study on expression of C-MYC, P53, C-ERBB-2 and epidermal growth factor receptor in human thyroid tumors.. 1991 , 24, 563-570 | 6 |
| 1816 | The c-erbB-2 protein in primary and metastatic breast carcinomas. 1991 , 15, 281-9 | 17 |
| 1815 | Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. 1991 , 47, 87-98 | 353 |
| 1814 | Die Genetik urologischer Tumoren Teil 2: Klassische und zytogenetische Konzepte der Karzinogenese und chromosomale Aberrationen bei speziellen urologischen Tumoren. 1991 , 22, 1-9 | 10 |
| 1813 | Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. 1991 , 2, 347-54 | 216 |

| | | |
|------|---|-----|
| 1812 | Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. 1991 , 2, 47-53 | 34 |
| 1811 | Significance of Immunohistochemically Detected c-erbB-2 Protein Expression in Stage III Breast Cancer, with Reference to Nuclear Deformity, DNA Content and Prognosis. 1991 , | |
| 1810 | New insights into the causes of cancer. 1991 , 38, 201-21 | 9 |
| 1809 | Cytosol albumin content in operable breast cancer. Correlations to steroid hormone receptors, other prognostic factors and prognosis. 1991 , 30, 797-802 | 18 |
| 1808 | Adjuvant therapy for node-negative breast cancer. The use of prognostic factors in selecting patients. 1991 , 67, 1741-3 | 10 |
| 1807 | Medical management of early-stage breast cancer. 1991 , 15, 157-232 | 1 |
| 1806 | Human pituitary adenomas do not overexpress thec-erbB-2 oncoprotein. 1991 , 2, 210-213 | 1 |
| 1805 | Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas. 1991 , 117, 603-7 | 36 |
| 1804 | The prognostic value of tumor-associated carbohydrate structures correlated with gene amplifications in human breast carcinomas. 1991 , 21, 499-507 | 16 |
| 1803 | Anchorage-independent growth and the expression of cellular proto-oncogenes in normal human epidermal keratinocytes and in human squamous cell carcinoma cell lines. 1991 , 71, 303-11 | 9 |
| 1802 | The molecular biology of breast cancer. 1991 , 1072, 33-50 | 20 |
| 1801 | Diagnostic utility of oncogenes and their products in human cancer. 1991 , 1072, 193-214 | 8 |
| 1800 | An immunohistochemical study of the incidence and significance of C-erbB-2 oncoprotein overexpression in ovarian neoplasia. 1991 , 1, 285-289 | 14 |
| 1799 | Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. 1991 , 82, 835-40 | 158 |
| 1798 | An evaluation of the putative human mammary tumour retrovirus associated with peripheral blood monocytes. 1991 , 63, 534-40 | 7 |
| 1797 | Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. 1991 , 63, 727-35 | 44 |
| 1796 | Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. 1991 , 63, 146-50 | 147 |
| 1795 | C-erb B-2 amplification in cystic renal disease. 1991 , 40, 509-13 | 34 |

| | | |
|------|--|-----|
| 1794 | Alterations in copy number of c-erbB-2 and c-myc proto-oncogenes in advanced stage of human breast cancer. 1991 , 41, 19-23 | 1 |
| 1793 | Expression of p21RAS in odontogenic tumors. 1991 , 99, 15-20 | 18 |
| 1792 | Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. 1991 , 45, 69-81 | 6 |
| 1791 | Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. 1991 , 45, 196-206 | 25 |
| 1790 | DNA ploidy and cell-cycle analysis: tools for assessment of cancer prognosis. 1991 , 5, 422-38 | 5 |
| 1789 | Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. 1991 , 47, 66-71 | 59 |
| 1788 | Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. 1991 , 47, 118-23 | 33 |
| 1787 | c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. 1991 , 47, 833-8 | 73 |
| 1786 | Analysis of gene amplification in head-and-neck squamous-cell carcinoma. 1991 , 48, 511-5 | 105 |
| 1785 | Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. 1991 , 49, 44-9 | 222 |
| 1784 | The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. 1991 , 49, 323-8 | 269 |
| 1783 | Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. 1991 , 49, 616-23 | 49 |
| 1782 | Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. 1991 , 49, 650-5 | 325 |
| 1781 | Expression of the ERBB2 protein in benign and malignant salivary gland tumors. 1991 , 3, 128-35 | 38 |
| 1780 | Gene amplification and gene dosage in cell lines derived from squamous cell carcinoma of the head and neck. 1991 , 3, 443-54 | 38 |
| 1779 | Amplification of oncogenes in mammary carcinoma shown by fine-needle biopsy. 1991 , 67, 1396-400 | 4 |
| 1778 | Human neu oncogene is expressed in endometrial but not in ovarian adenocarcinomas. 1991 , 67, 1713 | 6 |
| 1777 | Bladder cancer. Human leukocyte antigen II, interleukin-6, and interleukin-6 receptor expression determined by the polymerase chain reaction. 1991 , 67, 2087-95 | 28 |

| | | |
|------|--|-----|
| 1776 | Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. 1991 , 67, 2142-9 | 43 |
| 1775 | Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. 1991 , 67, 2914-8 | 120 |
| 1774 | C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. 1991 , 68, 331-4 | 69 |
| 1773 | Correlation of nuclear morphometry with progression of breast cancer. 1991 , 68, 2012-6 | 98 |
| 1772 | Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. 1991 , 4, 189-95 | 48 |
| 1771 | Correlation between estrogen receptor status and histological malignancy in human breast cancer. 1991 , 46, 185-9 | 2 |
| 1770 | Bilateral breast cancer: one disease or two?. 1991 , 19, 233-44 | 42 |
| 1769 | Breast biopsy nuclear pellets are a convenient source of DNA for routine determination of Her-2/neu gene amplification. 1991 , 19, 57-61 | 2 |
| 1768 | Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. 1991 , 18, 11-7 | 92 |
| 1767 | Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. 1991 , 20, 3-10 | 19 |
| 1766 | Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors. 1991 , 20, 25-32 | 13 |
| 1765 | Response to treatment of breast cancer. 1991 , 18 Suppl 1, S147-55 | 3 |
| 1764 | Immunohistochemischer Tumorzellnachweis im Knochenmark von Patientinnen mit Mammakarzinom. 1991 , 250, 222-258 | |
| 1763 | Synthesis and evaluation of new protein-tyrosine kinase inhibitors. Part 1. pyridine-containing stilbenes and amides.. 1991 , 1, 211-214 | 9 |
| 1762 | Importance of oncogene research to the cancer clinician. 1991 , 3, 168-76 | 1 |
| 1761 | Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. 1991 , 163, 77-80 | 55 |
| 1760 | Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. 1991 , 163, 105-10 | 68 |
| 1759 | Oncoprotein immunoreactivity in human endocrine tumours. 1991 , 163, 117-27 | 39 |

| | | |
|------|--|-----------|
| 1758 | p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. 1991 , 164, 75-81 | 176 |
| 1757 | Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. 1991 , 165, 187-201 | 70 |
| 1756 | Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. 1991 , 11, 117-27 | 252 |
| 1755 | Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer. 1991 , 10, 217-27 | 26 |
| 1754 | Fibroblasts are critical determinants in prostatic cancer growth and dissemination. 1991 , 10, 263-74 | 78 |
| 1753 | Amplification of the c-erbB oncogene is associated with malignancy in primary tumours of neuroepithelial tissue. 1991 , 238, 221-4 | 19 |
| 1752 | Proto-oncogene expression in dermal naevi and melanomas. 1991 , 283, 500-5 | 18 |
| 1751 | c-erbB-2 expression in different histological types of invasive breast carcinoma. 1991 , 44, 211-4 | 60 |
| 1750 | Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase. 1991 , 2, 651-61 | 4 |
| 1749 | Role of oxygen free radicals in the molecular mechanisms of carcinogenesis: A review* The collection and analysis of references, the planning, and outlining, as well as the early writing of certain segments of this article were carried out while at CPSC. This writing represents, however, the contribution of the author in his private capacity, and implies no endorsement by the CPSC. 1991 , 2, 83-113 | 20 |
| 1748 | Lack of C-erbB-2 protein expression in pulmonary carcinoid tumours. 1991 , 44, 343 | 5 |
| 1747 | Effect of oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] on azoxymethane-induced biochemical changes related to early colon carcinogenesis in male F344 rats. 1991 , 197, 77-84 | 13 |
| 1746 | Transgenic models of tumor development. <i>Science</i> , 1991 , 254, 1161-7 | 33.3 281 |
| 1745 | A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. 1991 , 129, 832-7 | 178 |
| 1744 | Growth factors and cancer. <i>Science</i> , 1991 , 254, 1146-53 | 33.3 1044 |
| 1743 | The role of the retinoblastoma gene in breast cancer development. 1992 , 61, 59-68 | 17 |
| 1742 | Pathology and Laboratory Medicine. 1991 , 265, 3154 | |
| 1741 | Oncogenes. 1991 , 127, 707 | 5 |

| | | |
|------|---|------|
| 1740 | Pediatrics. 1991 , 265, 3156 | |
| 1739 | Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. 1991 , 5, 503-13 | 56 |
| 1738 | Diagnostic Applications of Recombinant Nucleic Acid Technology: Neoplastic Disease. 1992 , 23, 19-23 | 5 |
| 1737 | DNA Technology in the Clinical Laboratory. 1992 , 23, 721-722 | |
| 1736 | Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. 1992 , 66, 106-12 | 63 |
| 1735 | Over-expression of cellular oncogenes in cystadenocarcinomas of the ovary. 1992 , 1, 347-52 | |
| 1734 | P53 and cathepsin-d are independent of established prognostic factors in breast-cancer. 1992 , 1, 507-12 | 2 |
| 1733 | Multivariate-analysis of prognostic factors in 232 patients with clinical stage-I endometrial adenocarcinoma using the new figo surgical staging system. 1992 , 1, 665-72 | |
| 1732 | Breast cancer (3). 1992 , 327, 473-80 | 172 |
| 1731 | Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. 1992 , 12, 954-61 | 1214 |
| 1730 | Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. 1992 , 45, 594-6 | 44 |
| 1729 | c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. 1992 , 45, 16-20 | 76 |
| 1728 | AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. 1992 , 89, 9267-71 | 623 |
| 1727 | Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. 1992 , 175, 217-25 | 155 |
| 1726 | Genes, Oncogenes, and Hormones. 1992 , | |
| 1725 | Humanization of an anti-p185HER2 antibody for human cancer therapy. 1992 , 89, 4285-9 | 1468 |
| 1724 | ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. 1992 , 89, 5321-5 | 442 |
| 1723 | Spontaneous and mutagen-mediated amplification of a neo gene integrated at different genomic sites in rat 2 fibroblasts. 1992 , 13, 439-45 | 1 |

| | | |
|------|---|-----|
| 1722 | A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein. 1992 , 31, 147-50 | 7 |
| 1721 | Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. 1992 , 34, 517 | |
| 1720 | Increased tyrosine protein kinase activity in hairy cell and monocytic leukemias. 1992 , 303, 387-91 | 8 |
| 1719 | Expression of c-erbB-2 protein in papillary thyroid carcinomas. 1992 , 65, 832-7 | 60 |
| 1718 | Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. 1992 , 147, 1142-6 | 35 |
| 1717 | Unsettled questions regarding ovarian cancer. 1992 , 155, 7-18 | 3 |
| 1716 | Expression of the ERBB3 gene product in breast cancer. 1992 , 66, 1116-21 | 202 |
| 1715 | c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. 1992 , 66, 728-34 | 25 |
| 1714 | Protein tyrosine kinase growth factor receptors and their ligands in development, differentiation, and cancer. 1993 , 60, 43-73 | 27 |
| 1713 | The molecular and genetic characterization of human soft tissue tumors. 1993 , 60, 75-120 | 10 |
| 1712 | Stable transformation of a mosquito cell line results in extraordinarily high copy numbers of the plasmid. 1992 , 89, 5725-9 | 40 |
| 1711 | Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. 1992 , 89, 2287-91 | 102 |
| 1710 | Overexpression of the p185erbB-2 tyrosine kinase growth factor receptor: control or chaos. 1992 , 6, 357-8 | |
| 1709 | Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. 1992 , 12, 5563-70 | 48 |
| 1708 | Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. 1992 , 89, 5867-71 | 139 |
| 1707 | Annulate lamellae in a large cell lung carcinoma cell line with high expression of tyrosine kinase receptor and proto-oncogenes. 1992 , 16, 439-49 | 13 |
| 1706 | Towards a molecular basis for tamoxifen resistance in breast cancer. 1992 , 3, 503-11 | 41 |
| 1705 | [Function of oncogenes in neuroepithelial tumors]. 1992 , 60, 146-53 | 2 |

| | | |
|------|--|---------|
| 1704 | Negative autoregulation of the neu gene is mediated by a novel enhancer. 1992 , 12, 2739-48 | 26 |
| 1703 | Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. 1992 , 89, 10435-9 | 56 |
| 1702 | Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. 1992 , 89, 10578-82 | 954 |
| 1701 | Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. 1992 , 89, 8165-9 | 118 |
| 1700 | Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors. 1992 , 71, 331-6 | 2 |
| 1699 | Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. 1992 , 12, 491-8 | 120 |
| 1698 | Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2. 1992 , 11, 519-27 | 29 |
| 1697 | High level Escherichia coli expression and production of a bivalent humanized antibody fragment. 1992 , 10, 163-7 | 202 |
| 1696 | Approaches to proto-oncogene and tumour suppressor gene identification. 1992 , 28, 258-63 | 9 |
| 1695 | Patterns in Protein Sequence and Structure. 1992 , | 6 |
| 1694 | Detection of the HER-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from oestrogen and progesterone receptor assays. 1992 , 28, 322-6 | 5 |
| 1693 | Hormonal therapy for stomach cancer. 1992 , 39, 137-9 | 12 |
| 1692 | Detailed analysis of an amplified region at chromosome 11q13 in malignant tumors. 1992 , 13, 21-4 | 26 |
| 1691 | The type 1 (EGFR-related) family of growth factor receptors and their ligands. 1992 , 4, 1-24 | 296 |
| 1690 | Identification of heregulin, a specific activator of p185erbB2. <i>Science</i> , 1992 , 256, 1205-10 | 333 890 |
| 1689 | Epidermal growth factor receptor in human brain tumors. 1992 , 15, 31-7 | 25 |
| 1688 | Differential expression of the neu oncogene in mouse liver and pancreatic cell lines. 1992 , 186, 363-70 | 2 |
| 1687 | Corrigendum. 1992 , 29, 291-292 | |

| | | |
|------|---|-----|
| 1686 | c-myc oncogene copy number in squamous carcinoma of the head and neck. 1992 , 13, 168-71 | 17 |
| 1685 | Progress in molecular biology of breast cancer. 1992 , 28, 623-5 | 7 |
| 1684 | Applications of image cytometry in the diagnostic laboratory. 1992 , 12, 41-48 | |
| 1683 | NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. 1992 , 44, 245-53 | 62 |
| 1682 | The immune system and gynaecological cancer. 1992 , 6, 641-56 | 2 |
| 1681 | Correlation of nucleolar organizer regions and nuclear morphometry assessed by automatic image analysis in breast cancer with aneuploidy, K167 immunostaining, histopathologic grade and lymph node involvement. 1992 , 188, 1009-17 | 19 |
| 1680 | Association between chromosome 11q13 amplification and prognosis of patients with oesophageal carcinomas. 1992 , 28A, 755-7 | 24 |
| 1679 | DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study. 1992 , 28, 711-6 | 21 |
| 1678 | c-erbB-2 oncogene in breast cancer: the right target or a decoy?. 1992 , 23, 971-3 | 11 |
| 1677 | The role of axillary dissection in operable breast cancer. 1992 , 1, 41-49 | 31 |
| 1676 | Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. 1992 , 43, 21-5 | 25 |
| 1675 | Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. 1992 , 43, 13-9 | 40 |
| 1674 | Oral cancer progression and c-erbB-2/neu proto-oncogene expression. 1992 , 65, 215-20 | 63 |
| 1673 | Expression of c-erbB2, TGF-beta 1 and pS2 genes in primary human breast cancers. 1992 , 28, 700-5 | 23 |
| 1672 | Quantitative Immunohistochemistry. 1992 , 24, III-53 | 15 |
| 1671 | The role of erbB-2 and its ligands in growth control of malignant breast epithelium. 1992 , 43, 229-36 | 21 |
| 1670 | Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. 1992 , 28, 263-7 | 34 |
| 1669 | Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?. 1992 , 28, 644-8 | 106 |

| | | |
|------|---|-----|
| 1668 | Immunohistochemical quantification of steroid receptors and other prognosis factors in human breast cancer patients. 1992 , 26, 146-58 | 7 |
| 1667 | Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. 1992 , 43, 95-103 | 20 |
| 1666 | Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. 1992 , 61, 95-103 | 73 |
| 1665 | Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. 1992 , 23, 1141-50 | 51 |
| 1664 | Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. 1992 , 23, 1388-94 | 52 |
| 1663 | Cytogenetic study of breast cancer: clinicopathologic significance of homogeneously staining regions in 84 patients. 1992 , 23, 542-7 | 28 |
| 1662 | Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. 1992 , 23, 974-9 | 335 |
| 1661 | HER-2/neu expression: a major prognostic factor in endometrial cancer. 1992 , 47, 179-85 | 195 |
| 1660 | ras oncogene product p21 expression and prognosis of human ovarian tumors. 1992 , 46, 45-50 | 21 |
| 1659 | Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. 1992 , 69, 205-16 | 490 |
| 1658 | Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. 1992 , 69, 559-72 | 535 |
| 1657 | p185 HER2/neu epitope mapping with murine monoclonal antibodies. 1992 , 11, 267-76 | 28 |
| 1656 | Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. 1992 , 10, 1128-32 | 76 |
| 1655 | Prognostic indicators in node-negative early stage breast cancer. 1992 , 92, 539-48 | 18 |
| 1654 | Malignancies of undertermined primary origin. 1992 , 38, 217-260 | 11 |
| 1653 | Genes in the diagnosis of malignant disease. 1992 , 209, S15-26 | 1 |
| 1652 | The role of positron emission tomography in oncology and other whole-body applications. 1992 , 22, 268-84 | 59 |
| 1651 | Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. 1992 , 164, 323-6 | 61 |

| | | |
|------|---|-----|
| 1650 | [Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells]. 1992 , 32, 31-4 | 1 |
| 1649 | Different Assays for Her-2/neu Evaluation in Breast Cancer. 1992 , 78, 106-110 | 3 |
| 1648 | Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. 1992 , 49, 162-5 | 11 |
| 1647 | Correlations between c-erb beta-2 oncogene amplification and the expression of its mRNA and protein in human breast carcinomas. 1992 , 49, 9-14 | 5 |
| 1646 | Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic human ovaries. 1992 , 7, 114-118 | 8 |
| 1645 | Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. 1992 , 10, 1436-43 | 102 |
| 1644 | Detection of malignant potential in Barrett's epithelium. 1992 , 5, 45-50 | 4 |
| 1643 | Oncogenes in Ovarian Cancer. 1992 , 6, 813-827 | 16 |
| 1642 | Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic human ovaries. 1992 , 7, 47-51 | 4 |
| 1641 | An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. 1992 , 20, 117-20 | 22 |
| 1640 | Cancer staging: future directions for the TNM classification. 1992 , 8, 107-10 | 5 |
| 1639 | Biology of metastasis: clinical implications. 1992 , 8, 267-73 | 4 |
| 1638 | Detection of the ligand activity of the c-erbB-2 protein in calf serum. 1992 , 83, 15-9 | 5 |
| 1637 | Absence of activating mutations in the transmembrane domain of the c-erbB-2 protooncogene in human lung cancer. 1992 , 83, 1299-303 | 8 |
| 1636 | Specific detection of c-erbB-2 mRNA expression in gastric cancers by the polymerase chain reaction following reverse transcription. 1992 , 66, 84-7 | 17 |
| 1635 | The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. 1992 , 21, 25-31 | 11 |
| 1634 | Overexpression of c-Ki-ras and c-fos in human pancreatic carcinomas. 1992 , 11, 43-7 | 15 |
| 1633 | Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. 1992 , 31, 5434-41 | 97 |

| | | |
|------|---|----|
| 1632 | Alterations of the c-erbB2 gene in human breast cancer. 1992 , 118, 468-73 | 15 |
| 1631 | Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. 1992 , 118, 474-9 | 62 |
| 1630 | Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. 1992 , 1, 97-105 | 63 |
| 1629 | Expression polymerase chain reaction: a sensitive method for analysis of gene expression in human tumours. 1992 , 1, 309-14 | 8 |
| 1628 | Immunohistochemical detection of ras 21 in oral squamous cell carcinomas. 1992 , 74, 469-72 | 10 |
| 1627 | Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors. 1992 , 251, 45-50 | 3 |
| 1626 | Amplification and overexpression of the c-erbB-2 protooncogene in human gastric cancer. 1992 , 27, 172-8 | 18 |
| 1625 | Therapy of small breast cancer: a prospective study on 1036 patients with special emphasis on prognostic factors. 1992 , 23, 907-14 | 25 |
| 1624 | Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status. 1992 , 420, 345-51 | 52 |
| 1623 | Expression of c-erbB-2 protein and epidermal growth factor receptor in normal tissues of the female genital tract and in the placenta. 1992 , 420, 385-93 | 29 |
| 1622 | Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. 1992 , 420, 433-40 | 18 |
| 1621 | Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. 1992 , 421, 193-202 | 29 |
| 1620 | New cell lines of human breast cancer origin. 1992 , 21, 63-75 | 6 |
| 1619 | Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. 1992 , 23, 43-9 | 27 |
| 1618 | Detection and temporal appearance of multiple copies of c-erb-B2 genes in advanced mammary carcinoma using fine needle biopsies and the polymerase chain reaction. 1992 , 23, 191-200 | 20 |
| 1617 | Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. 1992 , 22, 273-84 | 26 |
| 1616 | C-erbB-2 protein in the sera of breast cancer patients. 1992 , 24, 97-102 | 59 |
| 1615 | Nobel seminar: Molecular medicine--cell biology in disease. Cancer and HIV: from viral genes to therapy?. 1992 , 232, 3-9 | 1 |

| | | |
|------|---|-----|
| 1614 | Expression of cytokeratin and erbB-2 oncoprotein in Paget's disease of the nipple. An immunohistochemical study. 1992 , 100, 1041-7 | 20 |
| 1613 | Transfection of murine P19S18 embryonal carcinoma cells with the oncogene neu induces an epithelioid phenotype. 1992 , 51, 129-35 | 1 |
| 1612 | Estrogen and progesterone receptors in cytology: a comprehensive review. 1992 , 8, 475-91 | 72 |
| 1611 | Oncogenes. 1992 , 14, 235-42 | 4 |
| 1610 | Chromatin structure changes suggest a compensatory response to c-myc gene amplification in malignant fibrous histiocytoma. 1992 , 49, 148-56 | 3 |
| 1609 | Fusion and amplification of two originally non-syntenic chromosomal regions in a mammary carcinoma cell line. 1992 , 5, 40-9 | 31 |
| 1608 | Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. 1992 , 50, 64-8 | 28 |
| 1607 | An attempt to define sets of cooperating genetic alterations in human breast cancer. 1992 , 51, 542-7 | 14 |
| 1606 | Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. 1992 , 51, 548-54 | 53 |
| 1605 | Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes. 1992 , 51, 798-804 | 2 |
| 1604 | Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. 1992 , 52, 218-24 | 54 |
| 1603 | Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells. 1992 , 52, 311-6 | 18 |
| 1602 | Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women. 1992 , 52, 707-12 | 33 |
| 1601 | Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. 1992 , 5, 213-8 | 100 |
| 1600 | Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. 1992 , 5, 320-7 | 72 |
| 1599 | Clinicopathologic comparisons between estrogen receptor-positive and -negative gastric cancers. 1992 , 51, 231-5 | 17 |
| 1598 | Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer. 1992 , 69, 1607-32 | 29 |
| 1597 | Future directions for the American Joint Committee on Cancer. 1992 , 69, 1639-44 | 10 |

| | | |
|------|---|-----|
| 1596 | Conservation therapy for invasive lobular carcinoma of the breast. 1992 , 69, 2789-95 | 47 |
| 1595 | Expression of transforming growth factor-alpha in gastric carcinoma and normal gastric mucosa cells. 1992 , 69, 2871-5 | 17 |
| 1594 | C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. 1992 , 69, 2953-60 | 57 |
| 1593 | Significance of c-erbB-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer. 1992 , 70, 770-6 | 26 |
| 1592 | Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. 1992 , 70, 1775-81 | 29 |
| 1591 | The future of prognostic factors in outcome prediction for patients with cancer. 1992 , 70, 2367-77 | 135 |
| 1590 | An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. 1992 , 70, 2493-8 | 131 |
| 1589 | Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. 1993 , 71, 162-71 | 30 |
| 1588 | Growth factor receptor and related oncogene determination in mesenchymal tumors. 1993 , 71, 3526-30 | 23 |
| 1587 | Gene amplification detected in carcinoma cells from human urinary bladder washings by the polymerase chain reaction method. 1993 , 71, 3605-10 | 30 |
| 1586 | Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. 1993 , 71, 3942-6 | 71 |
| 1585 | An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. 1993 , 72, 51-6 | 59 |
| 1584 | Chromatin organization and breast cancer prognosis. Two-dimensional and three-dimensional image analysis. 1993 , 72, 1239-46 | 19 |
| 1583 | Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. 1993 , 72, 2083-8 | 98 |
| 1582 | Time dependency of the influence of prognostic factors on relapse in breast cancer. 1993 , 72, 2993-3001 | 44 |
| 1581 | The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. 1993 , 72, 3131-5 | 97 |
| 1580 | Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. 1993 , 72, 3179-84 | 114 |
| 1579 | Cellular oncogenes and suppressor genes as prognostic markers in cancer. 1993 , 26, 439-47 | 34 |

| | | |
|------|---|-----|
| 1578 | Tyrosine kinase receptors in the control of epithelial growth and morphogenesis during development. 1993 , 15, 185-90 | 33 |
| 1577 | Neu and its ligands: from an oncogene to neural factors. 1993 , 15, 815-24 | 255 |
| 1576 | Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer. 1993 , 53, 11-6 | 13 |
| 1575 | Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 1993 , 53, 401-8 | 52 |
| 1574 | Amplification of fgfr4 gene in human breast and gynecological cancers. 1993 , 54, 378-82 | 127 |
| 1573 | Novel protein kinases expressed in human breast cancer. 1993 , 54, 571-7 | 66 |
| 1572 | c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study. 1993 , 55, 63-5 | 2 |
| 1571 | Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. 1993 , 55, 429-35 | 57 |
| 1570 | c-erbB-2 amplification in mammary carcinoma. 1993 , 17G, 132-8 | 22 |
| 1569 | Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. 1993 , 7, 31-40 | 32 |
| 1568 | Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. 1993 , 156, 212-7 | 86 |
| 1567 | Intraoperative cytology in breast cancer diagnosis: comparison between cytologic and frozen section techniques. 1993 , 9, 623-31 | 12 |
| 1566 | Recombination between separate MYC amplification structures in COLO320 cells. 1993 , 6, 190-7 | 6 |
| 1565 | FLT4 receptor tyrosine kinase gene mapping to chromosome band 5q35 in relation to the t(2;5), t(5;6), and t(3;5) translocations. 1993 , 7, 144-51 | 18 |
| 1564 | FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. 1993 , 7, 219-26 | 144 |
| 1563 | Whole chromosome 17 loss in ovarian cancer. 1993 , 8, 195-8 | 30 |
| 1562 | Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. 1993 , 8, 306-11 | 38 |
| 1561 | An animal model for in vivo evaluation of tumor glycolytic rates with positron emission tomography. 1993 , 53, 104-9 | 6 |

| | | |
|------|---|----|
| 1560 | Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies. 1993 , 3, 116-121 | 5 |
| 1559 | Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer. 1993 , 3, 271-278 | 14 |
| 1558 | Expression of the c-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas. 1993 , 86, 473-9 | 22 |
| 1557 | Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. 1993 , 21, 39-43 | 23 |
| 1556 | The p185erbB2 protein is localized on cell organelles involved in cell motility. 1993 , 11, 453-61 | 32 |
| 1555 | Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study. 1993 , 23, 329-36 | 32 |
| 1554 | Molecular cytogenetics of multiple drug resistance. 1993 , 12, 63-89 | 15 |
| 1553 | Predicting recurrence in axillary-node negative breast cancer patients. 1993 , 25, 127-39 | 48 |
| 1552 | Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens. 1993 , 26, 217-24 | 15 |
| 1551 | Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer. 1993 , 28, 121-35 | 16 |
| 1550 | Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy. 1993 , 28, 231-9 | 20 |
| 1549 | William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer. 1993 , 27, 83-93 | 56 |
| 1548 | Cell-signaling targets for antitumour drug development. 1993 , 32, 1-19 | 47 |
| 1547 | Epidermal growth factor receptor in breast cancer: correlation of quantitative immunocytochemical assays to prognostic factors. 1993 , 25, 203-10 | 7 |
| 1546 | Immunohistochemical expression of the mucin-type glycoprotein A-80 and prognosis in human breast cancer. 1993 , 67, 1418-22 | 5 |
| 1545 | Glutathione S-transferase expression in benign and malignant ovarian tumours. 1993 , 68, 235-9 | 88 |
| 1544 | Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. 1993 , 68, 1140-5 | 97 |
| 1543 | Assessing genetic heterogeneity in production cell lines: detection by peptide mapping of a low level Tyr to Gln sequence variant in a recombinant antibody. 1993 , 11, 1293-7 | 36 |

| | | |
|------|---|----|
| 1542 | Expression of c-erbB-2 protein, neuron-specific enolase and DNA flow cytometry in locally advanced transitional cell carcinoma of the urinary bladder. 1993 , 22, 327-33 | 11 |
| 1541 | p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. 1993 , 84, 394-401 | 80 |
| 1540 | Analysis of oncogenes and tumor suppressor genes in human breast cancer. 1993 , 84, 871-8 | 35 |
| 1539 | Analysis of genetic alterations related to the development and progression of breast carcinoma. 1993 , 84, 1159-64 | 13 |
| 1538 | Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay. 1993 , 84, 1279-86 | 13 |
| 1537 | Accumulation of anchorage independent cells showing amplified genes (CAD) during the in vitro propagation of CHEF18 Chinese hamster cells. 1993 , 26, 161-70 | 4 |
| 1536 | Interaction of tyrosine kinase oncoproteins with cellular membranes. 1993 , 1155, 307-22 | 31 |
| 1535 | Gene amplification and tumor progression. 1993 , 1155, 25-41 | 57 |
| 1534 | Clinical and biological prediction of axillary and internal mammary lymph node metastases in breast cancer. 1993 , 2, 51-8 | 17 |
| 1533 | Detection of c-erbB-2 amplification in breast cancer by in situ hybridization. 1993 , 2, 234-238 | 5 |
| 1532 | P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer. 1993 , 2, 27-32 | 6 |
| 1531 | Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen-receptor positive breast carcinomas in-vivo. 1993 , 2, 93-99 | 8 |
| 1530 | Revisiting the role of mutagenesis in the induction of lung cancers in rats by diesel emissions. 1993 , 303, 91-5 | 19 |
| 1529 | Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. 1993 , 119, 249-52 | 28 |
| 1528 | Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice. 1993 , 119, 652-6 | 12 |
| 1527 | erbB-2/Her-2 gene amplification and overexpression in parotid gland tumors. 1993 , 250, 150-3 | 1 |
| 1526 | erbB-3, a third member of the erbB/epidermal growth factor receptor gene family: its expression in head and neck cancer cell lines. 1993 , 250, 392-5 | 14 |
| 1525 | Immunohistochemical overexpression of C-erbB-2 in the prognosis of breast cancer. 1993 , 23, 885-90 | 4 |

| | | |
|------|--|-----|
| 1524 | A retrospective study on the clinical and biological prediction of axillary lymph node metastasis in breast cancer. 1993 , 23, 573-9 | 7 |
| 1523 | Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer. 1993 , 22, 111-27 | 13 |
| 1522 | Biological significance of autologous tumor-killing activity and its induction therapy. 1993 , 37, 75-83 | 10 |
| 1521 | Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. 1993 , 37, 255-63 | 414 |
| 1520 | Immunohistochemical study of neu protein overexpression in clinging in situ duct carcinoma of the breast. 1993 , 422, 375-80 | 21 |
| 1519 | Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). 1993 , 16, 93-104 | 54 |
| 1518 | Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. 1993 , 24, 195-208 | 302 |
| 1517 | Genetik [Kristallisationspunkt der gyn ologischen Onkologie. 1993 , 254, 15-20 | |
| 1516 | M glichkeiten und Grenzen der adjuvanten systemischen Therapie des Mammakarzinoms unter Ber cksichtigung von Selektionsparametern. 1993 , 254, 755-765 | |
| 1515 | Quantifizierung des c-neu-Nachweises beim Mammakarzinom. 1993 , 254, 836-838 | |
| 1514 | Vergleich der prognostischen Wertigkeit der Onkogenproteins c-neu und des Lymphknotenstatus beim Mammakarzinom. 1993 , 254, 840-842 | |
| 1513 | c-erbB-2-Onkogen berexpression beim Ovarialkarzinomen: Prognostische Bedeutung und Korrelation mit histologischen Befunden bei 275 Patientinnen. 1993 , 254, 948-949 | |
| 1512 | Molekulargenetische Charakterisierung der Epidermal-Growth-Factor-Receptor Expression in Tumorzelllinien und xenotransplantierten Tumoren. 1993 , 254, 1051-1053 | |
| 1511 | Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases. 1993 , 252, 169-77 | 4 |
| 1510 | Detection of HER-2 oncogene amplification in breast cancer by differential polymerase chain reaction from single cryosections. 1993 , 64, 209-12 | 11 |
| 1509 | EGF-R and steroid receptors in breast cancer: a comparison with tumor grading, tumor size, lymph node involvement, and age. 1993 , 26, 221-7 | 6 |
| 1508 | Molecular aspects of mesenchymal-epithelial interactions. 1993 , 9, 511-40 | 193 |
| 1507 | Isolation of a novel substrate-competitive tyrosine kinase inhibitor, desmal, from the plant <i>Desmos chinensis</i> . 1993 , 320, 169-72 | 19 |

| | | |
|------|---|----|
| 1506 | Drug resistance associated with altered DNA topoisomerase II. 1993 , 33, 113-27 | 71 |
| 1505 | Quantum leaps in treatment of high-risk breast cancer? Prove it!. 1993 , 29A, 1488-93 | 5 |
| 1504 | HER-2/neu amplification in human breast cancer: Southern or slot blotting for amplification analysis?. 1993 , 29A, 650 | 1 |
| 1503 | Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status. 1993 , 29A, 426-8 | 14 |
| 1502 | Amplified met gene linked to double minutes in human glioblastoma. 1993 , 29A, 1991-5 | 24 |
| 1501 | Prognostic value of serum tetranectin in patients with metastatic breast cancer. 1993 , 32, 631-6 | 31 |
| 1500 | Non palpable breast carcinomas. Histological and immunohistochemical studies of 160 cases. 1993 , 189, 267-74 | 2 |
| 1499 | Use of endocrine therapy to study the biology of breast cancer. 1993 , 19 Suppl B, 65-77 | 1 |
| 1498 | C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma. 1993 , 189, 261-6 | 14 |
| 1497 | An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. 1993 , 189, 283-92 | 35 |
| 1496 | HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples. 1993 , 29A, 1593-7 | 30 |
| 1495 | Proliferation, basement membrane changes, metastasis and vascularization patterns in human breast cancer. 1993 , 189, 851-61 | 9 |
| 1494 | neu mutations and loss of normal allele in schwannomas induced by N-ethyl-N-nitrosourea in rats. 1993 , 70, 45-50 | 7 |
| 1493 | The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. 1993 , 168, 228-32 | 28 |
| 1492 | Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades. 1993 , 75, 195-206 | 19 |
| 1491 | Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator. 1992 , 29A, 66-9 | 12 |
| 1490 | c-erbB-2/neu in colorectal carcinoma: a potential prognostic value?. 1992 , 29A, 170 | 2 |
| 1489 | What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. 1993 , 189, 1233-52 | 20 |

| | | |
|------|---|-----|
| 1488 | HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. 1993 , 75, 41-4 | 22 |
| 1487 | Detection of aneuploidy and possible deletion in paraffin-embedded rhabdomyosarcoma cells with FISH. 1993 , 68, 99-103 | 30 |
| 1486 | Double minutes are frequently found in ovarian carcinomas. 1993 , 71, 125-31 | 14 |
| 1485 | Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer. 1993 , 65, 120-4 | 32 |
| 1484 | Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?. 1993 , 24, 469-76 | 196 |
| 1483 | c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry. 1993 , 25, 124-32 | 19 |
| 1482 | The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. 1993 , 698, 31-47 | 13 |
| 1481 | Molecular and biochemical reprogramming of oncogenesis through the activity of prooxidants and antioxidants. 1993 , 686, 262-78; discussion 278-9 | 77 |
| 1480 | DISCUSSION OF THE PAPER. 1993 , 686, 278-279 | 5 |
| 1479 | Subsets of glioblastoma multiforme defined by molecular genetic analysis. 1993 , 3, 19-26 | 520 |
| 1478 | Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. 1993 , 36, 2950-5 | 143 |
| 1477 | An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. 1993 , 122, 199-208 | 82 |
| 1476 | Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. 1993 , 90, 1746-50 | 617 |
| 1475 | Influence of a hamster tumor suppressor gene on transformation by viral and cellular oncogenes. 1993 , 14, 1209-14 | 1 |
| 1474 | Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. 1993 , 62, 153-77 | 130 |
| 1473 | Laboratory Analysis forHER-2/neuGene Amplification and Protein Overexpression. 1993 , 24, 557-561 | 2 |
| 1472 | Argyrophilic nucleolar organizer regions in breast-carcinoma - correlation with clinicopathological and biological variables and prognostic value. 1993 , 2, 203-7 | 2 |
| 1471 | Prognostic-significance of p53 and C-erbb-2 expression in operable breast-cancer. 1993 , 2, 587-91 | 2 |

- 1470 The prognostic-significance of proliferating cell nuclear antigen in breast-cancer - correlation with DNA ploidy, C-erbB-2 expression, histopathology, lymph-node metastases and patient survival. **1993**, 2, 985-9
- 1469 Prediction of the prognosis of patients with gastric-cancer by erbB-2 tissue status and expression of proliferating cell nuclear antigen. **1993**, 2, 1033-7
- 1468 SERUM ERBB-2 PROTEIN FOR THE DIAGNOSIS OF GASTRIC-CANCER. **1993**, 3, 325
- 1467 c-erbB-2 DNA amplification and mRNA expression in human primary breast tumors and its relationship to other prognostic factors. **1993**, 8, 29-35 5
- 1466 Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B-2 expression in patients with breast cancer. **1993**, 128, 242-6 30
- 1465 Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. **1993**, 90, 1843-7 175
- 1464 The Significance of the Extracellular Matrix in Mammary Epithelial Carcinogenesis. **1993**, 7, 89-113
- 1463 Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma. **1993**, 67, 578-84 33
- 1462 Prognostic significance of c-erbB-2 expression in node negative breast cancer. **1993**, 67, 625-9 69
- 1461 Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. **1993**, 67, 706-12 22
- 1460 Prognostic indicators in early breast cancer. **1993**, 305, 176-82 22
- 1459 Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. **1993**, 150, 126-31 106
- 1458 Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. **1993**, 150, 1427-33 136
- 1457 Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis. **1993**, 32, 289-94 15
- 1456 Tumor markers for breast cancer. **1993**, 4, 807-19 26
- 1455 Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. **1993**, 14, 30-7 8
- 1454 Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. **1993**, 13, 6711-22 168
- 1453 A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. **1993**, 13, 2247-57 124

| | | |
|------|--|-----|
| 1452 | Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. 1993 , 100, 213-7 | 41 |
| 1451 | Improved quantitation of HER-2/neu gene copy number in breast tumor-derived DNA samples. 1993 , 100, 444-50 | 6 |
| 1450 | Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results. 1993 , 4, 643-50 | 7 |
| 1449 | Heterologous epidermal growth factor receptor (EGF-R) expression in larynx cancer cell lines: evidence for the existence of structurally modified receptors. 1993 , 113, 789-92 | 2 |
| 1448 | Molecular basis of cancer: oncogenes and tumor suppressor genes. 1993 , 37, 11-22 | 11 |
| 1447 | Molecular genetic changes in human breast cancer. 1993 , 61, 25-56 | 47 |
| 1446 | [The erbB gene family: significance for tumor development, prognosis and new therapeutic modalities]. 1993 , 53, 742-53 | 1 |
| 1445 | New prognostic factors in prostatic carcinoma. 1993 , 24, 438-49 | 23 |
| 1444 | Mechanisms of multistep carcinogenesis and carcinogen risk assessment. 1993 , 100, 9-20 | 167 |
| 1443 | Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.. 1993 , 12, 961-971 | 162 |
| 1442 | c-myc expression in renal carcinoma: correlation with clinical parameters. 1993 , 72, 143-7 | 9 |
| 1441 | Localization of a bidirectional DNA replication origin in the native locus and in episomally amplified murine adenosine deaminase loci. 1993 , 13, 2971-81 | 52 |
| 1440 | 17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. 1993 , 90, 10803-7 | 81 |
| 1439 | A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines.. 1993 , 12, 2369-2375 | 91 |
| 1438 | Immunohistochemical Detection of c-erbB-2 Expression by Neoplastic Human Tissue using Monospecific and Bispecific Monoclonal Antibodies. 1993 , 8, 233-239 | 4 |
| 1437 | Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. 1993 , 11, 1936-42 | 399 |
| 1436 | Perspectives on the future of cancer markers. 1993 , 39, 2444-2451 | 27 |
| 1435 | c-myc oncogene expression in estrogen-dependent and -independent breast cancer. 1993 , 39, 353-355 | 43 |

| | | |
|------|--|-----|
| 1434 | Role of Growth Factors in Pancreatic Endocrine Cells: Growth and Differentiation. 1993 , 22, 875-887 | 3 |
| 1433 | Tumor Markers for Breast Cancer: Current Utilities and Future Prospects. 1994 , 8, 485-506 | 11 |
| 1432 | Overview of the Biologic Markers of Breast Cancer. 1994 , 8, 73-100 | 43 |
| 1431 | Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. 1994 , 51, 47-51 | 22 |
| 1430 | Detection of amplified sequences at 5q11-->q13 in a homogenously staining region found by fluorescent in situ hybridization in a case of B-cell non-Hodgkin's lymphoma. 1994 , 65, 179-83 | 3 |
| 1429 | The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.. 1994 , 13, 1331-1340 | 185 |
| 1428 | c-erbB-2 oncogene expression in salivary gland tumours. 1994 , 56, 206-12 | 22 |
| 1427 | A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.. 1994 , 13, 3302-3311 | 144 |
| 1426 | Molecular analysis of gene amplification in tumors. 2001 , Chapter 10, Unit 10.5 | 1 |
| 1425 | Positron emission tomography scanning in cancer. 1994 , 12, 74-87 | 23 |
| 1424 | Mechanisms of deregulated her2/neu expression in breast-cancer cell-lines. 1994 , 4, 599-608 | 3 |
| 1423 | C-erbb-2, ras p21, and C-myc expression in breast-carcinoma - prognostic value and correlation with clinicopathological and biologic variables. 1994 , 4, 255-60 | |
| 1422 | Her2 Neu overexpression counteracts the growth effects of C-myc in breast-cancer cells. 1994 , 4, 965-9 | 0 |
| 1421 | The Polymerase Chain Reaction. 1994 , | 104 |
| 1420 | Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. 1994 , 8, 23-32 | 152 |
| 1419 | Prognostische Relevanz der Amplifikation der Onkogene c-erb B-2 und c-myc beim Mammakarzinom. 1994 , 18, 255-259 | |
| 1418 | Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. 1994 , 86, 1860-5 | 64 |
| 1417 | Anatomy and Histology of the Uterine Corpus. 1994 , 327-366 | 4 |

| | | |
|------|--|-----|
| 1416 | Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. 1994 , 47, 117-21 | 14 |
| 1415 | SH2 and SH3 domains in signal transduction. 1994 , 64, 87-110 | 107 |
| 1414 | Influence of a mutation in the transmembrane domain of the p185c-erbB2 oncogene-encoded protein studied by molecular dynamics simulations. 1994 , 11, 983-1002 | 15 |
| 1413 | Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. 1994 , 3, 565-8 | 91 |
| 1412 | C-erbB-2 immunostaining: problems with interpretation. 1994 , 47, 816-22 | 75 |
| 1411 | Image cytometry: current applications and future trends. 1994 , 31, 1-34 | 17 |
| 1410 | Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer?. 1994 , 28, 395-403 | 16 |
| 1409 | Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. 1994 , 29, 813-9 | 91 |
| 1408 | Clinical significance of autologous tumor killing (ATK) activity and its induction therapy in human cancer. 1994 , 8, 113-22 | 1 |
| 1407 | DNA amplifications and elevated expression of proto-oncogene in addition to altered DNA ploidy in metastatic brain tumors. 1994 , 12, 267-75 | 4 |
| 1406 | Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity. 1994 , 39, 318-24 | 7 |
| 1405 | Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy. 1994 , 22, 305-8 | 16 |
| 1404 | Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance. 1994 , 72, 156-63 | 21 |
| 1403 | The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies. 1994 , 4, 194-199 | 10 |
| 1402 | Synthesis of [L-3-Deoxymimosine4]-angiotensin I as an approach to the preparation of selective protein-tyrosine kinase (PTK) inhibitors. 1994 , 50, 9873-9882 | 15 |
| 1401 | Synthesis of a series of brominated 1-phenyl-2-pyridylethenes as inhibitors of the protein-tyrosine kinase p56lck. 1994 , 4, 1729-1732 | 2 |
| 1400 | Salivary duct carcinoma--a highly aggressive salivary gland tumour with overexpression of c-erbB-2. 1994 , 172, 35-44 | 84 |
| 1399 | Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. 1994 , 173, 65-75 | 106 |

| | | |
|------|--|-----|
| 1398 | Analysis of epidermal growth factor receptor mRNA expression by polymerase chain reaction assay in 94 human breast adenocarcinoma tumors. 1994 , 30, 275-82 | 4 |
| 1397 | Comparison of estrogen and progesterone receptor status to lymphocyte immunity against tumor antigens in breast cancer patients. 1994 , 30, 299-304 | 8 |
| 1396 | Detection of prostate-specific antigen immunoreactivity in breast tumors. 1994 , 32, 301-10 | 117 |
| 1395 | Do we really need prognostic factors for breast cancer?. 1994 , 30, 117-26 | 68 |
| 1394 | Demonstration of gene-amplification by PCR in archival paraffin-embedded breast cancer tissue. 1994 , 30, 147-52 | 1 |
| 1393 | Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. 1994 , 29, 11-27 | 93 |
| 1392 | Breast cancer: prognostic significance of c-erbB-2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. 1994 , 29, 237-45 | 22 |
| 1391 | C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. 1994 , 29, 287-95 | 25 |
| 1390 | Antiestrogen action and growth factor regulation. 1994 , 31, 61-71 | 20 |
| 1389 | Amplification and differential expression of members of the erbB-gene family in human glioblastoma. 1994 , 22, 201-7 | 83 |
| 1388 | Infrequent transforming mutations in the transmembrane domain of the neu oncogene in spontaneous rat schwannomas. 1994 , 9, 230-5 | 3 |
| 1387 | Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. 1994 , 73, 135-9 | 20 |
| 1386 | Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. 1994 , 73, 148-53 | 79 |
| 1385 | c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. 1994 , 73, 664-71 | 36 |
| 1384 | Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. 1994 , 73, 1460-6 | 51 |
| 1383 | Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. 1994 , 73, 1785-94 | 105 |
| 1382 | Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. 1994 , 73, 2359-65 | 182 |
| 1381 | Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. 1994 , 73, 2771-8 | 25 |

| | | |
|------|---|-----|
| 1380 | Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. 1994 , 73, 2978-84 | 75 |
| 1379 | Targeted toxins as anticancer agents. 1994 , 74, 1006-12 | 43 |
| 1378 | Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. 1994 , 74, 1021-5 | 31 |
| 1377 | Molecular medicine quietly comes of age. New opportunities in the treatment of patients with breast cancer. 1994 , 74, 2215-7 | 2 |
| 1376 | Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. 1994 , 74, 2281-6 | 56 |
| 1375 | Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. 1994 , 74, 2956-63 | 84 |
| 1374 | Localization of amplified MYC gene sequences to double minute chromosomes in acute myelogenous leukemia. 1994 , 9, 62-7 | 48 |
| 1373 | Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. 1994 , 10, 160-70 | 102 |
| 1372 | The Heregulin gene can be included in the 8p12 amplification unit in human breast cancer. 1994 , 11, 66-9 | 7 |
| 1371 | Immunofluorescent quantification of tyrosine phosphorylation of cellular proteins in whole cells by flow cytometry. 1994 , 15, 327-34 | 30 |
| 1370 | Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. 1994 , 11, 250-4 | 26 |
| 1369 | Expression of C-erb B2 in tumours and tumour-like lesions of the thyroid. 1994 , 56, 459-61 | 10 |
| 1368 | erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. 1994 , 56, 522-8 | 35 |
| 1367 | Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. 1994 , 57, 90-7 | 43 |
| 1366 | Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. 1994 , 57, 498-503 | 47 |
| 1365 | Interferon gamma-induced reduction in erbB-2 tyrosyl phosphorylation in human ovarian carcinoma cells. 1994 , 58, 538-42 | 5 |
| 1364 | Transcriptional activation of the urokinase receptor gene in invasive colon cancer. 1994 , 58, 650-7 | 37 |
| 1363 | Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. 1994 , 58, 763-8 | 33 |

| | | |
|------|--|-----|
| 1362 | Oncogene amplifications in early-stage human prostate carcinomas. 1994 , 59, 637-8 | 30 |
| 1361 | Image analysis in quantitative PCR. An application for the measurement of c-erbB-2 oncogene amplification in DNA from human tumours. 1994 , 9, 223-8 | 13 |
| 1360 | Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. 1994 , 120, 737-42 | 32 |
| 1359 | Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. 1994 , 120, 378-81 | 33 |
| 1358 | Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. 1994 , 1198, 11-26 | 395 |
| 1357 | Somatic genetic changes in human breast cancer. 1994 , 1198, 113-30 | 58 |
| 1356 | The biology of erbB-2/neu/HER-2 and its role in cancer. 1994 , 1198, 165-84 | 370 |
| 1355 | Prospective study correlating P120 antigen expression with established prognostic factors in breast cancer. 1994 , 3, 69-77 | 11 |
| 1354 | Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. 1994 , 3, 109-13 | 56 |
| 1353 | Reproducibility of pathological grading in breast cancer. 1994 , 3, 124-129 | 4 |
| 1352 | Use of chromosome microdissection, the polymerase chain reaction, and dot blot hybridization to analyze double minute chromosomes. 1994 , 11, 69-76 | 0 |
| 1351 | Simultaneous Assay of ErbB-2 Protein and Carcinoembryonic Antigen in Cyst Fluid as an Aid in Diagnosing Cystic Lesions of the Breast. 1994 , 1, 25-30 | 9 |
| 1350 | Co-expression of epidermal growth factor-receptor and c-erb B-2 proto-oncogene product in human salivary-gland adenocarcinoma cell line HSG and the implications for HSG cell autocrine growth. 1994 , 39, 569-80 | 6 |
| 1349 | Clinical radioimmunolocalization with a rat monoclonal antibody directed against c-erbB-2. 1994 , 24-25, 93-8 | 11 |
| 1348 | Tumor targeting in a murine tumor xenograft model with the (sFv) ² divalent form of anti-c-erbB-2 single-chain Fv. 1994 , 24-25, 267-78 | 7 |
| 1347 | Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. 1994 , 1, 18-27 | 73 |
| 1346 | Demonstration of c-erbB-2 oncogene overexpression in salivary gland neoplasms by in situ hybridization. 1994 , 23, 226-31 | 10 |
| 1345 | Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains. 1994 , 12, 890-7 | 40 |

| | | |
|------|--|-----|
| 1344 | Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. 1994 , 8, 155-61 | 124 |
| 1343 | Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. 1994 , 69, 772-6 | 75 |
| 1342 | Critical determination of the frequency of c-erbB-2 amplification in breast cancer. 1994 , 70, 434-9 | 21 |
| 1341 | erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. 1994 , 70, 819-25 | 81 |
| 1340 | Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. 1994 , 70, 1095-101 | 31 |
| 1339 | Epidermal growth factor binding by membranes of human renal cell carcinomas: establishment of an epidermal growth factor receptor assay for clinical use. 1994 , 1, 319-23 | 7 |
| 1338 | Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. 1994 , 25, 455-61 | 41 |
| 1337 | Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast. 1994 , 24, 349-56 | 32 |
| 1336 | c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. 1994 , 25, 247-52 | 61 |
| 1335 | BE-23372M, a novel and specific inhibitor for epidermal growth factor receptor kinase. 1994 , 85, 253-9 | 8 |
| 1334 | c-erbB-2 oncoprotein is not an independent prognostic parameter in primary breast carcinoma. An immunohistochemical study. 1994 , 102, 612-22 | 7 |
| 1333 | Vanadate, molybdate and tungstate for orthomolecular medicine. 1994 , 43, 177-82 | 19 |
| 1332 | Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques. 1994 , 75, 1-5 | 7 |
| 1331 | The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. 1994 , 733, 393-406 | 108 |
| 1330 | Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src. 1994 , 37, 3353-62 | 77 |
| 1329 | Neu is not involved in N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide- induced bladder carcinoma or 2-amino-4-(5-nitro-2-furyl)thiazole transformation of rat bladder epithelial cells. 1994 , 84, 7-13 | |
| 1328 | neu is not involved in N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder carcinoma or 2-amino-4-(5-nitro-2-furyl)thiazole transformation of rat bladder epithelial cells. 1994 , 84, 125-31 | 2 |
| 1327 | c-myc mRNA overexpression is associated with lymph node metastasis in colorectal cancer. 1994 , 30A, 1113-7 | 24 |

| | | |
|------|--|-----|
| 1326 | c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. 1994 , 330, 1260-6 | 825 |
| 1325 | Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. 1994 , 229, 107-22 | 10 |
| 1324 | Independent control of transcription initiations from two sites by an initiator-like element and TATA box in the human c-erbB-2 promoter. 1994 , 348, 80-8 | 13 |
| 1323 | Functional interaction between the epidermal growth factor receptor and c-Src kinase activity. 1994 , 352, 296-300 | 24 |
| 1322 | Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. 1994 , 25, 1075-83 | 88 |
| 1321 | The neu-oncogene: more than a prognostic indicator?. 1994 , 25, 1264-8 | 62 |
| 1320 | c-erbB-2 amplification in breast cancer: detection in formalin-fixed, paraffin-embedded tissue by in situ hybridization. 1994 , 25, 413-8 | 20 |
| 1319 | Expression of neu/c-erbB-2 in human brain tumors. 1994 , 25, 772-80 | 40 |
| 1318 | In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein. 1994 , 34, 119-28 | 3 |
| 1317 | The GRB family of SH2 domain proteins. 1994 , 62, 223-44 | 44 |
| 1316 | [Adjuvant treatments of early breast cancer without lymph node involvement]. 1994 , 15, 210-5 | |
| 1315 | Cloning and activation of the Syrian hamster neu proto-oncogene. 1994 , 140, 251-5 | 6 |
| 1314 | Oncogene transgenic mice as therapeutic models in cancer research. 1994 , 30A, 533-7 | 8 |
| 1313 | c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study. 1994 , 30A, 16-22 | 65 |
| 1312 | Clinical therapy and HER-2 oncogene amplification in breast cancer: chemo- vs radiotherapy. 1994 , 49, 39-42 | 3 |
| 1311 | NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant. 1994 , 105, 1-10 | 53 |
| 1310 | European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2). 1994 , 30A, 1148-60 | 1 |
| 1309 | Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. 1994 , 149, 123-6 | 57 |

| | | |
|------|--|-----|
| 1308 | Analysis of c-erbB-2 amplification in salivary gland tumours by differential polymerase chain reaction. 1994 , 30B, 47-50 | 8 |
| 1307 | Role of DNA ploidy and ERB-B2 oncogene expression in the prognosis of endometrial carcinoma. 1994 , 190, 1039-43 | 4 |
| 1306 | Serum c-erbB-2 in breast cancer patients. 1994 , 33, 901-4 | 16 |
| 1305 | The role of mitotic recombination in carcinogenesis. 1994 , 24, 323-53 | 63 |
| 1304 | Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors. 1994 , 37, 2224-31 | 37 |
| 1303 | Current management of carcinoma of the breast. 1994 , 220, 121-36 | 21 |
| 1302 | Quantitative Analysis of c-erbB-2 Protein in Breast Cancer Tissue by Enzyme Immunoassay. 1994 , | |
| 1301 | BE-23372M, a novel protein tyrosine kinase inhibitor. I. Producing organism, fermentation, isolation and biological activities. 1994 , 47, 289-93 | 9 |
| 1300 | Regulation of the Ras signalling pathway by protein-tyrosine kinases. 1994 , 22, 455-60 | 8 |
| 1299 | Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. 1994 , 91, 8132-6 | 570 |
| 1298 | Immune response against tumors. 1994 , 57, 281-351 | 55 |
| 1297 | Chemoimmunoconjugates for the treatment of cancer. 1994 , 56, 301-87 | 26 |
| 1296 | Tyrosine-specific protein kinase participates in the pathogenesis of acute immune complex alveolitis in rats. 1994 , 61, 19-22 | 1 |
| 1295 | Immunohistochemical study of c-erbB-2 oncoprotein expression in extramammary Paget's disease. 1994 , 188, 100-2 | 15 |
| 1294 | The Family of c-erbB Genes: From Basic Research to Clinical Oncology. 1994 , 17, 346-357 | 3 |
| 1293 | Activation of the Src family of tyrosine kinases in mammary tumorigenesis. 1994 , 64, 111-23 | 30 |
| 1292 | p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. 1994 , 69, 846-52 | 89 |
| 1291 | Analysis of the IGF-II receptor gene copy number in breast carcinoma. 1994 , 69, 120-4 | 8 |

| | | |
|------|---|-----|
| 1290 | Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients. 1994 , 70, 304-8 | 16 |
| 1289 | Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. 1994 , 101, 166-76 | 109 |
| 1288 | Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. 1994 , 101, 493-9 | 23 |
| 1287 | Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer. 1994 , 31 (Pt 2), 171-3 | 4 |
| 1286 | Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. 1994 , 14, 735-43 | 195 |
| 1285 | Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. 1994 , 91, 7202-6 | 129 |
| 1284 | Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study. 1994 , 33, 493-8 | 4 |
| 1283 | Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. 1994 , 26, 261-7 | 42 |
| 1282 | Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. 1994 , 91, 1711-5 | 77 |
| 1281 | Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. 1994 , 219, 596-601; discussion 602-4 | 38 |
| 1280 | Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. 1994 , 219, 332-41 | 81 |
| 1279 | Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. 1994 , 14, 7068-77 | 184 |
| 1278 | Involvement of pp60c-src with two major signaling pathways in human breast cancer. 1994 , 91, 83-7 | 242 |
| 1277 | Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. 1994 , 91, 2156-60 | 602 |
| 1276 | Ligand-directed retroviral targeting of human breast cancer cells. 1995 , 92, 9747-51 | 117 |
| 1275 | The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. 1995 , 92, 744-7 | 200 |
| 1274 | Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. 1995 , 108, 157-62 | 38 |
| 1273 | Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder. 1995 , 71, 69-72 | 27 |

| | | |
|------|--|-----|
| 1272 | Association of Epidermal Growth Factor-related Peptides and Type I Receptor Tyrosine Kinase Receptors with Prognosis of Human Colorectal Carcinomas. 1995, | |
| 1271 | Expression of the multidrug-resistance (MDR) gene in breast cancer. 1995, 7, 449-51 | 5 |
| 1270 | Proliferating cell nuclear antigen (pcna) and C-erbB-2 oncoprotein in breast-carcinoma with correlations to histopathological parameters and prognosis. 1995, 2, 99-105 | 2 |
| 1269 | Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. 1995, 75, 1418-25 | 110 |
| 1268 | The influence of heregulins on human Schwann cell proliferation. 1995, 15, 1329-40 | 243 |
| 1267 | Biological indices in the assessment of breast cancer. 1995, 48, M221-38 | 11 |
| 1266 | Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. 1995, 40, 209-12 | 26 |
| 1265 | Oncogenes in tumor progression. 1995, 3, 17-53 | |
| 1264 | Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. 1995, 72, 56-64 | 50 |
| 1263 | Platyfish and swordtails: a genetic system for the analysis of molecular mechanisms in tumor formation. 1995, 11, 185-9 | 94 |
| 1262 | Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. 1995, 75, 2139-46 | 23 |
| 1261 | Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. 1995, 75, 2147-52 | 103 |
| 1260 | Prognostic value of erb-B2 and myc amplification in breast cancer imprints. 1995, 75, 2681-7 | 38 |
| 1259 | The molecular basis of ovarian cancer. 1995, 76, 1992-7 | 45 |
| 1258 | LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells. 1995, 14, 103-10 | 20 |
| 1257 | Melanoma formation in Xiphophorus: a model system for the role of receptor tyrosine kinases in tumorigenesis. 1995, 17, 1017-23 | 19 |
| 1256 | Receptor tyrosine kinases expressed in metastatic colon cancer. 1995, 60, 791-7 | 128 |
| 1255 | Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab') ₂ for efficient lysis of p185HER2 overexpressing tumor cells. 1995, 62, 319-24 | 41 |

| | | |
|------|---|-----|
| 1254 | Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. 1995 , 63, 560-7 | 66 |
| 1253 | c-erbB growth-factor-receptor proteins in ovarian tumours. 1995 , 64, 202-6 | 42 |
| 1252 | Amplification of the MET gene in glioma. 1995 , 12, 63-5 | 36 |
| 1251 | 11q13 amplification in local recurrence of human primary breast cancer. 1995 , 12, 128-33 | 34 |
| 1250 | Genetic alterations in breast cancer. 1995 , 14, 227-51 | 229 |
| 1249 | Comparison of immunoreactivity of neu oncoprotein in fine-needle aspirates and paraffin-embedded materials. 1995 , 12, 142-5 | 4 |
| 1248 | c-erbB-2 in retrospect: is it time for molecular cytology?. 1995 , 12, 145-7 | 2 |
| 1247 | Tumor genes and their proteins in cytologic and surgical specimens: relevance and detection systems. 1995 , 13, 411-22 | 3 |
| 1246 | Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials?. 1995 , 23, 227-32 | 10 |
| 1245 | Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line. 1995 , 9, 141-50 | 11 |
| 1244 | Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. 1995 , 9, 151-65 | 23 |
| 1243 | Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells. 1995 , 163, 589-96 | 48 |
| 1242 | The biology of growth regulation in normal and malignant breast epithelium: from bench to clinic. 1995 , 20, 223-36 | 6 |
| 1241 | A flow cytometric study of c-erbB-3 expression in breast cancer. 1995 , 41, 280-6 | 5 |
| 1240 | The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. 1995 , 41, 137-45 | 8 |
| 1239 | Analysis of c-erbB2 protein content of human glioma cells and tumor tissue. 1995 , 23, 31-40 | 10 |
| 1238 | MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. 1995 , 34, 97-117 | 130 |
| 1237 | Protein tyrosine phosphatase activity as a diagnostic parameter in breast cancer. 1995 , 33, 245-56 | 18 |

| | | |
|------|---|-----|
| 1236 | Increased phosphotyrosine in breast cancer tissue is associated with a worse prognosis. 1995 , 35, 277-82 | 2 |
| 1235 | The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. 1995 , 35, 283-91 | 165 |
| 1234 | Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction. 1995 , 33, 89-92 | 14 |
| 1233 | ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors. 1995 , 35, 201-10 | 12 |
| 1232 | Microdissection and microcloning of chromosomal alterations in human breast cancer. 1995 , 33, 95-102 | 6 |
| 1231 | The role of amphiregulin in breast cancer. 1995 , 33, 103-14 | 55 |
| 1230 | Aberrant function of the Ras signal transduction pathway in human breast cancer. 1995 , 35, 133-44 | 176 |
| 1229 | The neu-protein and breast cancer. 1995 , 426, 107-15 | 53 |
| 1228 | Molecular biology of testicular germ cell tumors: current status. 1995 , 73, 355-67 | 7 |
| 1227 | Relationship between ERBB2 and E-cadherin expression in human breast cancer. 1995 , 427, 259-63 | 13 |
| 1226 | Gene amplifications in advanced-stage human prostate cancer. 1995 , 22, 343-7 | 27 |
| 1225 | Immunity to oncogenic proteins. 1995 , 145, 33-59 | 153 |
| 1224 | Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. 1995 , 1, 644-8 | 92 |
| 1223 | Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma. 1995 , 71, 753-7 | 23 |
| 1222 | Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates. 1995 , 72, 732-7 | 14 |
| 1221 | Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. 1995 , 72, 1259-66 | 115 |
| 1220 | Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. 1995 , 71, 438-41 | 41 |
| 1219 | Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?. 1995 , 2 Suppl 2, 76-88 | 32 |

| | | |
|------|--|------|
| 1218 | Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research. 1995 , 1, 128-154 | 1 |
| 1217 | A Plea for Standardization of Biomarker Assays in the Study of High Risk, Premalignant and Malignant Breast Disease. 1995 , 1, 199-201 | 2 |
| 1216 | Epidermal growth factor-related peptides and their receptors in human malignancies. 1995 , 19, 183-232 | 2150 |
| 1215 | Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug. 1995 , 2, 223-7 | 57 |
| 1214 | High-dose therapy for breast cancer. 1995 , 9, 191-200 | 7 |
| 1213 | Selective inhibition of the tyrosine kinase pp60src by analogs of 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one. 1995 , 5, 1007-1010 | 27 |
| 1212 | Detection of neu differentiation factor with a biospecific affinity sensor during chromatography. 1995 , 705, 163-9 | 0 |
| 1211 | Proliferative indices and oncoprotein expression in benign and malignant breast biopsies. 1995 , 2, 416-23 | 8 |
| 1210 | Type 1 growth factor receptors: an overview of recent developments. 1995 , 4, 11-18 | 21 |
| 1209 | Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. 1995 , 6, 349-55 | 48 |
| 1208 | SH2 and SH3 domains: potential targets for anti-cancer drug design. 1995 , 34, 125-32 | 67 |
| 1207 | Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. 1995 , 6, 135-45 | 48 |
| 1206 | Characterization of cell surface antigens expressed in the HMA-1 breast cancer cell line. 1995 , 25, 244-50 | 4 |
| 1205 | Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. 1995 , 17, 15-21 | 51 |
| 1204 | Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. 1995 , 18, 15-23 | 20 |
| 1203 | Subject Index Vol. 52,1995. 1995 , 52, 519-520 | |
| 1202 | Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.. 1995 , 14, 4267-4275 | 279 |
| 1201 | Mouse mammary tumors express elevated levels of RNA encoding the murine homology of SKY, a putative receptor tyrosine kinase. 1995 , 270, 6872-80 | 48 |

| | | |
|------|---|-----|
| 1200 | Biosynthetic processing of neu differentiation factor. Glycosylation trafficking, and regulated cleavage from the cell surface. 1995 , 270, 19188-96 | 74 |
| 1199 | Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. 1995 , 13, 1129-35 | 250 |
| 1198 | Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. 1995 , 13, 2094-103 | 241 |
| 1197 | A novel type of unstable homogeneously staining region with a head-to-tail arrangement: spontaneous decay and reintegration of DNA elements into a plethora of new chromosomal sites. 1995 , 68, 33-8 | 1 |
| 1196 | Regulation of her2/neu gene-expression (review). 1995 , 2, 497-503 | 8 |
| 1195 | Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. 1995 , 75, 1320-6 | 94 |
| 1194 | Genetics of Colorectal and Breast Cancer. 1995 , 15, 957-971 | 4 |
| 1193 | Prediction of Recurrence for Advanced Breast Cancer. 1995 , 4, 601-632 | 10 |
| 1192 | Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. 1995 , 270, 7061-7 | 65 |
| 1191 | Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. 1995 , 92, 3353-7 | 132 |
| 1190 | G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). 1995 , 4, 415-21 | 27 |
| 1189 | Application of a simplified comparative genomic hybridization technique to screen for gene amplification in pediatric solid tumors. 1995 , 15, 831-44 | 16 |
| 1188 | Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. 1995 , 270, 25715-21 | 182 |
| 1187 | c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. 1995 , 48, 129-32 | 51 |
| 1186 | c-Myb repression of c-erbB-2 transcription by direct binding to the c-erbB-2 promoter. 1995 , 270, 9384-9 | 44 |
| 1185 | HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. 1995 , 121, 1265-70 | 68 |
| 1184 | Pyrimidine nucleoside phosphorylase-activity and biological characteristics of breast-cancer. 1995 , 7, 1139-44 | |
| 1183 | Rodent p53 suppresses the transforming activity of the activated Neu oncogene by modulating the Basal promoter activity of Neu. 1995 , 6, 1087-92 | 1 |

| | | |
|------|--|-----|
| 1182 | Activation of C-myc, C-Neu and int-2 oncogenes in the transformation of the human breast epithelial-cell line mcf-10f treated with chemical carcinogens in-vitro. 1995 , 6, 963-8 | 2 |
| 1181 | Genome scanning using endogenous LTR-like elements for rapid DNA-fingerprinting of breast-cancer and transformed human breast epithelial-cells. 1995 , 7, 25-31 | |
| 1180 | P53 and C-erbb-2 alterations in in-situ and invasive ductal breast carcinomas - a genetic and immunohistochemical analysis. 1995 , 7, 343-7 | 2 |
| 1179 | Induction of tumorigenicity by galectin-3 in a nontumorigenic human breast-carcinoma cell-line. 1995 , 7, 1079-87 | 21 |
| 1178 | Role of p53 in mcf-10f cell immortalization and chemically-induced neoplastic transformation. 1995 , 7, 1289-96 | 2 |
| 1177 | Engineering disulfide-linked single-chain Fv dimers [(sFv') ₂] with improved solution and targeting properties: anti-digoxin 26-10 (sFv') ₂ and anti-c-erbB-2 741F8 (sFv') ₂ made by protein folding and bonded through C-terminal cysteinyl peptides. 1995 , 8, 301-14 | 40 |
| 1176 | Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. 1995 , 160, 221-66 | 36 |
| 1175 | Hormonal modulation of neu-induced mammary carcinogenesis: evidence against a single-step induction of mammary cancer by neu. 1995 , 16, 1455-9 | 5 |
| 1174 | Post-translational processing of membrane-associated neu differentiation factor proisoforms expressed in mammalian cells. 1995 , 270, 4775-83 | 36 |
| 1173 | Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85. 1995 , 270, 19022-7 | 43 |
| 1172 | Prognostic Factors in Cancer. 1995 , | 30 |
| 1171 | Immunoconjugates and immunotoxins for therapy of carcinomas. 1995 , 33, 349-88 | 10 |
| 1170 | Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. 1995 , 16, 311-7 | 47 |
| 1169 | Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. 1995 , 9, 882-95 | 219 |
| 1168 | Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives. 1995 , 38, 4693-703 | 7 |
| 1167 | Genomic instability and cancer. 1995 , 337, 1-7 | 69 |
| 1166 | Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. 1995 , 1, 1-19 | 66 |
| 1165 | The use of anthracyclines in the adjuvant treatment of breast cancer. 1995 , 21, 199-214 | 3 |

| | | |
|------|---|-----|
| 1164 | HER-2/neu-targeting gene therapy--a review. 1995 , 159, 65-71 | 58 |
| 1163 | Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. 1995 , 159, 11-8 | 152 |
| 1162 | Genetic changes in breast cancer--consequences for therapy?. 1995 , 159, 59-63 | 4 |
| 1161 | The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes--a review. 1995 , 159, 83-96 | 230 |
| 1160 | Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. 1995 , 159, 35-42 | 36 |
| 1159 | The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. 1995 , 159, 19-27 | 217 |
| 1158 | Growth factors and their receptors in neoplastic mammary glands. 1995 , 49, 389-99 | 28 |
| 1157 | Chromosome mapping of human (ZNF147) and mouse genes for estrogen-responsive finger protein (efp), a member of the RING finger family. 1995 , 25, 581-3 | 11 |
| 1156 | Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. 1995 , 25, 130-8 | 75 |
| 1155 | HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. 1995 , 85, 729-34 | 75 |
| 1154 | Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. 1995 , 26, 210-6 | 80 |
| 1153 | neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. 1995 , 26, 601-6 | 34 |
| 1152 | Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. 1995 , 373, 245-9 | 115 |
| 1151 | Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. 1995 , 173, 1829-34 | 17 |
| 1150 | EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. 1995 , 21, 167-78 | 27 |
| 1149 | Modellsysteme für die Untersuchung genetischer Faktoren in der Krebsentstehung. 1995 , 82, 209-218 | 2 |
| 1148 | Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. 1995 , 34, 499-504 | 73 |
| 1147 | The Immunology of Breast Cancer. 1995 , 4, 279-300 | 2 |

| | | |
|------|---|------|
| 1146 | CD44 variant exon epitopes in primary breast cancer and length of survival. 1995 , 345, 615-9 | 321 |
| 1145 | Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. 1995 , 191, 1122-32 | 11 |
| 1144 | Adjuvant chemotherapy in the node-negative breast cancer patient. 1996 , 76, 327-41 | 8 |
| 1143 | Detection of C-ERBB-2 Amplification in Transitional Cell Bladder Carcinoma Using Competitive PCR Technique. 1996 , 156, 2089-2093 | 29 |
| 1142 | Sensitivity of breast and ovarian cancer cells for interferons (IFNs) and retinoids. 1996 , 784, 294-303 | |
| 1141 | Hormonal control of growth factor receptor expression. 1996 , 784, 336-48 | 6 |
| 1140 | Rate-determining steps for tyrosine phosphorylation by the kinase domain of v-fps. 1996 , 35, 1533-9 | 27 |
| 1139 | The erbB oncogenes as prognostic markers in oral squamous cell carcinomas. 1996 , 172, 681-3 | 37 |
| 1138 | Real time quantitative PCR. 1996 , 6, 986-94 | 4222 |
| 1137 | Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. 1996 , 32A, 134-40 | 8 |
| 1136 | Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. 1996 , 32A, 231-4 | 32 |
| 1135 | DNA amplification on chromosome 3q26.1-q26.3 in squamous cell carcinoma of the lung detected by reverse chromosome painting. 1996 , 32A, 1205-8 | 40 |
| 1134 | Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. 1996 , 32A, 1148-55 | 32 |
| 1133 | Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. 1996 , 99, 185-9 | 52 |
| 1132 | Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. 1996 , 226, 214-22 | 125 |
| 1131 | Prognostic significance of c-erbB-2 mRNA in ovarian carcinoma. 1996 , 62, 268-77 | 43 |
| 1130 | p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression. 1996 , 221, 140-5 | 25 |
| 1129 | Changes of expressions of phosphotyrosine phosphatases in rat hepatocellular carcinoma induced by 3'-methyl-4-dimethylamino-azobenzene. 1996 , 227, 406-12 | 6 |

| | | |
|------|---|-----|
| 1128 | Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. 1996 , 15, 749-57 | 11 |
| 1127 | The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. 1996 , 27, 955-63 | 38 |
| 1126 | Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. 1996 , 27, 119-24 | 170 |
| 1125 | Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. 1996 , 98, 151-155 | 23 |
| 1124 | Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry. 1996 , 32A, 2334-41 | 12 |
| 1123 | The biochemistry of metastasis. 1996 , 32, 135-66 | 34 |
| 1122 | The effects of dihydrotestosterone on the expression of p185(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP. 1996 , 59, 441-7 | 13 |
| 1121 | Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides. 1996 , 6, 9-16 | 22 |
| 1120 | . 1996 , | 49 |
| 1119 | Section Reviews: Biologicals & Immunologicals: Extracellular matrix components and their receptors as targets for therapeutic intervention in inflammation and metastasis. 1996 , 5, 1117-1126 | |
| 1118 | Biomarker expression in prostatic intraepithelial neoplasia. 1996 , 30, 153-66 | 45 |
| 1117 | The Role of Biomarkers in Detecting Early Changes Relating to Exposure to Occupational Carcinogens. 1996 , 38, 170-178 | 4 |
| 1116 | Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. 1996 , 53, 192-7 | 27 |
| 1115 | ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.. 1996 , 15, 254-264 | 441 |
| 1114 | C-erb B2 oncoprotein expression. Correlation with the Ki-67 labeling index and AgNOR counts in breast carcinoma on fine needle aspiration cytology. 1996 , 40, 1217-20 | 5 |
| 1113 | c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. 1996 , 14, 2702-8 | 332 |
| 1112 | A polymerase chain reaction-based assay for the rapid detection of gene amplification in human tumors. 1996 , 5, 147-50 | 26 |
| 1111 | Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. 1996 , 16, 5726-36 | 125 |

| | | |
|------|---|-----|
| 1110 | Estudio de la expresi3n del ant3geno nuclear de proliferaci3n celular y p185 en el carcinoma no microc3nico de pulm3n. 1996 , 32, 165-169 | 1 |
| 1109 | Variations in c-erbB-2 proto-oncogene status in breast cancer tumors as detected by two different cDNA probes. 1996 , 5, 181-6 | 3 |
| 1108 | [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]. 1996 , 56, 177-83 | 4 |
| 1107 | Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of alpha2-integrin expression in human mammary epithelial cells. 1996 , 16, 6178-89 | 59 |
| 1106 | Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. 1996 , 85, 634-41 | 59 |
| 1105 | Hereditary onset of multiple seborrheic keratoses: a variant of Leser Tr3lat sign?. 1996 , 23, 191-5 | 3 |
| 1104 | A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. 1996 , 16, 5276-87 | 829 |
| 1103 | Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. 1996 , 74, 1749-56 | 154 |
| 1102 | Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. 1996 , 93, 3636-41 | 649 |
| 1101 | Receptor protein tyrosine kinases. 265-284 | 1 |
| 1100 | An inbred colony of oncogene transgenic mice: diversity of tumours and potential as a therapeutic model. 1996 , 73, 65-72 | 8 |
| 1099 | A tyrosine kinase profile of prostate carcinoma. 1996 , 93, 5958-62 | 187 |
| 1098 | Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer. 1996 , 35, 23-30 | 5 |
| 1097 | Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. 1996 , 40, 164-73 | 52 |
| 1096 | Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. 1996 , 88, 8-16 | 64 |
| 1095 | Incidence of homogeneously staining regions in non-Hodgkin lymphomas. 1996 , 87, 1-3 | 17 |
| 1094 | Isolation and structural characterization of recombinant human neu differentiation factor expressed in Escherichia coli. 1996 , 1292, 168-76 | 7 |
| 1093 | Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. 1996 , 26, 501-7 | 13 |

| | | |
|------|--|-----|
| 1092 | Decreased expression of the DCC gene in human breast carcinoma. 1996 , 26, 900-3 | 10 |
| 1091 | The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. 1996 , 122, 118-21 | 6 |
| 1090 | The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. 1996 , 7, 79-86 | 14 |
| 1089 | Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. 1996 , 92, 70-4 | 63 |
| 1088 | The biology of mammary transgenes: five rules. 1996 , 1, 61-73 | 39 |
| 1087 | Preclinical testing of an anti-erbB-2 recombinant toxin. 1996 , 38, 19-25 | 15 |
| 1086 | The significance of heregulin in breast cancer tumor progression and drug resistance. 1996 , 38, 57-66 | 100 |
| 1085 | Transgenic mouse models of breast cancer. 1996 , 39, 119-35 | 43 |
| 1084 | Expression of L-PHA-binding proteins in breast cancer: reconstitution and molecular characterization of beta 1-6 branched oligosaccharides in three-dimensional cell culture. 1996 , 38, 313-24 | 11 |
| 1083 | FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. 1996 , 39, 203-12 | 48 |
| 1082 | Prognostic significance of c-erbB-2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis. 1996 , 39, 213-20 | 9 |
| 1081 | Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle. 1996 , 38, 227-35 | 39 |
| 1080 | Prognostic significance of serum c-erbB-2 protein in breast cancer patients. 1996 , 40, 251-5 | 63 |
| 1079 | Amplifications of oncogene erbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction. 1996 , 40, 271-81 | 9 |
| 1078 | Genetic analysis of breast cancer progression. 1996 , 1, 139-51 | 8 |
| 1077 | ErbB2 activation and signal transduction in normal and malignant mammary cells. 1996 , 1, 199-206 | 15 |
| 1076 | Overexpression of p53, c-erbB-2 and epidermal growth factor receptor in human breast carcinomas. 1996 , 46, 46-53 | 8 |
| 1075 | Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer. 1996 , 66, 64-70 | 12 |

| | | |
|------|---|-----|
| 1074 | HER-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China. 1996 , 22, 171-5 | 6 |
| 1073 | c-erbB-2/neu protein expression, DNA ploidy and S phase in breast cancer. 1996 , 29, 403-12 | 4 |
| 1072 | SAS is amplified predominantly in surface osteosarcoma. 1996 , 14, 700-5 | 24 |
| 1071 | c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. 1996 , 180, 383-8 | 207 |
| 1070 | ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. 1996 , 77, 71-8 | 174 |
| 1069 | Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. 1996 , 77, 490-8 | 176 |
| 1068 | Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri. 1996 , 77, 710-6 | 14 |
| 1067 | Serial serum c-erbB-2 levels in patients with breast carcinoma. 1996 , 78, 267-72 | 37 |
| 1066 | Biorecognition of antibodies in vivo: potential in drug targeting. 1996 , 9, 309-15 | 4 |
| 1065 | Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. 1996 , 65, 129-33 | 17 |
| 1064 | Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. 1996 , 69, 225-35 | 202 |
| 1063 | Microsatellite instability in sporadic human breast cancers. 1996 , 68, 447-51 | 40 |
| 1062 | ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. 1996 , 16, 130-7 | 18 |
| 1061 | Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. 1996 , 15, 227-38 | 23 |
| 1060 | The metastatic phenotype--prognostic implications. 1996 , 24, 71-96 | 11 |
| 1059 | Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. 1996 , 35, 751-7 | 70 |
| 1058 | Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. 1996 , 18, 185-98 | 10 |
| 1057 | Vectors for cancer gene therapy. 1996 , 15, 385-401 | 29 |

| | | |
|------|---|-----|
| 1056 | Invasion and metastasis. 1996 , 15, 77-89 | 68 |
| 1055 | Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. 1996 , 14, 95-106 | 24 |
| 1054 | Glutathione S-Transferase-pi Expression in Prechemotherapy and Postchemotherapy Tumor Samples from Patients with Locally Advanced Breast Carcinomas. 1996 , 2, 246-252 | 1 |
| 1053 | Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. 1996 , 87, 385-94 | 54 |
| 1052 | H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. 1996 , 2, 776-82 | 186 |
| 1051 | c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. 1996 , 73, 620-3 | 24 |
| 1050 | C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. 1996 , 74, 229-33 | 103 |
| 1049 | Differential expression of gp200-MR6 molecule in benign hyperplasia and down-regulation in invasive carcinoma of the breast. 1996 , 74, 1005-11 | 13 |
| 1048 | Immunohistochemical study of the proliferating ability and malignant potential of transitional cell carcinoma in the human urinary bladder. 1996 , 3, S32-4 | |
| 1047 | A Heterodimeric Nuclear Protein Complex Binds Two Palindromic Sequences in the Proximal Enhancer of the Human erbB-2 Gene. 1996 , 271, 5183-5188 | 10 |
| 1046 | Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. 1996 , 271, 18989-95 | 131 |
| 1045 | HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. 1996 , 271, 4813-8 | 70 |
| 1044 | Activated neu induces rapid tumor progression. 1996 , 271, 7673-8 | 103 |
| 1043 | Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. 1996 , 271, 22796-801 | 342 |
| 1042 | The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. 1996 , 271, 30897-903 | 96 |
| 1041 | ¹⁸⁶ Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with ¹²⁵ I and ¹³¹ I-labeled counterparts. 1996 , 11, 133-44 | 14 |
| 1040 | Association of signaling proteins with a nonmitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase-inactive p185c-neu. 1996 , 15, 31-40 | 9 |
| 1039 | Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. 1996 , 271, 7992-8 | 102 |

| | | |
|------|---|-----|
| 1038 | Transforming Growth Factor-alpha and c-erbB-2 Oncogene Products in Ovarian Epithelial Tumors. 1996 , 4, 129-135 | |
| 1037 | Regulated binding of PTP1B-like phosphatase to N-cadherin: control of cadherin-mediated adhesion by dephosphorylation of beta-catenin. 1996 , 134, 801-13 | 194 |
| 1036 | Mechanisms of preferential metastasis of breast cancer to bone - (Review). 1996 , 9, 103-9 | 4 |
| 1035 | Relationship between oncogene amplification, aneuploidy and altered expression of p53 in breast cancer. 1996 , 8, 359-65 | |
| 1034 | Immunohistochemical analysis of epidermal growth factor receptor (EGF-R) and c-erbB-2 and correlation with pathological prognostic variables in endometrial carcinomas. 1996 , 8, 1119-26 | |
| 1033 | HER-2/neu in bladder carcinoma. 1996 , 8, 957-61 | 1 |
| 1032 | Aberrant FGF-2, FGF-3, FGF-4 and C-erb-B2 gene copy number in human ovarian, breast and endometrial tumours. 1996 , 13, 19-35 | 13 |
| 1031 | Antibody binding sites. 1996 , 49, 329-450 | 17 |
| 1030 | Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. 1997 , 7, 391-417 | 25 |
| 1029 | Growth factors in lung cancer. 1997 , 355-380 | |
| 1028 | Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. 1997 , 27, 371-7 | 25 |
| 1027 | Karyotypic evolution of cells in culture: a new concept. 1998 , 178, 1-40 | 22 |
| 1026 | A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer. 1997 , 50, 254-6 | 5 |
| 1025 | Secondary dimerization between members of the epidermal growth factor receptor family. 1997 , 272, 12052-6 | 83 |
| 1024 | Cross-talk between phorbol ester-mediated signaling and tyrosine kinase proto-oncogenes. I. Activation of protein kinase C stimulates tyrosine phosphorylation and activation of ErbB2 and ErbB3. 1997 , 272, 31172-81 | 27 |
| 1023 | Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. 1997 , 89, 1505-15 | 107 |
| 1022 | Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. 1997 , 272, 14110-4 | 85 |
| 1021 | 1.6 Genetic Engineering of Antibodies and Derivatives from Mammalian Cells. | |

| | | |
|------|--|-----|
| 1020 | Proto-oncogene products as target antigens for cancer vaccines. 1997 , 11, 863-8 | 1 |
| 1019 | Immunoliposomes for cancer treatment. 1997 , 40, 399-435 | 78 |
| 1018 | Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase. 1997 , 272, 33298-304 | 23 |
| 1017 | The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase. 1997 , 272, 12158-63 | 20 |
| 1016 | Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7. 1997 , 272, 8490-7 | 65 |
| 1015 | HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. 1997 , 272, 29482-6 | 51 |
| 1014 | Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). 1997 , 89, 1524-9 | 35 |
| 1013 | A c-erbB-2 promoter-specific nuclear matrix protein from human breast tumor tissues mediates NF-kappaB DNA binding activity. 1997 , 272, 15715-20 | 20 |
| 1012 | Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. 1997 , 4, 75-84 | |
| 1011 | HER2-targeted gene transfer. 1997 , 8, 719-27 | 31 |
| 1010 | Biomarkers--the new frontier in the pathology of invasive and preinvasive neoplasias. 1997 , 72, 59-61 | 1 |
| 1009 | Oncogene Expression and Amplification in Barrett Adenocarcinoma. 1997 , 4, 203-211 | 2 |
| 1008 | Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: diagnostic and clinical implications. 1997 , 89, 1473-6 | 12 |
| 1007 | [New drugs in therapy of breast carcinoma: current status and outlook]. 1997 , 37, 54-61 | |
| 1006 | Serum erbB-2 in ductal carcinoma in situ of the breast--a marker of microinvasion?. 1997 , 36, 651-2 | 1 |
| 1005 | Mammalian Cell Biotechnology in Protein Production. 1997 , | 14 |
| 1004 | erbB signalling in clinical breast cancer: relationship to endocrine sensitivity. 1997 , 4, 297-305 | 3 |
| 1003 | Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. 1997 , 17, 5410-25 | 124 |

| | | |
|------|--|-----|
| 1002 | neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. 1997 , 17, 3155-63 | 89 |
| 1001 | In vivo effects of estrogens on c-erbB-2 oncoprotein levels in chorionic villous tissue and maternal serum. 1997 , 11, 237-41 | 2 |
| 1000 | HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. 1997 , 71, 343-71 | 119 |
| 999 | Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. 1998 , 72, 1-23 | 30 |
| 998 | Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. 1997 , 94, 14719-24 | 324 |
| 997 | Retinoid and Growth Factor Signal Transduction. 1997 , 3, 141-159 | |
| 996 | Growth factor receptor tyrosine kinases. 1997 , 17-76 | |
| 995 | c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. 1997 , 75, 1667-73 | 29 |
| 994 | Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. 1997 , 158, 245-7 | 42 |
| 993 | p53 and HER-2 alterations in renal cell carcinoma. 1997 , 50, 636-42 | 22 |
| 992 | Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities. 1997 , 53, 287-98 | 9 |
| 991 | Human adenovirus vectors for gene transfer into mammalian cells. 1997 , 40, 137-206 | 142 |
| 990 | Molecular cloning of human GRB-7 co-amplified with CAB1 and c-ERBB-2 in primary gastric cancer. 1997 , 232, 5-9 | 40 |
| 989 | Expression of the activated p185erbB2 tyrosine kinase in human epithelial cells leads to MAP kinase activation but does not confer oncogenicity. 1997 , 231, 251-9 | 6 |
| 988 | p53 and HER-2/neu overexpression in ovarian borderline tumors. 1997 , 65, 218-24 | 31 |
| 987 | Aromatase in the normal breast and breast cancer. 1997 , 61, 281-286 | 81 |
| 986 | c-erbB-3 protein expression in ductal carcinoma in situ of the breast. 1997 , 33, 1846-50 | 27 |
| 985 | Steroid hormones and cancer: (III) observations from human subjects. 1997 , 23, 163-77; quiz 177-8, 183 | 23 |

| | | |
|-----|--|-----|
| 984 | Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. 1997 , 23, 30-5 | 63 |
| 983 | Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. 1997 , 262, 99-119 | 33 |
| 982 | Altered gene expression in skin melanomas is correlated with the level of skin infiltration and metastatic spreading. 1997 , 9, 57-61 | |
| 981 | Cancer genes and molecular oncology in the clinic. 1997 , 349 Suppl 2, S116-8 | 7 |
| 980 | Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. 1997 , 71, 173-9 | 92 |
| 979 | Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. 1997 , 52, 109-18 | 99 |
| 978 | High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. 1997 , 15, 3363-7 | 279 |
| 977 | Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. 1997 , 15, 2518-25 | 196 |
| 976 | HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. 1997 , 15, 2894-904 | 662 |
| 975 | Phosphorylation-directed antibodies in high-flux screens for compounds that modulate signal transduction. 1997 , 23, 490-3 | 3 |
| 974 | Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. 1997 , 43, 2114-2120 | 19 |
| 973 | Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: a comparison of immunohistochemical method versus ligand binding assay. 1997 , 54, 220-5 | 14 |
| 972 | Role of c-Src tyrosine kinase in EGF-induced mitogenesis. 1997 , 2, d501-18 | 97 |
| 971 | A novel image cytometric method for quantitation of immunohistochemical staining of cytoplasmic antigens. 1997 , 14, 87-99 | 10 |
| 970 | Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of P53 product in the different ploidy classes. 1997 , 15, 31-45 | 10 |
| 969 | Elevated serum levels of the c-erbB-2 encoded oncoprotein fragment in cases of pure preeclampsia and HELLP syndrome. 1997 , 23, 213-7 | 3 |
| 968 | Clinicopathological characteristics of primary breast cancer in older geriatric women: a study of 39 Japanese patients over 80 years old. 1997 , 88, 693-9 | 6 |
| 967 | Prognostic Factors in Breast Cancer. 1997 , 3, 267-283 | 3 |

| | | |
|-----|---|-----|
| 966 | Altered gene expression in skin melanomas is correlated with the level of skin infiltration and metastatic spreading. 1997 , 9, 57-61 | |
| 965 | Identification of a cell surface protein with a role in stimulating human keratinocyte proliferation, expressed during development and carcinogenesis. 1997 , 109, 194-9 | 8 |
| 964 | The increasing efficacy of breast cancer treatment. 1997 , 9, 338-42 | 8 |
| 963 | Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. 1997 , 14, 1435-44 | 55 |
| 962 | Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. 1997 , 14, 1827-35 | 36 |
| 961 | A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. 1997 , 14, 2099-109 | 151 |
| 960 | The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. 1997 , 15, 537-47 | 284 |
| 959 | BRK tyrosine kinase expression in a high proportion of human breast carcinomas. 1997 , 15, 799-805 | 131 |
| 958 | Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. 1997 , 15, 953-60 | 82 |
| 957 | Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. 1997 , 15, 1385-94 | 83 |
| 956 | HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. 1997 , 15, 1513-25 | 137 |
| 955 | An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. 1997 , 15, 473-81 | 49 |
| 954 | Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. 1997 , 15, 2841-8 | 117 |
| 953 | Interleukin-6: an antagonizing problem becomes a solution. 1997 , 15, 952-3 | 2 |
| 952 | Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. 1997 , 75, 1674-7 | 6 |
| 951 | The molecular genetics of pancreatic cancer. 1997 , 6, 1-18 | 30 |
| 950 | c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma. 1997 , 47, 209-16 | 5 |
| 949 | Methodology for selection of human antibodies to membrane proteins from a phage-display library. 1997 , 204, 193-203 | 25 |

| | | |
|-----|--|-----|
| 948 | Molecular cytogenetic characterization of cancer cell alterations. 1997 , 93, 10-21 | 47 |
| 947 | Fluorescence in situ hybridization assessment of chromosome 8 copy number in stage I and stage II infiltrating ductal carcinoma of the breast. 1997 , 97, 101-5 | 24 |
| 946 | Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. 1997 , 7, 1002-5 | 63 |
| 945 | Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland. 1997 , 2, 175-85 | 13 |
| 944 | ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. 1997 , 2, 97-107 | 88 |
| 943 | Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia. 1997 , 2, 119-29 | 37 |
| 942 | Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma. 1997 , 66, 449-53 | 10 |
| 941 | Guidelines for systemic therapy of early stage breast cancer. 1997 , 43, 259-76 | 10 |
| 940 | Macromolecular interstitial clearance, tumour vascularity, other prognostic factors and breast cancer survival. 1997 , 42, 113-20 | 6 |
| 939 | Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. 1997 , 42, 1-5 | 81 |
| 938 | Possibilities of a viral etiology for human breast cancer. A review. 1997 , 56, 131-42 | 51 |
| 937 | Targeting signal transduction for disease therapy. 1997 , 14, 83-9 | 14 |
| 936 | Interphase cytogenetics in pathology: principles, methods, and applications of fluorescence in situ hybridization (FISH). 1997 , 108, 381-90 | 36 |
| 935 | Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. 1997 , 430, 365-72 | 38 |
| 934 | Identification of an amplified gene cluster in glioma including two novel amplified genes isolated by exon trapping. 1997 , 101, 190-7 | 18 |
| 933 | HER-2/neu signal transduction in human breast and ovarian cancer. 1997 , 15, 1-8 | 156 |
| 932 | Facts in cancer genetics. 1997 , 32, 9-17 | 3 |
| 931 | Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. 1997 , 183, 195-203 | 51 |

| | | |
|-----|--|-----|
| 930 | c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. 1997 , 30, 195-201 | 44 |
| 929 | Distinct characteristics of heregulin signals mediated by HER3 or HER4. 1997 , 173, 187-95 | 34 |
| 928 | Gene expression changes associated with chemically induced rat mammary carcinogenesis. 1997 , 20, 204-15 | 75 |
| 927 | Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. 1997 , 79, 513-520 | 34 |
| 926 | Mechanisms of bone metastasis. 1997 , 80, 1546-1556 | 418 |
| 925 | Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. 1997 , 70, 590-7 | 81 |
| 924 | Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. 1997 , 73, 875-9 | 48 |
| 923 | Common patterns of genetic evolution in human solid tumors. 1997 , 29, 1-27 | 100 |
| 922 | Determination of p185 and adenylosuccinate lyase (ASL) activity in preneoplastic colon lesions and intestinal mucosa of human subjects. 1998 , 31, 523-8 | 8 |
| 921 | Tumor oxygenation correlates with molecular growth determinants in breast cancer. 1998 , 48, 97-106 | 54 |
| 920 | A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. 1998 , 48, 21-32 | 37 |
| 919 | Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression. 1998 , 49, 119-28 | 33 |
| 918 | Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines. 1998 , 51, 71-81 | 12 |
| 917 | The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. 1998 , 17, 195-202 | 25 |
| 916 | Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. 1998 , 49, 195-208 | 77 |
| 915 | Molecular prognostic markers in breast cancer. 1998 , 52, 185-200 | 24 |
| 914 | The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. 1998 , 52, 43-53 | 74 |
| 913 | HER-2/neu as a predictive marker of response to breast cancer therapy. 1998 , 52, 65-77 | 210 |

| | | |
|-----|---|-----|
| 912 | Circulating tumor markers in breast cancer: accepted utilities and novel prospects. 1998 , 52, 239-59 | 67 |
| 911 | The relationship between prognostic and predictive factors in the management of breast cancer. 1998 , 52, 261-88 | 126 |
| 910 | c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. 1998 , 52, 55-64 | 44 |
| 909 | The role of oncogenes in drug resistance. 1998 , 27, 283-92 | 7 |
| 908 | A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. 1998 , 17, 3052-65 | 956 |
| 907 | Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. 1998 , 17, 3385-97 | 286 |
| 906 | Amplification and expression of the c-erbB-2 oncogene in Mullerian-derived genital-tract tumors. 1998 , 71, 165-71 | 6 |
| 905 | Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. 1998 , 5, 1538-44 | 39 |
| 904 | Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement. 1998 , 16, 179-90 | 24 |
| 903 | The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. 1998 , 16, 547-54 | 18 |
| 902 | The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. 1998 , 16, 301-10 | 64 |
| 901 | Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. 1998 , 16, 2087-94 | 112 |
| 900 | Overexpression of the RON gene in human breast carcinoma. 1998 , 16, 2927-33 | 172 |
| 899 | Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. 1998 , 17, 123-7 | 93 |
| 898 | Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. 1998 , 17, 425-32 | 42 |
| 897 | Active signaling by Neu in transgenic mice. 1998 , 17, 1877-84 | 47 |
| 896 | c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. 1998 , 17, 1949-57 | 106 |
| 895 | The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. 1998 , 17, 2087-93 | 77 |

| | | |
|-----|--|-----|
| 894 | Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. 1998 , 17, 2235-49 | 301 |
| 893 | The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. 1998 , 17, 2107-13 | 30 |
| 892 | Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. 1998 , 77, 1405-12 | 173 |
| 891 | Homogeneously staining regions in 223 breast carcinomas: cytogenetic and clinicopathological correlations. 1998 , 78, 1214-8 | 6 |
| 890 | Development of a new metastatic human breast carcinoma xenograft line. 1998 , 77, 595-604 | 3 |
| 889 | Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer. 1998 , 106, 1075-80 | 3 |
| 888 | Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. 1998 , 30, 219-227 | 27 |
| 887 | p53 protein expression in human breast cancer: an immunohistochemical study including correlation with steroid receptor status, proliferation indices, collagen type IV, laminin, C-erbB-2 oncoprotein and Cathepsin D. 1998 , 7, 42-48 | 1 |
| 886 | The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. 1998 , 1377, M25-37 | 72 |
| 885 | Histological and biological characteristics of microinvasion in mammary carcinomas 1998, 48, 800-5 | 8 |
| 884 | Immunohistochemical studies on expression of human vascular smooth muscle myosin heavy chain isoforms in normal mammary glands, benign mammary disorders and mammary carcinomas. 1998 , 48, 433-9 | 13 |
| 883 | Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions. 1998 , 48, 518-25 | 28 |
| 882 | Utilization of polymerase chain reaction technology in the detection of solid tumors. 1998 , 82, 1419-42 | 131 |
| 881 | Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. 1998 , 83, 2502-2508 | 62 |
| 880 | Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. 1998 , 76, 459-63 | 34 |
| 879 | Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. 1998 , 77, 937-41 | 52 |
| 878 | Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. 1998 , 78, 661-6 | 185 |
| 877 | Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). 1998 , 79, 580-7 | 40 |

| | | |
|-----|---|-----|
| 876 | Protein tyrosine kinases: structure, substrate specificity, and drug discovery. 1998 , 47, 197-223 | 66 |
| 875 | Prognostic significance of c-erbB-2 oncoprotein expression in intestinal-type adenocarcinoma of the sinonasal tract. 1998 , 20, 224-31 | 25 |
| 874 | Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate. 1998 , 12, 298-303 | 2 |
| 873 | Activation of c-Neu tyrosine kinase by o,p'-DDT and beta-HCH in cell-free and intact cell preparations from MCF-7 human breast cancer cells. 1998 , 12, 83-92 | 22 |
| 872 | Amplification of oncogenes in human cancer cells. 1998 , 20, 473-9 | 135 |
| 871 | Quantitative Structure-Activity Relationship of Flavonoid Inhibitors of p56lck Protein Tyrosine Kinase: A Classical/Quantum Chemical Approach. 1998 , 17, 07-13 | 4 |
| 870 | Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. 1998 , 185, 236-45 | 143 |
| 869 | Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. 1998 , 37, 36-43 | 82 |
| 868 | Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway. 1998 , 70, 587-95 | 22 |
| 867 | Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells. 1998 , 176, 383-91 | 12 |
| 866 | Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter. 1998 , 21, 2-12 | 39 |
| 865 | Involvement of tyrosine phosphorylation of p185c-erbB2/neu in tumorigenicity induced by x-rays and the neu oncogene in human breast epithelial cells. 1998 , 21, 225-233 | 34 |
| 864 | Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. 1998 , 21, 261-72 | 129 |
| 863 | Radiation-induced tumorigenesis in preneoplastic mouse mammary glands in vivo: significance of p53 status and apoptosis. 1998 , 22, 199-207 | 15 |
| 862 | A novel splice variant of HER2 with increased transformation activity. 1998 , 23, 62-8 | 111 |
| 861 | Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. 1998 , 5, 743-50 | 36 |
| 860 | Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. 1998 , 5, 64-76 | 26 |
| 859 | Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors. 1998 , 17, 179-89 | 8 |

| | | |
|-----|---|-----|
| 858 | Lipid-Secreting Carcinoma of the Breast: A Case Report and Review of the Literature. 1998 , 5, 171-173 | 9 |
| 857 | Antisense strategies for the treatment of hematological malignancies and solid tumors. 1998 , 77, 1-12 | 19 |
| 856 | The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv. 1998 , 76, 451-8 | 12 |
| 855 | The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. 1998 , 16, 413-28 | 574 |
| 854 | In vitro and in vivo behaviour of NDF-expanded monkey Schwann cells. 1998 , 10, 291-300 | 34 |
| 853 | Molecular Distinction Between Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ. 1998 , 4, 336-343 | |
| 852 | Genetic alterations in endometrial carcinomas. 1998 , 8, 415-422 | 3 |
| 851 | c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. 1998 , 33, 325-31 | 53 |
| 850 | p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression. 1998 , 33, 522-30 | 12 |
| 849 | Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. 1998 , 93, 192-9 | 48 |
| 848 | Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. 1998 , 49, 629-37 | 18 |
| 847 | Changes in heregulin beta1 (HRGbeta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line. 1998 , 138, 163-71 | 6 |
| 846 | Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. 1998 , 16, 823-33 | 34 |
| 845 | Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis. 1998 , 50, 359-62 | 8 |
| 844 | Characterisation of benign lesions and carcinomas of the female breast in a sub-Saharan African population. 1998 , 194, 623-9 | 14 |
| 843 | High-dose chemotherapy: how resistant is breast cancer?. 1998 , 1, 62-72 | 14 |
| 842 | Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. 1998 , 34, 476-81 | 20 |
| 841 | ERBB2 oncogene in human breast cancer and its clinical significance. 1998 , 34, 791-808 | 346 |

| | | |
|-----|--|----------|
| 840 | Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. 1998 , 34, 2076-81 | 76 |
| 839 | Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. 1998 , 2, 581-91 | 311 |
| 838 | Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. 1998 , 27, 209-12 | 20 |
| 837 | Overexpression of cyclin-D1, bcl-2, and bax proteins, proliferating cell nuclear antigen (PCNA), and DNA-ploidy in squamous cell carcinoma of the oral cavity. 1998 , 29, 1189-94 | 40 |
| 836 | Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. 1998 , 66, 1159-63; discussion 1163-4 | 51 |
| 835 | Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. 1998 , 16, 102-26 | 22 |
| 834 | Increasing complexity of the Ras signaling pathway. 1998 , 273, 19925-8 | 438 |
| 833 | Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. 1998 , 273, 28238-46 | 227 |
| 832 | Identification of a novel AP-2 consensus DNA binding site. 1998 , 243, 307-16 | 16 |
| 831 | Targeting human breast cancer cells that overexpress HER-2/neu mRNA by an antisense iron responsive element. 1998 , 246, 353-8 | 3 |
| 830 | Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. 1998 , 50, 331-40 | 72 |
| 829 | Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. 1998 , 153, 1797-806 | 49 |
| 828 | Reovirus therapy of tumors with activated Ras pathway. <i>Science</i> , 1998 , 282, 1332-4 | 33.3 556 |
| 827 | Determination of cytosol c-erbB-2 protein in breast cancer by sandwich enzyme immunoassay. 1998 , 28, 92-6 | 6 |
| 826 | Cloning and characterization of Krct, a member of a novel subfamily of serine/threonine kinases. 1998 , 7, 2157-66 | 19 |
| 825 | Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. 1998 , 55, 475-81 | 88 |
| 824 | Treatment of breast cancer. 1998 , 339, 974-84 | 576 |
| 823 | Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. 1998 , 139, 4756-64 | 71 |

| | | |
|-----|---|-----|
| 822 | Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression. 1998 , 17, 335-42 | 42 |
| 821 | Genetic and epigenetic regulation of human breast cancer progression and metastasis. 1998 , 5, 155-197 | 22 |
| 820 | Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?. 1998 , 90, 1320-1 | 55 |
| 819 | Editorial. 1998 , 11, 1-1 | |
| 818 | CGH-detected DNA sequence copy number amplifications can be confirmed by interphase-FISH: new possibilities for prognostic approaches in oral squamous cell carcinomas. 1998 , 2, 555-60 | 8 |
| 817 | c-erbB-2 status is an independent predictor of survival after first recurrence. 1998 , 12, 123-8 | 1 |
| 816 | Biomarkers in Barrett's esophagus (review). 1998 , 13, 855-64 | 5 |
| 815 | Gene Analysis in Solid Tumors: In Situ Hybridization. 1998 , 21, 327-333 | 1 |
| 814 | Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. 1998 , 8, 425-442 | 18 |
| 813 | ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. 1998 , 95, 6809-14 | 91 |
| 812 | SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression. 1998 , 77, 1448-53 | 9 |
| 811 | Prognostic value of histological and biological markers in pharyngeal squamous cell carcinoma: a case-control study. 1998 , 77, 1932-6 | 11 |
| 810 | Stem cells in breast epithelia. 1998 , 79, 193-206 | 23 |
| 809 | Antisense- and antigene-based drug design strategies in oncology. 1998 , 227-266 | 1 |
| 808 | Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. 1998 , 16, 2659-71 | 881 |
| 807 | Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. 1998 , 55, 548-55 | 90 |
| 806 | Histological features and prognosis of patients with mucoepidermoid carcinoma of the parotid gland. 1998 , 112, 944-7 | 22 |
| 805 | Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells. 1998 , 330 (Pt 1), 241-6 | 9 |

| | | |
|-----|---|-----|
| 804 | Detection of c-erbB-2 mRNAs using dig-labelled oligonucleotide probe with in situ hybridisation in human breast carcinoma: comparison with immunohistochemical results. 1998 , 16, 201-9 | 11 |
| 803 | Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. 1998 , 16, 2409-16 | 58 |
| 802 | Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. 1998 , 66, 59-63 | 24 |
| 801 | The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. 1998 , 3, 237-252 | 273 |
| 800 | Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation. 1998 , 92, 1471-1490 | 264 |
| 799 | Expression of the ErbB Family of Receptors in Ovarian Cancer. 1998 , 5, 161-165 | 10 |
| 798 | Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. 1998 , 19, 364-73 | 16 |
| 797 | Overexpression of c-erbB-3 in various stages of human squamous cell carcinomas. 1998 , 55, 161-7 | 25 |
| 796 | Genetic alterations in head and neck squamous cell carcinomas. 1999 , 32, 897-904 | 24 |
| 795 | Biologic Approaches to Managing Advanced Breast Cancer. 1999 , 6, 7-11 | 3 |
| 794 | C-erbB-2 Expression in Primary Breast Cancer. 1999 , 14, 16-26 | 19 |
| 793 | HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer. 1999 , 6, 233-240 | 18 |
| 792 | Clinical use of serum c-erbB-2 in patients with ovarian masses. 1999 , 48, 133-7 | 13 |
| 791 | Quantitation of c-erbB-2 gene amplification in breast cancer tissue by competitive PCR. 1999 , 20, 153-61 | 6 |
| 790 | Identification of different gene expression patterns in low and high grade non-Hodgkin's lymphomas by differential display. 1999 , 33, 343-50 | 5 |
| 789 | Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. 1999 , 17, 1983-7 | 391 |
| 788 | Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?. 1999 , 17, 3653-63 | 82 |
| 787 | Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. 1999 , 17, 1974-82 | 254 |

| | | |
|-----|---|-----|
| 786 | Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. 1999 , 17, 2180-9 | 127 |
| 785 | Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. 1999 , 45, 1442-53 | 187 |
| 784 | Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications. 1999 , 45, 1148-1156 | 216 |
| 783 | The 3rd Annual NIH Symposium on Therapeutic Oligonucleotides. Bethesda, Maryland, USA. December 4, 1998. Abstracts. 1999 , 9, 359-431 | 6 |
| 782 | Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer. 1999 , 14, 1021-37 | 7 |
| 781 | HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. 1999 , 14, 663-71 | 12 |
| 780 | Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. 1999 , 14, 1111-6 | 10 |
| 779 | Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. 1999 , 15, 525-33 | 30 |
| 778 | erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. 1999 , 140, 3615-22 | 42 |
| 777 | Concepts in Ras-directed therapy. 1999 , 8, 2121-2140 | 43 |
| 776 | HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization. 1999 , 1, 98-103 | 11 |
| 775 | Receptor tyrosine kinase and p16/CDKN2 expression in a case of tripe palms associated with non-small-cell lung cancer. 1999 , 199, 290-5 | 1 |
| 774 | Serum c-erbB-2 levels in monitoring of operable breast cancer patients. 1999 , 29, 336-9 | 18 |
| 773 | Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. 1999 , 91, 2096-101 | 113 |
| 772 | Immunohistochemical detection of erbB-4 expression in extramammary Paget's disease. 1999 , 79, 172 | 1 |
| 771 | Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas. 1999 , 38, 931-8 | 19 |
| 770 | Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide. 1999 , 20, 229-36 | 22 |
| 769 | Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. 1999 , 10, 1621-36 | 156 |

| | | |
|-----|--|-----|
| 768 | Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. 1999 , 96, 1415-20 | 401 |
| 767 | Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. 1999 , 274, 574-83 | 27 |
| 766 | Molecular genetics and the assessment of human cancers. 1999 , 1999, 1-19 | |
| 765 | A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2. 1999 , 274, 859-66 | 24 |
| 764 | New developments in chemotherapy of advanced breast cancer. 1999 , 10, S139-S146 | 11 |
| 763 | An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. 1999 , 274, 5263-6 | 150 |
| 762 | c-Src, receptor tyrosine kinases, and human cancer. 1999 , 76, 61-119 | 185 |
| 761 | The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples. 1999 , 37, 649-54 | 6 |
| 760 | Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. 1999 , 27, 4008-17 | 74 |
| 759 | Growth factor signal transduction and hormone independence in breast cancer. 1999 , 2, 11-80 | |
| 758 | Herceptin: breaking new ground. 1999 , 14, 1-4 | 6 |
| 757 | HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. 1999 , 3, 237-42 | 11 |
| 756 | Regulation of the c-met proto-oncogene promoter by p53. 1999 , 274, 3565-72 | 41 |
| 755 | The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. 1999 , 96, 10869-74 | 101 |
| 754 | Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors. 1999 , 94, 1933-40 | 79 |
| 753 | Translational control by an upstream open reading frame in the HER-2/neu transcript. 1999 , 274, 24335-41 | 85 |
| 752 | A model-based approach for assessing in vivo combination therapy interactions. 1999 , 96, 13023-8 | 18 |
| 751 | A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. 1999 , 274, 15633-45 | 179 |

| | | |
|-----|---|----|
| 750 | Biological basis of genetic predisposition to breast cancer. 1999 , 2, 137-158 | 1 |
| 749 | Chemosensitivity testing of oral cancer cells treated with a p185neu-specific agent. 1999 , 107, 338-43 | 2 |
| 748 | Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. 1999 , 45, 73-83 | 54 |
| 747 | Molecular detection of minimal residual disease in colorectal and breast cancer. 1999 , 34, 385-90 | 13 |
| 746 | Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems. 1999 , 5, 369-374 | 52 |
| 745 | Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors. 1999 , 889, 45-51 | 22 |
| 744 | Anti-HER2 immunoliposomes for targeted drug delivery. 1999 , 886, 293-6 | 16 |
| 743 | Molecular Medicine and Personalized Therapy for Breast Cancer Patients. 2015 , 321-334 | |
| 742 | Early Breast Cancers. 2015 , 61-112 | |
| 741 | Management of Metastatic Breast Cancer. 2015 , 473-497 | |
| 740 | The Cancer Cell-Kill Paradigm and Beyond. 2015 , 101-128 | |
| 739 | Liver Metastases from Breast Cancer. 2015 , 15-31 | |
| 738 | Targeted Therapies. 2015 , 345-352 | |
| 737 | Lack of prognostic value of human epidermal growth factor-like receptor 2 status in inflammatory breast cancer (IBC): a meta-analysis. 2014 , 15, 9615-9 | 2 |
| 736 | A modern paradigm for treating HER2-positive advanced breast cancer: Dual HER2 blockade and antibody-drug conjugates. 2015 , 4, 78 | |
| 735 | Cytokine Networks and Cancer Stem Cells. 2015 , 67-87 | 1 |
| 734 | Copy Number Changes in Carcinomas: Applications. 2015 , 95-104 | |
| 733 | Molecular targeted therapy of breast cancer. 2015 , 18, 65-69 | |

- 732 The EGFR/ERBB Receptor Family. **2015**, 107-164 0
- 731 The Role of Pharmacogenomics in Individualized Medicine. **2015**, 93-112 0
- 730 Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy. **2015**, 119-136
- 729 Anti-HER2/neu Therapy in DCIS. **2015**, 99-108
- 728 Expression of growth factor receptor family before and after targeted therapy in human epidermal growth factor receptor-2 positive breast cancer tissues. **2015**, 11, 12-19 1
- 727 Tumors of the breast. 426-446
- 726 Adjuvant Systemic Treatment for Breast Cancer: An Overview. **2016**, 311-321
- 725 HER2-Targeted Therapy. **2016**, 391-410
- 724 Molecular Targeted Anticancer Drugs. **2016**, 175-238
- 723 Metastatic Breast Cancer. **2016**, 451-474
- 722 Histopathological Investigation of Nuclear Y-box Binding Protein-1 Expression in Salivary Gland Carcinoma. **2016**, 147, 102-104
- 721 Overview. **2016**, 1284-1302.e3 1
- 720 Systemic Therapy. **2016**, 335-390
- 719 Breast Cancer. **2016**, 433-446
- 718 Introduction. **2016**, 1-12
- 717 Cardiotoxicity in Breast Cancer Survivors. **2016**, 193-212
- 716 Introduction and background biology. **2016**, 1-13
- 715 Concepts in Pharmacogenomics and Personalized Medicine. **2016**, 1-32

714 Adjuvant Therapy for HER2-Positive Early Breast Cancer. **2016**, 189-203

713 Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. **2016**, 27-107

712 Screening of Clinical Practice in Management of Progression on Trastuzumab in metastatic breast cancer. **2016**, 5,

711 An Overview of Cancer Genes. **2017**, 121-142

710 Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. **2017**, 709-726

709 An evolving cancer instigates clonally unrelated neighboring cells to form distant metastases.

708 Small Molecule Inhibitors. **2017**, 771-795

707 A STUDY OF EXPRESSION OF HER2/NEU IN CARCINOMA BREAST WITH REFERENCE TO CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC INDEX. **2016**, 5, 6726-6732

706 Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. **2017**, 1-31

705 Targeted Therapies and Immunotherapy in Bladder Cancer. **2017**, 111-122

704 Cardiotoxicity in Long-Term Survivors. **2017**, 291-308

703 Therapeutische Grundlagen in der gyn&ologischen Onkologie. **2017**, 183-253

702 Clinical study of anti-androgen therapy for advanced salivary duct carcinoma with androgen receptor. **2017**, 43, 49-55

701 Molecular Techniques in Immunopathology. **2017**, 585-600

1

700 Concurrent Use of Radiation Therapy and Targeted Molecules in the Breast Cancer Treatment. **2017**, 645-653

699 Valutazione Economica Dell'impatto Organizzativo di Differenti Tecniche di Ibridazione in Situ per la Determinazione Dello Stato di HER2 nel Carcinoma Alla Mammella. **2017**, 4, grhta.5000265

698 Encyclopedia of Cancer. **2017**, 2053-2055

697 Cancer Genomics and Precision Medicine: A Way Toward Early Diagnosis and Effective Cancer Treatment. **2017**, 31-41

- 696 ~~HER2~~-~~MINISOG~~ ~~2017~~, 106
- 695 HER2-Positive Esophagogastric Junction Adenocarcinoma with Lung and Para-Aortic Lymph Node Metastases Treated with Conversion Surgery Following the Administration of a Trastuzumab Containing Chemotherapy Regimen: A Case Report. **2017**, 41, 929-934
- 694 Targeted genomic screen reveals focal long non-coding RNA copy number alterations in cancer.
- 693 miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
- 692 Systems-level Analysis of 32 TCGA Cancers Reveals Disease-dependent tRNA Fragmentation Patterns and Very Selective Associations with Messenger RNAs and Repeat Elements.
- 691 Comparison of Estrogen, Progesterone and Her2 Receptors in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical Study. **2017**, 10,
- 690 CORRELATION OF HER2/NEU EXPRESSION AND HISTOPATHOLOGICAL GRADING AND STAGING OF COLORECTAL CARCINOMAS. **2017**, 6, 4407-4411 1
- 689 A Pan-Cancer Transcriptome Analysis Reveals Pervasive Regulation through Tumor-Associated Alternative Promoters. 3
- 688 A comparison of breast cancer survival among young, middle-aged, and elderly patients in southern Iran using Cox and empirical Bayesian additive hazard models. **2017**, 39, e2017043 3
- 687 HER-2 ONCOPROTEIN EXPRESSION IN UROTHELIAL CARCINOMA. **2017**, 6, 5985-5990
- 686 HER-2/NEU EXPRESSION IN STOMACH AND GASTRO-OESOPHAGEAL JUNCTION CARCINOMA IN ENDOSCOPIC BIOPSY SPECIMENS. **2017**, 6, 6123-6126
- 685 Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. **2017**, 5, 57-63
- 684 The reliability of assessment of Ki-67 and HER-2/neu expression on breast carcinoma agarose cell blocks. **2017**, 37, 221-227 1
- 683 A comparative study of HER-2 status evaluation in breast carcinoma by silver in-situ hybridization and fluorescence in-situ hybridization using ASCO/CAP guidelines. **2017**, 37, 328-332
- 682 Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer. **2018**, 39, 79-87
- 681 Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective. **2018**, 39, 368
- 680 Profiling copy number alterations in cell-free tumour DNA using a single-reference.
- 679 An In-Vivo Investigation of the Cardio-Protective Potential of Aspirin, Ebestradiol and Calcipotriol for Trastuzumab Treatment of Her-2 Positive Breast Cancer. **2018**, 11, 123-139

678 SORLA-driven endosomal trafficking regulates the oncogenic fitness of HER2.

677 Incidence and Risk Factors of the Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab. **2018**, 35, 177-183

676 Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results. **2018**, 6, 1-10

675 Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. **2018**, 14, 160-165 2

674 COMPARISON OF THE HISTOPATHOLOGICAL AND CLINICAL PROGNOSTIC PARAMETERS IN HUMAN EPIDERMAL GROWTH FACTOR 2 (HER2) 2+/AMPLIFIED AND HER2 2+/NON-AMPLIFIED GROUPS OF THE CASES WITH INVASIVE BREAST CARCINOMA. 222-229

673 STUDY OF HORMONE RECEPTOR STATUS IN CARCINOMA BREAST. **2018**, 7, 4188-4191

672 Historical Perspectives. **2019**, 15-59

671 Adjuvant Therapy for HER2-Positive Early-Stage Breast Cancer. **2019**, 383-411

670 Digitalisierung in der Medizin: Im disruptiven Wandel wandelbar bleiben. **2019**, 143-157

669 Clinical Implications According to Diagnostic Methods of Human Epidermal Growth Factor Receptor 2 Positivity in Breast Cancer: A Retrospective Study. **2018**, 6, 60-72

668 Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues.

667 Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. **2019**, 143-161

666 Identification of Prognostic and Heterogeneous Breast Cancer Biomarkers Based on Fusion Network and Multiple Scoring Strategies. **2019**, 529-534 2

665 Adjuvant Therapy for HER-2-Positive Early Breast Cancer. **2019**, 173-185

664 Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer. **2019**, 191-221 0

663 Neoadjuvant therapy for HER2-positive breast cancer. **2019**, 10, 83-90

662 Role of Heat Shock Protein 90 in Mammary Tumorigenesis. **2019**, 103-124

661 Expression of and and their association with recurrent breast cancer.. **2019**, 8, 248-254 0

- 660 Estrogen Induces CK2 α ; Activation via Generation of Reactive Oxygen Species. **2019**, 25, 23-31 1
- 659 RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence. 1
- 658 ????????, ?????????? ??????. **2019**, 122, 839-843
- 657 Dynamical rearrangement of human epidermal growth factor receptor 2 upon antibody binding: effects on the dimerization.
- 656 In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina. **2019**, 6, 357-366
- 655 Breast. **2020**, 123-131
- 654 H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~DeBakey Clinical Medical Research Award. **2019**, 129, 3963-3965 2
- 653 Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer. **2019**, 11, e6036 2
- 652 Pretreatment Prediction of Neoadjuvant Chemotherapy Response in HER-2 Positive Breast Cancer Patients Using Diffuse Optical Tomography Imaging. **2020**,
- 651 Development of HER2-targeted Therapies for Gastrointestinal Cancer. **2020**, 16, 29
- 650 Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer. **2020**, 63, 194-199 0
- 649 In vitro and in vivo Evaluation of the Radiochemical Compound Based on 99mTechnetium Labeled DARPIn 9_29 for Molecular Visualization of Malignancies Overexpressing Her2/neu. **2020**, 65, 37-41
- 648 Clinicopathological value of ErbB2 gene and protein expression in osteochondroma. **2020**, 54, 34-41
- 647 Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes. **2020**, 12, 3145-3153 1
- 646 CURRENT POINT OF VIEW ON PROGNOSTIC AND PREDICTIVE ROLES AND PRACTICAL APPLICATION OF HER2 RECEPTOR β DETECTION. LITERATURE REVIEW. **2020**, 19, 6-12
- 645 Assessment of Cardiac Function by Advanced Echocardiography in Breast Cancer Patients (HER2 Positive vs HER2 Negative). **2020**, 11,
- 644 An integrated model of clinical information and gene expression for prediction of survival in breast cancer patients. **2020**,
- 643 Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides. **2021**, 26, 2

| | | |
|-----|---|---|
| 642 | Affibody-mediated PNA-based pretargeted co-treatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts. 2021, | 1 |
| 641 | Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. 2021, 11, 731148 | 1 |
| 640 | Prediction of HER2 expression in breast cancer by combining PET/CT radiomic analysis and machine learning. 2021, 1 | 1 |
| 639 | A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation. 2021, 11, | |
| 638 | HER-2 positivity is a high risk of recurrence of stage I gastric cancer. 2021, 36, 1327-1337 | 1 |
| 637 | Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. 2021, 12, 741451 | 0 |
| 636 | Auf dem Weg zur Präzisionsonkologie: Biomarker, molekulargenetische Tumorprofile und Big Data. 2020, 193-207 | |
| 635 | Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy. 2020, 21, | 7 |
| 634 | Survival analysis in breast cancer using proteomic data from four independent datasets. | 1 |
| 633 | Synergistic Effects of Metformin-Lapatinib Combination on the Expression of Bax in SK-BR3 Cells. 2020, 11, | |
| 632 | Estrogen Receptor Positive Breast Cancer: 8p11-p12 Amplicon and Therapeutic Response. 2021, | |
| 631 | Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. 2020, 1277, 127-141 | |
| 630 | Survey of low ER-positive expression and its correlation with other clinical and pathological factors in breast cancer. 2020, 63, S129-S133 | |
| 629 | Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast Cancer. | |
| 628 | Trastuzumab: A Milestone in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. 2020, 41, 54-56 | |
| 627 | Treatment options for HER2-positive metastatic breast cancer. 2020, 2, 28 | |
| 626 | A Comparative Analysis of Body Mass Index with Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Pre- and Postmenopausal Breast Cancer Patients. 2020, 11, 210-216 | 0 |
| 625 | Detecting Subclones from Spatially Resolved RNA-Seq Data. 2020, 102-107 | |

- 624 Application of Pharmacogenomics in Drug Discovery and Development. **2020**, 257-276
- 623 Cancer biology and other disorders: beneficial role of camptothecin and novel derivatives. **2020**, 1-46
- 622 Using Multiple Machine Learning Algorithms for Cancer Prognosis in Lung Adenocarcinoma. **2020**,
- 621 The Quiet Revolution in Breast Cancer Care: From Laboratory to Survival. **2020**, 2, 37
- 620 Mathematical modelling of Her2 (ErbB2) PI3K/AKT signalling pathways during breast carcinogenesis to include PTPD2. **2020**, 5, 4946-4958
- 619 Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer. **2020**, 15, 30-49 1
- 618 Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer. 1
- 617 Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer.. **2022**, 29, 1808-1812 1
- 616 Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation. **2021**, 13, 1
- 615 Personomics An innovative tool of precision medicine and its role in the individualized treatment of patients with breast cancer. **2020**, 1-8
- 614 An Overview of HER-targeted therapy with lapatinib in breast cancer.
- 613 Significance of Oncogene Amplifications in Breast Cancer in Atomic Bomb Survivors: Associations with Radiation Exposure and Histological Grade. **2009**, 285-293
- 612 Biological effects of peptide antibodies raised to HER-2/neu. Implications for therapy of human breast cancer. **2002**, 779-780
- 611 Peptide vaccine strategy for immunotherapy of HER-2/neu overexpressing cancers. **2002**, 700-701
- 610 Breast Cancer Metastasis. **2000**, 339-352
- 609 Immunophenotypic Characterization of Infiltrating Poly- and Mononuclear Cells in Childhood Brain Tumors. **2005**, 13-161
- 608 Tumor models for preclinical development of targeted agents. **2005**, 63, 43-66
- 607 Antimetastasis. **2005**, 287-298

606 Chemosensitization. **2005**, 335-348

605 Herceptin Resistance. **2006**, 459-467

604 Role of TGF- β in Tumor Progression and Metastasis. **2006**, 469-489

603 Development of Therapeutic Genes for Breast Cancer Treatment. **2007**, 435-446

602 Intercellular Targets of Prostate Cancer. **2007**, 475-486

601 Molecular Targets in Ovarian Cancer and Endometrial Cancer. **2008**, 291-308

600 Targeted Therapy For Breast Cancer. **2008**, 309-342

599 Combining Targeted Therapies. **2008**, 361-381

598 Traitement adjuvant et cancer du sein surexprimant HER2. **2007**, 197-208

597 Traitements adjuvants des cancers du sein HER2 positif. **2007**, 425-443

596 Anticancer antibodies. **2003**, 119, 472-85

18

595 Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Resistant Breast Cancer. **2006**, 308-326

594 Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer. **2006**, 327-348

593 Mechanisms of Breast Cancer Resistance to Chemotherapy. **2006**, 783-803

592 Morphological detection of hormone and growth factor receptors in breast cancer. **2007**, 176, 201-9

591 Gentechnische Grundlagen für biotechnologische Anwendungen. **2008**, 476-509

590 Tiermodelle in der biomedizinischen Forschung. **2008**, 207-241

589 Advanced and futuristic approaches for breast cancer diagnosis. **2020**, 6,

1

| | | |
|-----|---|-----|
| 588 | A study of human epidermal growth factor receptor-2 (HER-2) in carcinoma esophagus (Single Institutional Tertiary Cancer Centre study from Northeast part of India). 5, 108-112 | |
| 587 | Monoclonal Antibodies for Cancer Immunotherapy. 2021 , 273-312 | 1 |
| 586 | Structural and dynamic characterization of the C-terminal tail of ErbB2: disordered but not random. | |
| 585 | Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. 2020 , 15, e0241775 | 2 |
| 584 | Análisis del comportamiento clínico-patológico del cáncer de mama mucinoso: primer estudio multicéntrico en México. Revisión a 10 años. 2020 , 34, 133-133 | |
| 583 | Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. 1987 , 7, 2019-2023 | 102 |
| 582 | Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation. 1987 , 7, 2597-2601 | 37 |
| 581 | Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph. 1988 , 8, 3770-3776 | 18 |
| 580 | Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA. 1989 , 9, 4903-4913 | 23 |
| 579 | Homologous plasmid recombination is elevated in immortally transformed cells. 1989 , 9, 4009-4017 | 14 |
| 578 | Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy. 2021 , 145, 728-735 | 0 |
| 577 | Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases. 2021 , 43, 401-411 | 0 |
| 576 | Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. 2001 , 3, 245-54 | 13 |
| 575 | Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. 1995 , 14, 4267-75 | 138 |
| 574 | The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. 1994 , 13, 1331-40 | 80 |
| 573 | A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. 1994 , 13, 3302-11 | 59 |
| 572 | A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. 1989 , 8, 159-66 | 36 |
| 571 | HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. 1989 , 8, 167-73 | 54 |

- 570 Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth factor and insulin receptors. **1989**, 8, 2943-54 27
- 569 Cell-type specific interaction of Neu differentiation factor (NDF/hereregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. **1993**, 12, 961-71 65
- 568 A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. **1993**, 12, 2369-75 31
- 567 ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. **1996**, 15, 254-64 179
- 566 Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. **1991**, 10, 2077-86 31
- 565 EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. **1988**, 7, 995-1001 70
- 564 Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. **1988**, 7, 1003-11 167
- 563 Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. **1988**, 7, 2043-52 98
- 562 Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. **1988**, 7, 1647-51 59
- 561 Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659---Glu659). **1990**, 9, 181-90 22
- 560 The int-2 gene product acts as an epithelial growth factor in transgenic mice. **1990**, 9, 907-13 73
- 559 p185neu is expressed in yolk sac during rat postimplantation development. **1994**, 185 (Pt 1), 181-7
- 558 Clinical decision-making in early breast cancer. **1993**, 217, 207-25 70
- 557 Canadian National Breast Screening Study. **1993**, 149, 138
- 556 A somatic cell hybrid map of the long arm of human chromosome 17, containing the familial breast cancer locus (BRCA1). **1993**, 52, 702-10 30
- 555 Distal deletion of chromosome 1p in ductal carcinoma of the breast. **1989**, 45, 73-82 92
- 554 Oncogenes and human breast cancer. **1989**, 44, 577-84 33
- 553 Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. **1997**, 151, 761-8 69

| | | |
|-----|--|-----|
| 552 | NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia. 1997 , 151, 1685-94 | 25 |
| 551 | Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. 1996 , 148, 549-58 | 52 |
| 550 | Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene. 1996 , 149, 1177-91 | 18 |
| 549 | Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. 1996 , 149, 1553-64 | 118 |
| 548 | Biological response modifiers in cancer. 2006 , 8, 33 | 4 |
| 547 | Expression of c-ErbB2 in human neuroblastoma tissues, adrenal medulla adjacent to tumor, and developing mouse neural crest cells. 1995 , 146, 660-72 | 8 |
| 546 | HER-2/neu oncogene expression and proliferation in breast cancers. 1990 , 137, 103-11 | 46 |
| 545 | Biological grading of breast cancer using antibodies to proliferating cells and other markers. 1989 , 135, 783-92 | 46 |
| 544 | Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. 1989 , 135, 39-61 | 73 |
| 543 | Oncogene amplification in breast cancer. 1991 , 138, 835-45 | 19 |
| 542 | Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. 1992 , 140, 23-31 | 29 |
| 541 | Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. 1991 , 138, 1527-34 | 41 |
| 540 | Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. 1993 , 142, 1339-46 | 99 |
| 539 | Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. 1993 , 143, 1731-42 | 303 |
| 538 | Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. 1994 , 145, 1337-48 | 19 |
| 537 | Adjuvant trastuzumab: progress, controversies, and the steps ahead. 2006 , 13, 8-13 | 6 |
| 536 | Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. 2006 , 13, 99-107 | 40 |
| 535 | Tumour-associated upregulation of the IL-4 receptor complex. 1990 , 10, 96-8 | 8 |

| | | |
|-----|---|----|
| 534 | The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. 2003 , 114, 315-33; discussion 333-4 | 43 |
| 533 | From the editor's desk: the emergence of "personalized medicine" in medical care. 2007 , 10, 1-2 | |
| 532 | A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. 2007 , 3, 665-73 | 14 |
| 531 | Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. 1989 , 62, 379-92 | 36 |
| 530 | Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer. 2009 , 7, Doc03 | 1 |
| 529 | Trastuzumab in the management of early and advanced stage breast cancer. 2007 , 1, 19-31 | 31 |
| 528 | HER2 breast cancer therapies: a review. 2009 , 3, 289-301 | 43 |
| 527 | Breast cancer (metastatic). 2007 , 2007, | 1 |
| 526 | Predictive markers in primary breast cancer compared with lymph node and bloodspread metastases. 2009 , 1, 57-63 | 2 |
| 525 | Application of hazard models for patients with breast cancer in Cuba. 2011 , 4, 148-56 | |
| 524 | Systems approaches to molecular cancer diagnostics. 2010 , 10, 531-42 | 5 |
| 523 | Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. 2011 , 16, 70-4 | 77 |
| 522 | Breast cancer (metastatic). 2010 , 2010, | 4 |
| 521 | Silencing of Her2, CCNB1 and PKC Genes by siRNA Results in Prolonged Retardation of Neuroblastoma Cell Division. 2011 , 3, 29-39 | 1 |
| 520 | Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. 2012 , 135, 312-7 | 12 |
| 519 | Personalized therapy for pancreatic cancer: Myth or reality in 2010?. 2010 , 1, 24-33 | 4 |
| 518 | Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience. 2012 , 5, 530-6 | 22 |
| 517 | The Immunohistochemical Expression of the Oestrogen Receptor (ER), HER-2/NEU and Cytokeratin 8/18 and 5/6 in Invasive Breast Carcinoma. 2012 , 6, 1495-8 | 1 |

| | | |
|-----|---|----|
| 516 | Mouse mammary gland is refractory to the effects of ethanol after natural lactation. 2013 , 63, 38-47 | 1 |
| 515 | Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. 2013 , 3, 211-20 | 12 |
| 514 | HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. 2006 , 26, 4235-43 | 47 |
| 513 | Chemotherapy and cardiotoxicity. 2008 , 9, 75-83 | 42 |
| 512 | Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico. 2010 , 29, 265-71 | 2 |
| 511 | Closing the personalized medicine information gap: HER2 test documentation practice. 2013 , 19, 838-44 | 5 |
| 510 | Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. 2014 , 7, 1108-13 | 3 |
| 509 | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia. 2013 , 44, 108-14 | |
| 508 | Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer. 2013 , 6, 165-73 | 3 |
| 507 | Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer. 2014 , 39, 206-12 | 5 |
| 506 | Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer. 2013 , 1, 3-7 | 13 |
| 505 | Utilization of HER2 genetic testing in a multi-institutional observational study. 2012 , 18, 704-12 | 9 |
| 504 | Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters. 2014 , 7, 2544-50 | 9 |
| 503 | Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer. 2014 , 7, 1459-64 | |
| 502 | Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer. 2014 , 4, 293-302 | 1 |
| 501 | HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis. 2014 , 7, 4222-30 | 4 |
| 500 | Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues. 2014 , 7, 6752-9 | 10 |
| 499 | Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer. 2014 , 4, 776-88 | 4 |

| | | |
|-----|--|----|
| 498 | HER4 is a novel prognostic biomarker in gastrointestinal stromal tumor specifically originated from stomach. 2014 , 4, 838-49 | 2 |
| 497 | The role of HER-2 in Breast Cancer. 2014 , 2, 4-9 | 5 |
| 496 | Downregulation of ER- β 36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen. 2015 , 5, 530-44 | 4 |
| 495 | High expression of Sirt7 served as a predictor of adverse outcome in breast cancer. 2015 , 8, 1938-45 | 21 |
| 494 | Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. 2015 , 18, 576-86 | 13 |
| 493 | Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. 2015 , 8, 6143-56 | 9 |
| 492 | HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features. 2015 , 8, 8008-17 | 8 |
| 491 | Clinicopathological classification and traditional prognostic indicators of breast cancer. 2015 , 8, 8500-5 | 14 |
| 490 | Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein DARPInminiSOG. 2015 , 7, 126-32 | 14 |
| 489 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. 2015 , 5, 2531-61 | 46 |
| 488 | Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples. 2015 , 8, 10565-74 | 5 |
| 487 | Synchronous primary breast cancer and hepatocellular carcinoma in a male patient: a case report. 2015 , 8, 11722-8 | 1 |
| 486 | Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. 2016 , 6, 2661-2678 | 13 |
| 485 | Kinase inhibitors of HER2/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loop. 2017 , 7, 1476-1485 | 10 |
| 484 | Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma. 2017 , 38, 153-157 | 1 |
| 483 | The Effect of the Targeted Recombinant Toxin DARPIn-PE40 on the Dynamics of HER2-Positive Tumor Growth. 2017 , 9, 103-107 | |
| 482 | Chromogenic in situ Hybridization Compared with Real time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer. 2017 , 12, 128-134 | 1 |
| 481 | LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells. 2018 , 8, 594-609 | 4 |

| | | |
|-----|---|----|
| 480 | HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran. 2018 , 19, 1721-1725 | 3 |
| 479 | Novel cancer cell lines derived from primary breast tumors in Chinese patients. 2018 , 10, 3956-3968 | 1 |
| 478 | Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study. 2008 , 19, 1347-54 | 6 |
| 477 | HER2-targeted multimodal imaging of anaplastic thyroid cancer. 2019 , 9, 2413-2427 | 8 |
| 476 | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer. 2019 , 12, 329-331 | 2 |
| 475 | The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. 2020 , 10, 1045-1067 | 22 |
| 474 | [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice]. 2020 , 52, 254-260 | 2 |
| 473 | Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. 2020 , 10, e035802 | 1 |
| 472 | Anticancer therapeutics: a brief account on wide refinements. 2020 , 10, 3599-3621 | 1 |
| 471 | Predictive Value of CD44 for Prognosis in Patients with Breast Cancer. 2020 , 21, 2561-2567 | 2 |
| 470 | SOX12 expression is associated with progression and poor prognosis in human breast cancer. 2020 , 12, 8162-8174 | 3 |
| 469 | Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. 2021 , 13, 17588359211006960 | 1 |
| 468 | A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. 2021 , 11, 2867-2892 | 1 |
| 467 | Diagnostic Potential of miR-30a and miR-200c in Invasive Breast Ductal Carcinoma. 2021 , 1, | |
| 466 | Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis. 2021 , 1 | 0 |
| 465 | HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. 2021 , 12, 1109 | 1 |
| 464 | The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience. 2021 , 1-8 | |
| 463 | Toward Understanding the Binding Synergy of Trastuzumab and Pertuzumab to Human Epidermal Growth Factor Receptor 2. 2021 , 18, 4553-4563 | 0 |

| | | |
|-----|--|---|
| 462 | Combinatorial in silico and in vivo evaluation of immune response elicitation by the affibody Z. 2021 , 101, 108368 | 0 |
| 461 | The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling. 2021 , 19, 480 | 1 |
| 460 | Experimental and computational assessment of the synergistic pharmacodynamic drug-drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells. 2021 , 1 | 0 |
| 459 | HER3 is an Actionable Target in Advanced Prostate Cancer. 2021 , | 2 |
| 458 | Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. 2021 , 1-11 | 1 |
| 457 | Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs. 2021 , 11, | 0 |
| 456 | Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study. 2021 , 27, 361 | 1 |
| 455 | Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients. 2021 , 11, 774088 | 2 |
| 454 | The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study. 2021 , 13, | 0 |
| 453 | Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. 2021 , 13, | 1 |
| 452 | Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. 2021 , | |
| 451 | T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. 2021 , 14, | 2 |
| 450 | Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyła (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.. 2021 , | 0 |
| 449 | Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models. 2021 , 11, 778728 | 1 |
| 448 | Application of Intelligent Sensors in Biomarker Detection Using Accurate Data Measurement and Calculation. 2021 , 2083, 032035 | |
| 447 | Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer. 2021 , 21, 184 | |
| 446 | A Retrospective analysis of biosimilar and reference trastuzumab in human epidermal growth factor receptor-2 positive early and/or locally advanced breast cancer patients treated with neoadjuvant-adjuvant setting: Safety and event-free survival outcomes. 2021 , 5, 97 | |
| 445 | Expresión de receptores hormonales como factor predictivo de respuesta al tratamiento en pacientes con cáncer de mama temprano y localmente avanzado con sobreexpresión de HER2 en un hospital privado. 2021 , 66, 258-262 | |

| | | |
|-----|---|---|
| 444 | Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development.. 2021 , 34, | 1 |
| 443 | Curcumin encapsulation in functional PLGA nanoparticles: A promising strategy for cancer therapies.. 2021 , 300, 102582 | 4 |
| 442 | Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.. 2022 , 61, 136-144 | 3 |
| 441 | Vaccination against Her-2/neu, with focus on peptide-based vaccines.. 2022 , 7, 100361 | 1 |
| 440 | Breast cancer: contribution of molecular biology to the management of the disease. 2001 , 3, 130-136 | 2 |
| 439 | Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpression. 2001 , 3, 172-182 | 1 |
| 438 | Adrenalectomy in an isolated adrenal gland metastasis of invasive lobular carcinoma. 2002 , 4, 43-45 | |
| 437 | A comparative study of HER2/neu amplification and overexpression using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients. 2002 , 4, 255-259 | 3 |
| 436 | ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. 2004 , 6, 12-21 | 1 |
| 435 | Predictive Value of CD44 for Prognosis in Patients with Breast Cancer. 2020 , 21, 2561-2567 | 2 |
| 434 | Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. 2020 , 10, e035802 | 1 |
| 433 | Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy.. 2021 , 12, | 2 |
| 432 | Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.. 2022 , 134, 63 | 0 |
| 431 | Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway.. 2022 , 10, | 0 |
| 430 | Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.. 2021 , 8, 812702 | |
| 429 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.. 2022 , 23, | |
| 428 | Pathophysiological role of ion channels and transporters in HER2-positive breast cancer.. 2022 , | 1 |
| 427 | Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.. 2022 , | 0 |

| | | |
|-----|---|---|
| 426 | Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.. 2022 , 20, 4 | |
| 425 | A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2+ cancer.. 2021 , 612, 121364 | 2 |
| 424 | Targeted nuclear medicine. Seek and destroy.. 2022 , 91, | 3 |
| 423 | Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics?. 2022 , | 1 |
| 422 | National Cancer Institute Experience in Micro-invasive Breast Carcinoma Treatment and Outcome. 2022 , 10, 104-112 | |
| 421 | Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.. 2022 , 27, 245-250 | 0 |
| 420 | Ado-trastuzumab emtansine associated spider telangiectasia.. 2022 , 10781552211073878 | |
| 419 | Morphological and immunohistochemical characterization and molecular classification of spontaneous mammary gland tumors in macropods.. 2022 , 3009858211069164 | |
| 418 | Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer.. 2022 , 29, 3051 | 0 |
| 417 | Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies.. 2022 , 36, 167 | 1 |
| 416 | HNMT Upregulation Induces Cancer Stem Cell Formation and Confers Protection against Oxidative Stress through Interaction with HER2 in Non-Small-Cell Lung Cancer.. 2022 , 23, | 1 |
| 415 | Inferring tumor-specific cancer dependencies through integrating ex-vivo drug response assays and drug-protein profiling. | |
| 414 | circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.. 2022 , 21, 8 | 1 |
| 413 | In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China.. 2021 , 11, 774577 | 4 |
| 412 | Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera), a trastuzumab biosimilar, under extended in-use conditions.. 2022 , 10781552221074649 | |
| 411 | Antiproliferative and proapoptotic activities of Sea Cucumber <i>H. Leucospilota</i> extract on breast carcinoma cell line (SK-BR-3).. 2022 , 49, 1191 | 0 |
| 410 | Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress.. 2022 , 13, 40 | 7 |
| 409 | Terapia personalizada en cáncer de mama precoz. Implicancias prácticas. 2022 , 33, 17-24 | |

| | | |
|-----|--|----|
| 408 | Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.. 2022, | 1 |
| 407 | Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-up of Prognostic Study Using Propensity Score Matching.. 2022, | 0 |
| 406 | Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer.. 2022, 18, 101355 | 1 |
| 405 | Quantification of protein-protein interactions and activation dynamics: A new path to predictive biomarkers.. 2022, 283, 106768 | 1 |
| 404 | Determination of c-erbB-2/Her-2/Neu status in breast cancer: comparative analysis between immunoenzymatic assay (ELISA) and immunohistochemistry. 2003, 5, 272-279 | |
| 403 | Mcl-1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer.. 2022, | 1 |
| 402 | Theranostic Interpolation of Genomic Instability in Breast Cancer.. 2022, 23, | 0 |
| 401 | The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quantification with in situ hybridization assay.. 2022, 1 | 0 |
| 400 | Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.. 2022, 41, 193 | 1 |
| 399 | Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.. 2022, 192, 593 | 0 |
| 398 | Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.. 2021, | 11 |
| 397 | HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer.. 2022, 62, 114-122 | 1 |
| 396 | State-of-the-art cancer biomarker detection by portable (Bio) sensing technology: A critical review. 2022, 177, 107248 | 2 |
| 395 | Oncogene expression in endocrine pancreatic tumors. 1988, 55, 355-61 | 13 |
| 394 | Zippered G-quadruplex/hemin DNAzyme: exceptional catalyst for universal bioanalytical applications. 2021, | 8 |
| 393 | [Model systems for investigation of genetic factors in tumorigenesis]. 1995, 82, 209-18 | |
| 392 | Abstracts of the 8th International Pituitary Pathology Meeting. October 5-9, 2001. Greece. 2001, 12, 189-254 | |
| 391 | Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature.. 2022, 16, 11795549211072880 | 0 |

| | | |
|-----|---|---|
| 390 | Recent advances in biosensor devices for HER-2 cancer biomarker detection.. 2022 , 14, 1301-1310 | 2 |
| 389 | Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers. | 2 |
| 388 | Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.. 2022 , 14, 17588359221085232 | 0 |
| 387 | Diverse roles of tumor-stromal PDGFB-to-PDGFR β signaling in breast cancer growth and metastasis.. 2022 , 154, 93-140 | 1 |
| 386 | CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.. 2022 , 18, 2609-2626 | 2 |
| 385 | Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer - A Systematic Review.. 2022 , 16, 11782234221086684 | 0 |
| 384 | HER2 Revisited: Reflections on the Future of Cancer Biomarker Research. 2022 , 97-119 | |
| 383 | A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.. 2022 , | 8 |
| 382 | Cxcl10 chemokine induces migration of ING4-deficient breast cancer cells via a novel crosstalk mechanism between the Cxcr3 and Egfr receptors. 2021 , MCB0038221 | 1 |
| 381 | Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin + Trastuzumab in Advanced Solid Tumors.. 2022 , 17, 141 | 0 |
| 380 | Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative.. 2022 , 14, | 1 |
| 379 | Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.. 2022 , 8, 22 | 0 |
| 378 | Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer.. 2022 , 29, 1430-1441 | 0 |
| 377 | Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.. 2022 , 15, 267-275 | 0 |
| 376 | Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab.. 2022 , 12, 819818 | |
| 375 | Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.. 2022 , 22, 242 | |
| 374 | Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.. 2022 , 24, 22 | 7 |
| 373 | Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.. 2022 , 12, 856974 | 4 |

| | | |
|-----|--|----|
| 372 | Trastuzumab/Pertuzumab combination therapy stimulates anti-tumor responses through complement-dependent cytotoxicity and phagocytosis.. 2022 , | 1 |
| 371 | Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).. 2022 , 22, 269 | |
| 370 | Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer.. 2022 , 13, 830097 | 1 |
| 369 | Systematic review and meta-analysis of genomic alterations in acral melanoma.. 2022 , | 1 |
| 368 | Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1S Cell-Cycle Transition. 2022 , 2, 131-145 | 1 |
| 367 | Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.. 2022 , | 4 |
| 366 | 68Ga-TP1580 as a novel molecular probe for HER2-positive tumor imaging using MicroPET. 1 | |
| 365 | Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study.. 2022 , | 0 |
| 364 | Low back pain in people aged 60 years and over.. 2022 , 376, e066928 | 1 |
| 363 | Temporal and spatial topography of cell proliferation in cancer.. 2022 , 24, 316-326 | 4 |
| 362 | Prediction of Short and Long Survival after Surgery for Breast Cancer Brain Metastases.. 2022 , 14, | |
| 361 | Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary.. 2022 , 12, 723140 | |
| 360 | Antibody drug conjugate: the "biological missile" for targeted cancer therapy.. 2022 , 7, 93 | 25 |
| 359 | Synthesis of Multiple Bispecific Antibody Formats with Only One Single Enzyme Based on Enhanced Trypsinase.. 2022 , 23, | 0 |
| 358 | Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer.. 2022 , 14, | |
| 357 | Synthesis and evaluation of novel HER-2 inhibitors to exert anti-breast cancer ability through epithelial-mesenchymal transition (EMT) pathway.. 2022 , 237, 114325 | 0 |
| 356 | An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.. 2022 , 15, 331-343 | 0 |
| 355 | Cascade Downregulation of HER Family by a Dual-Targeted Recombinant Protein-Drug Conjugate to Inhibit Tumor Growth and Metastasis.. 2022 , e2201558 | 1 |

| | | |
|-----|--|---|
| 354 | Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimens.. 2022 , | 1 |
| 353 | Genetics of cancer therapy-associated cardiotoxicity.. 2022 , | 2 |
| 352 | Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.. 2022 , 58, 151935 | |
| 351 | Clinical tissue biomarker digital image analysis: A review of current applications. 2022 , 28, 300633 | 2 |
| 350 | Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer. 2021 , 100, e27632 | 0 |
| 349 | PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland.. 2021 , 14, | 2 |
| 348 | . 2021 , 108, 11S8-11S18 | 0 |
| 347 | Epitope Mapping of an Anti-HER2 Monoclonal Antibody (HMab-181) Using Enzyme-Linked Immunosorbent Assay.. 2021 , 40, 255-260 | 0 |
| 346 | Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.. 2022 , 34, 41-45 | 0 |
| 345 | The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study.. 2021 , | 3 |
| 344 | . 2021 , 108, 11S35-11S45 | |
| 343 | Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study. 2021 , 36-46 | |
| 342 | Meme kanseri subgrupları için s-klf ve otoimmün tiroid hastaları için prognoz üzerine etkisi. 2021 , 2, 105-112 | |
| 341 | Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer. 2021 , 68-74 | |
| 340 | Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.. 2021 , 14, | 5 |
| 339 | HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy.. 2021 , 14, | 1 |
| 338 | Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study.. 2021 , 11, 744609 | 0 |
| 337 | Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.. 2021 , 22, | 2 |

| | | |
|-----|---|---|
| 336 | Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids.. 2021 , 13, | 1 |
| 335 | Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy.. 2021 , 11, 789078 | 0 |
| 334 | Impact of Chemotherapeutic Drugs Towards Oxidative Stress and Associated Multi-organ Physiological Responses. 2022 , 1-25 | |
| 333 | Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.. 2022 , OF1-OF11 | 1 |
| 332 | HER2 protein expression level is positively associated with the efficacy of neoadjuvant systemic therapy in HER2-positive breast cancer.. 2022 , 234, 153900 | 0 |
| 331 | SEC14L3 plays a tumor-suppressive role in breast cancer through a Wnt/ β -catenin-related way.. 2022 , 113161 | |
| 330 | An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic.. 2022 , 1-10 | 1 |
| 329 | Prostanoid Signaling in Cancers: Expression and Regulation Patterns of Enzymes and Receptors.. 2022 , 11, | 1 |
| 328 | The Ascension of Targeted Covalent Inhibitors.. 2022 , | 3 |
| 327 | Stimulatory role of nectin-4 and p95-ErbB2 in multilayered T47D cell proliferation.. 2022 , | 0 |
| 326 | Cancer Pharmacogenomics. 2005 , 339-357 | |
| 325 | Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy. 2005 , 531-552 | |
| 324 | Data_Sheet_1.PDF. 2019 , | |
| 323 | Image_1.tiff. 2020 , | |
| 322 | Image_2.tiff. 2020 , | |
| 321 | Image_3.tiff. 2020 , | |
| 320 | Image_1.JPEG. 2020 , | |
| 319 | Image_2.JPEG. 2020 , | |

318 Table_1.DOCX. 2020,

317 table_1.PDF. 2018,

316 Presentation_1.PDF. 2018,

315 Image_1.pdf. 2020,

314 Image_2.pdf. 2020,

313 Image_3.pdf. 2020,

312 Image_4.pdf. 2020,

311 Image_5.pdf. 2020,

310 Image_6.pdf. 2020,

309 Image_7.pdf. 2020,

308 Table_1.pdf. 2020,

307 Data_Sheet_1.PDF. 2018,

306 Data_Sheet_2.PDF. 2018,

305 A flow cytometric study of c-erbB-3 expression in breast cancer. 1995, 41, 280-286

1

304 The role of fluorescence in situ hybridization technologies in molecular diagnostics and disease management. 2000, 5, 309-19

3

303 The HER family as therapeutic targets in colorectal cancer.. 2022, 103681

0

302 Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE.. 2022,

0

301 Evaluating Trastuzumab in the treatment of HER2 positive breast cancer. 2020, 35, 1059-1075

1

| | | |
|-----|--|---|
| 300 | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer. 2019 , 12, 329-331 | 3 |
| 299 | ErbB inhibitors as neoadjuvant therapy for triple-positive breast cancer: a network meta-analysis.. 2021 , 13, 12129-12140 | |
| 298 | OUP accepted manuscript. | 0 |
| 297 | Long-Term Prognostic Significance of HER2-Low and HER2-Zero in Node-Negative Breast Cancer. | |
| 296 | Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.. 2022 , 20, eGS6655 | |
| 295 | Clinicopathological Characteristics of the SOX10+ Subset of HER2+ Breast Cancer. | |
| 294 | Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial.. 2022 , 11, 742-750 | |
| 293 | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population.. 2022 , 12, 842787 | |
| 292 | Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer.. 2022 , 15, 471-478 | 1 |
| 291 | No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients: A 10-Year Follow-Up Study in the Polish Population. 2022 , 13, 729 | 0 |
| 290 | Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals.. 2022 , 14, | 0 |
| 289 | Role of the Wnt and GTPase pathways in breast cancer tumorigenesis and treatment. 2022 , | 0 |
| 288 | Prognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast Cancer.. 2022 , 2, 316-323 | 2 |
| 287 | Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer.. 2022 , 8, 65 | 0 |
| 286 | Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status.. 2022 , 20, 142 | 2 |
| 285 | N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.. 2022 , 13, 2672 | 6 |
| 284 | The Physiological Structure and Function of Proteins. 1995 , 18-35 | |
| 283 | Physiological Structure and Function of Proteins. 2001 , 19-42 | |

| | | |
|-----|--|----|
| 282 | Molecular Characterization of the Transition to Malignancy in a Genetically Engineered Mouse-Based Model of Ductal Carcinoma In situ. 2004 , 2, 453-463 | 36 |
| 281 | HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. 2004 , 2, 606-619 | 22 |
| 280 | Transforming Potential of Alternatively Spliced Variants of Fibroblast Growth Factor Receptor 2 in Human Mammary Epithelial Cells. 2004 , 2, 643-652 | 76 |
| 279 | Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. 2004 , 3, 1335-1342 | 17 |
| 278 | HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.. 2022 , 42, 1-14 | 0 |
| 277 | Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.. 2022 , | 0 |
| 276 | Marsdenia tenacissima (Roxb.) Moon injection exerts a potential anti-tumor effect in prostate cancer through inhibiting ErbB2-GSK3 β HIF1 β signaling axis. 2022 , 115381 | 0 |
| 275 | Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation.. 2022 , | |
| 274 | Overexpression of galectin2 (LGALS2) predicts a better prognosis in human breast cancer.. 2022 , 14, 2301-2316 | |
| 273 | SlideGraph+: Whole Slide Image Level Graphs to Predict HER2 Status in Breast Cancer. 2022 , 102486 | 0 |
| 272 | Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. 2022 , 12, | |
| 271 | Concepts in Breast Surgery. 2022 , 907-919 | |
| 270 | Resistance Mechanisms to HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: A Systematic Review. 2022 , 102418 | 1 |
| 269 | New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. 2022 , 10, 27 | 0 |
| 268 | Use of Radionuclide-Based Imaging Methods in Breast Cancer. 2022 , | 0 |
| 267 | Contemporary breast cancer treatment-associated thrombosis. 2022 , 213, S8-S15 | |
| 266 | Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. 2022 , 14, 2795 | 0 |
| 265 | Long-term complications of chemotherapy. 2023 , 234-240 | |

- 264 Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. **2022**, 14, 175883592211065
- 263 Translational Epidemiology in Cancer Research: The Less Travelled Path. **2022**, 349-366
- 262 Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model. 0
- 261 Discordance of positive immunohistochemical results among different primary HER2 antibodies used in breast cancer: A comparison between Histofine[®] HER2 Kit (MONO) SV2-61[®] antibody and Ventana I-VIEW PATHWAY[®]HER2 4B5 antibody. **2022**,
- 260 Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. 9, 0
- 259 The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. **2022**, 11, 1195 0
- 258 Can artificial intelligence accelerate preclinical drug discovery and precision medicine?. 1-5
- 257 Comprehensive Analysis of the Expression and Prognostic Value of LMAN2 in HER2+ Breast Cancer. **2022**, 2022, 1-26
- 256 Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers. 12, 4
- 255 Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience. 12, 3
- 254 Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series.
- 253 Novel applications of molecular imaging to guide breast cancer therapy. **2022**, 22, 1
- 252 Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. 12, 5
- 251 Development of a biosensor based on a new marine luciferase fused to an affibody to assess Her2 expression in living cells. **2022**, 1221, 340084 1
- 250 Biological impediments to monoclonal antibodyBased cancer immunotherapy. **2004**, 3, 1493-1501 40
- 249 Atezolizumab With Neoadjuvant AntiHuman Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. 2
- 248 Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
- 247 Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor.

- 246 The role of epigenetic modifications in drug resistance and treatment of breast cancer. **2022**, 27, 4
- 245 Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis. 13,
- 244 Integrative Bioinformatics Analysis Reveals CHEK1 and UBE2C as Luminal A Breast Cancer Subtype Biomarkers. 13,
- 243 Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. 0
- 242 Update of the 100 Most Cited Articles on Breast Cancer: A Bibliometric Analysis. **2022**, 18, 258-270
- 241 Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors. 28, 0
- 240 Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. **2022**, 14, 3305 2
- 239 The Use of Human Tissues for Research: What Investigators Need to Know. 026119292211079 0
- 238 Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors. **2022**, 48, 1
- 237 The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90. **2022**, 23, 7792 0
- 236 Shedding Light on HER4 signaling in normal and malignant breast tissues. **2022**, 97, 110401 0
- 235 Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. **2022**, 173, 10-19 2
- 234 Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: Single origin, divergent evolution, and multiple outcomes. **2004**, 3, 941-953 24
- 233 Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma Cells. **2005**, 65, 840-849 24
- 232 The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer. **2005**, 65, 18-25 33
- 231 The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. **2022**, 14, 4-15 2
- 230 Natural Killer Cell Recognition and Control of Epithelial Cancers. **2022**, 28, 263-269
- 229 Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study. 0

| | | |
|-----|---|---|
| 228 | Research on Cancer Diagnosis Method Based on LightGBM-Gridsearchcv. 2022 , | 1 |
| 227 | Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. 2022 , | 1 |
| 226 | HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget Disease Models: In Vivo and Immunohistochemical Analyses. 2022 , 14, 3519 | 1 |
| 225 | IL-6: The Link Between Inflammation, Immunity and Breast Cancer. 12, | 2 |
| 224 | Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy. 2022 , 14, 3500 | 0 |
| 223 | Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital. | 0 |
| 222 | Imaging Features of Breast Cancer Subtypes on Mammography and Ultrasonography: an Analysis of 479 Patients. | |
| 221 | DNMT1 has prognostic values in HER2-positive breast cancer. | |
| 220 | Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. 2022 , 14, 3996 | 2 |
| 219 | Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis. | 1 |
| 218 | Novel psoralen derivatives as anti-breast cancer agents and their light-activated cytotoxicity against HER2 positive breast cancer cells. 2022 , 12, | 0 |
| 217 | HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study. 13, | 0 |
| 216 | HER2 gene amplification status in HER2 2+ breast cancer and its correlation with clinicopathological characteristics. 2022 , | |
| 215 | Tailoring antiHer2 treatment strategies in breast cancer and beyond. 2022 , 100892 | |
| 214 | Umbilical cord mesenchymal stem cells and breast cancer: a good therapeutic candidate or not? A minireview. | 1 |
| 213 | A Causal Framework for Making Individualized Treatment Decisions in Oncology. 2022 , 14, 3923 | 0 |
| 212 | HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. 2022 , 104205 | 0 |
| 211 | Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report. 2022 , 24, | 0 |

- 210 A Prospective Multi-Institutional Observational Study on ER, PR, HER2/NEU, and Ki-67 Expression and Discordance Pattern in Primary and Metastatic and Recurrent Carcinoma Breast and Its Therapeutic Implications and Prognostic Outcome.
- 209 Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer. **2022**, 12, 0
- 208 Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China. 1-10
- 207 Recent developments in the Medicinal Chemistry and therapeutic potential of anti-cancer Protacs based molecules. **2022**, 29,
- 206 Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling. **2022**, 18, e1010438
- 205 Phase interrogation of plasmonic tilted fiber Bragg grating biosensors through Jones Formalism. 1
- 204 Destabilized 3DTR ARE therapeutically degrades ERBB2 in drug-resistant ERBB2+ cancer models.
- 203 Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study. **2022**, 7, 100183
- 202 Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. **2022**, 349, 844-875 2
- 201 Targeted therapy for breast cancer: An overview of drug classes and outcomes. **2022**, 204, 115209 2
- 200 Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. **2022**, 65, 145-150 1
- 199 Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. **2022**, 28, 331-338 0
- 198 Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. Volume 14, 259-280 0
- 197 Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. 0
- 196 Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958). 0
- 195 Hyaluronidase responsive second near-infrared fluorescent nanocomplex for combined HER2 blockade and chemotherapy of HER2+ breast cancer. **2022**, 141, 213115 0
- 194 Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework. **2022**, 14, 175883592211128 0
- 193 Impact of Chemotherapeutic Drugs Towards Oxidative Stress and Associated Multi-organ Physiological Responses. **2022**, 3961-3985 0

| | | |
|-----|--|---|
| 192 | Introduction. 2022 , 1-20 | 0 |
| 191 | Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer. 2022 , 13, 100116 | 0 |
| 190 | Comparison of Time-Varying Pattern of Recurrence in Chinese Breast Cancer Patients with Different Molecular Subtypes: A Single-Center Retrospective Study. 2022 , 24, 451-469 | 0 |
| 189 | The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers. 2022 , 8, e10410 | 0 |
| 188 | The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. 2022 , 39, | 0 |
| 187 | Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: A multicenter study. 12, | 1 |
| 186 | Synthesis and comparative evaluation of ¹⁷⁷ Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes. 2022 , 12, | 1 |
| 185 | Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis. 2022 , 17, e0274140 | 1 |
| 184 | Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials. 1-8 | 0 |
| 183 | Activity of EGFR transmembrane region variants indicates specific transmembrane dimers are not required for EGFR activity. | 0 |
| 182 | The role of tumor phenotype in the surgical treatment of early-stage breast cancer. 2022 , | 0 |
| 181 | Optical biosensor based on weak value amplification for the high sensitivity detection of Pertuzumab in combination with Trastuzumab binding to the extracellular domain of HER2. 2022 , 30, 36839 | 0 |
| 180 | In vivo metabolic imaging identifies lipid vulnerability in a preclinical model of Her2+/Neu breast cancer residual disease and recurrence. 2022 , 8, | 0 |
| 179 | Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis. 2022 , 14, 4551 | 0 |
| 178 | Influence of Tamoxifen on Different Biological Pathways in Tumorigenesis and Transformation in Adipose-Derived Stem Cells, Mammary Cells and Mammary Carcinoma Cell Lines: An In Vitro Study. 2022 , 11, 2733 | 0 |
| 177 | Emerging Targeted Therapies for Early Breast Cancer. | 0 |
| 176 | Electrochemical biosensors based on polymer nanocomposites for detecting breast cancer: Recent progress and future prospects. 2022 , 102795 | 0 |
| 175 | HER2 induces cell scattering and invasion through p63 and E-cadherin. 2022 , 100, 403-412 | 0 |

| | | |
|-----|---|---|
| 174 | Cost-effectiveness analysis of neratinib plus capecitabine against lapatinib plus capecitabine for HER2-Positive metastatic breast cancer. | 0 |
| 173 | Molecular Pathology of Gastric Cancer. 2022 , 22, 264 | 0 |
| 172 | Antitumor activity of the protein kinase inhibitor 1-(E)-2-(deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole in breast cancer cell lines. 2022 , 22, | 0 |
| 171 | A Soft Label Deep Learning to Assist Breast Cancer Target Therapy and Thyroid Cancer Diagnosis. 2022 , 14, 5312 | 1 |
| 170 | Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. 2022 , 14, 5154 | 0 |
| 169 | Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. 2022 , 10, 2654 | 0 |
| 168 | The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPIn G3 for HER2 imaging in oncology. 2022 , 55, | 0 |
| 167 | Expression and Signaling Pathways of Nerve Growth Factor (NGF) and Pro-NGF in Breast Cancer: A Systematic Review. 2022 , 29, 8103-8120 | 0 |
| 166 | HER3 in cancer: from the bench to the bedside. 2022 , 41, | 2 |
| 165 | Molecular Diagnostics in Cancer. 1-14 | 0 |
| 164 | Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. 2022 , 10, e005119 | 1 |
| 163 | HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study. 2022 , 14, 4981 | 0 |
| 162 | Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer. 2022 , 101, e30892 | 0 |
| 161 | Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis. 13, | 0 |
| 160 | The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective. 2022 , 14, 5326 | 0 |
| 159 | MYC and therapy resistance in cancer: risks and opportunities. 2022 , 16, 3828-3854 | 0 |
| 158 | Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab. | 0 |
| 157 | Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review. 2022 , 10, 1727 | 0 |

- 156 HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. **2022**, 22, 0
- 155 Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial. 0
- 154 Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer. **2022**, 12, 1729 0
- 153 Metformin alleviates ethanol-induced cardiomyocyte injury by activating AKT/Nrf2 signaling in an ErbB2-dependent manner. 0
- 152 Investigation of cardiac dysfunction in women with metastatic breast cancer under treatment with monoclonal antibodies.. **2022**, 0
- 151 Characterization of 940 Chinese patients with triple-positive breast cancer by clinicopathological and treatment outcomes. 0
- 150 Escape from the HER2-activated DCIS-like state is skewed by divergent nucleocytoplasmic transport. 0
- 149 A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers. 0
- 148 A Case of Sustained Tumor Regression With MP0274, a Novel DARPIn Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. **2022**, 0
- 147 A sensitive Turn-on Fluorescent biosensor for the detection of biomarkers based on three-dimensional DNA walker. **2023**, 253, 124071 1
- 146 Satellite Noncoding RNAs (ncRNA) as Cancer Biomarkers? New Insights from FA-SAT ncRNA Molecular and Clinical Profiles in Feline Mammary Tumors. **2022**, 26, 622-632 0
- 145 Molecular Mechanisms of Breast Cancer Metastasis. 0
- 144 Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf). 0
- 143 Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. **2022**, 28, 423-428 0
- 142 Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. **2022**, 13, 2065 1
- 141 Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer. 0
- 140 Targeting HER2-positive breast cancer: advances and future directions. 3
- 139 Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma. 0

| | | |
|-----|---|---|
| 138 | Prognostic Variables in Male Breast Cancer. 2000 , 66, 502-511 | 4 |
| 137 | HER2-low breast cancer: Novel detections and treatment advances. 2023 , 181, 103883 | 0 |
| 136 | Synthesis and in vivo evaluation of [¹¹ C]tucatinib for HER2-targeted PET imaging. 2023 , 80, 129088 | 1 |
| 135 | RNA biomarker discovery and validation. 2023 , 723-742 | 0 |
| 134 | Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. 2023 , 37, 103-115 | 0 |
| 133 | An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. 2023 , 554, 216024 | 0 |
| 132 | Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer. 2023 , 67, 1-7 | 0 |
| 131 | Molecular Biomarkers at the Interface of Basic and Clinical Dengue Research. 2013 , 42, 608-610 | 1 |
| 130 | Cardiotoxicity in breast cancer patients receiving trastuzumab with or without prior anthracycline-based chemotherapy: A prospective study from a tertiary cancer institute at Guwahati, India. 2022 , 6, 66 | 0 |
| 129 | The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. 2022 , | 2 |
| 128 | Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. 2022 , 14, 5678 | 0 |
| 127 | Activity of EGFR transmembrane region variants indicates specific transmembrane dimers are not required for EGFR activity. 2022 , 479, 2465-2475 | 0 |
| 126 | The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients. 2022 , 12, 3042 | 0 |
| 125 | Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study. 2022 , | 0 |
| 124 | Transcriptomic Changes Associated with ERBB2 Overexpression in Colorectal Cancer Implicate a Potential Role of the Wnt Signaling Pathway in Tumorigenesis. 2023 , 15, 130 | 0 |
| 123 | Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer: An Analysis of a Large University Breast Cancer Centre. | 0 |
| 122 | Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm. 2022 , 132, | 0 |
| 121 | A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells. 2022 , 11, 4093 | 0 |

| | | |
|-----|---|---|
| 120 | Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. | 0 |
| 119 | Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis. 2022 , 188847 | 0 |
| 118 | A second-generation antibody drug conjugate to treat HER2-positive breast cancer. 2022 , | 0 |
| 117 | Ultrafast prediction of somatic structural variations by filtering out reads matched to pan-genome k-mer sets. | 0 |
| 116 | Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. 2022 , | 0 |
| 115 | Characteristics, treatment and outcomes of HER2 positive male breast cancer. 2022 , | 0 |
| 114 | Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer. 2022 , 152087 | 0 |
| 113 | Novel markers in breast pathology. 2023 , 82, 119-139 | 1 |
| 112 | Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status. 2022 , 53, | 0 |
| 111 | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. 2022 , 14, 6034 | 1 |
| 110 | Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2+HR+Breast Cancer. | 0 |
| 109 | Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. 2022 , | 0 |
| 108 | Translational Results of Zo-NANTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer. 2022 , 23, 15515 | 0 |
| 107 | Using Whole Slide Gray Value Map to Predict HER2 Expression and FISH Status in Breast Cancer. 2022 , 14, 6233 | 0 |
| 106 | An update on the pathological classification of breast cancer. 2023 , 82, 5-16 | 1 |
| 105 | A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. 2022 , 13, | 1 |
| 104 | Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases. | 0 |
| 103 | Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor. 12, | 1 |

| | | |
|-----|---|----|
| 102 | Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. 2022 , 29, 9891-9895 | 0 |
| 101 | Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer: a retrospective study. 12, | 0 |
| 100 | A B7.1-Antibody Fusion Protein Retains Antibody Specificity and Ability to Activate Via the T Cell Costimulatory Pathway. 1998 , 160, 3419-3426 | 7 |
| 99 | A RANTES-Antibody Fusion Protein Retains Antigen Specificity and Chemokine Function. 1998 , 161, 3729-3736 | 3 |
| 98 | A Single-Chain IL-12 IgG3 Antibody Fusion Protein Retains Antibody Specificity and IL-12 Bioactivity and Demonstrates Antitumor Activity. 1999 , 163, 250-258 | 12 |
| 97 | Physical Activity in Patients with Breast Cancer. 2022 , 293-311 | 0 |
| 96 | Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors. 2023 , 13, 168 | 1 |
| 95 | Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer. 12, | 0 |
| 94 | CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. 2023 , 22, | 0 |
| 93 | Involvement of ERCC1 (rs3212986) and ERCC2 (rs1799793 , rs13181) polymorphisms of DNA repair genes in breast cancer occurrence in Burkina Faso. | 0 |
| 92 | Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer ^{99m} Tc-HP-Ark2: a pilot study. 2023 , 21, | 0 |
| 91 | Cáncer de mama metastásico HER2 positivo. 2015 , 20, | 0 |
| 90 | A targeted isotope dilution mass spectrometry assay for Osteopontin quantification in plasma of metastatic breast cancer patients. | 0 |
| 89 | Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer. 11, | 0 |
| 88 | Novel HER2-Targeted Peptide for NIR-II Imaging of Tumor. 2023 , 20, 1394-1403 | 0 |
| 87 | Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. 2023 , 28, 943 | 0 |
| 86 | Recent advances in peptide-based therapeutic strategies for breast cancer treatment. 14, | 0 |
| 85 | A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number ≤ 4.0 per cell in China. 2023 , 23, | 0 |

- 84 Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer. 108155892311512 ○
- 83 The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study. 13, ○
- 82 HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. ○
- 81 Protein Cancer Biomarkers. **2023**, 148-179 ○
- 80 Review of the status of neoadjuvant therapy in HER2-positive breast cancer. 13, ○
- 79 Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2. **2023**, 34, 101436 ○
- 78 Pertuzumab, primer inhibidor de la dimerizaci3n HER. **2013**, 18, ○
- 77 Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. **2022**, 2617-2635 ○
- 76 Comprehensive analysis of the role of SFXN family in breast cancer. **2023**, 18, ○
- 75 The Effect of Dietary n-3 Polyunsaturated Fatty Acids on Non-obese and Obesity-Associated Breast Cancer. **2023**, ○
- 74 Emerging Trends in Monoclonal Antibody Therapies Targeting Cancer. **2023**, 1-48 ○
- 73 Introduction to Breast Cancer. **2023**, 1-22 ○
- 72 Cancer of unknown primary (CUP) through the lens of precision oncology in a single institution perspective. ○
- 71 Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer. Volume 15, 189-211 ○
- 70 Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications. **2023**, 162, 114676 ○
- 69 Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer. ○
- 68 NIR-responsive, lapatinib-loaded gold nanorods for combined photothermal and pharmacological treatment of HER2 positive breast cancer: In vitro evaluation and cell studies. **2023**, 82, 104347 ○
- 67 Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands. 10, ○

- 66 MULTIMODALITY TESTING OF HER2/NEU MARKER IN BREAST CANCER: A CORRELATIVE STUDY. 1413-1443 ○
- 65 Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. **2023**, 29, 3-8 ○
- 64 Double-strand breaks induce inverted duplication chromosome rearrangements by a DNA polymerase δ and Rad51-dependent mechanism. ○
- 63 HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study. **2023**, 30, 343-353 ○
- 62 Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab. ○
- 61 Prognostic impact of HER2-low expression in HER2-negative breast cancer under different hormone receptor status. **2023**, 28, 543-549 ○
- 60 Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study. Publish Ahead of Print, ○
- 59 A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes. **2023**, ○
- 58 Her2low breast cancer. New opportunities and challenges. **2022**, 30, 62-74 ○
- 57 HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study. ○
- 56 Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. **2023**, 9, ○
- 55 Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI -Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer. ○
- 54 Metformin alleviates ethanol-induced cardiomyocyte injury by activating AKT/Nrf2 signaling in an ErbB2-dependent manner. **2023**, 50, 3469-3478 ○
- 53 Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. **2023**, ○
- 52 HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review. **2023**, 24, 3590 ○
- 51 Targeting Breast Cancer: An Overlook on Current Strategies. **2023**, 24, 3643 ○
- 50 Application of Immunohistochemistry in Clinical Practices as a Standardized Assay for Breast Cancer. **2023**, 56, 1-8 ○
- 49 Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. ○

- 48 Lessons from other fields of medicine, Part 1: Breast cancer. **2023**, 101-118 ○
- 47 How cells sense and integrate information from different sources. ○
- 46 Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. **2023**, 355, 515-527 ○
- 45 Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2 -positive advanced or metastatic breast cancer patients. ○
- 44 Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression. **2023**, 23, ○
- 43 Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. **2023**, 15, 1385 ○
- 42 Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. **2023**, 15, 1413 ○
- 41 Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. **2023**, 115, 102527 ○
- 40 Suppression of Platelet-Derived Growth Factor Receptor-Alpha Overcomes Resistance to Trastuzumab through STAT3-Dependent IL-6 Reduction in HER2-Positive Breast Cancer Cells. **2023**, 11, 675 ○
- 39 An electrochemical biosensor to identify the phenotype of aggressive breast cancer cells. **2023**, 59, 3890-3893 ○
- 38 HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers. ○
- 37 Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes. **2023**, 30, 478-488 ○
- 36 Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine. 10, ○
- 35 Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer. **2023**, 335-353 ○
- 34 Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. **2023**, 15, 1508 ○
- 33 Self-Assembled Nanodelivery System with Rapamycin and Curcumin for Combined Photo-Chemotherapy of Breast Cancer. **2023**, 15, 849 ○
- 32 AntibodyDrug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. **2023**, 46, 131-148 1
- 31 Chemotherapy-Induced Cardiotoxicity in Cancer Treatment: Mechanisms and Its Prevention. **2023**, 1-31 ○

- 30 Blocking soluble TNF α sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. **2023**, 11, e005325 1
- 29 Network biology of lapatinib resistance in different types of HER2-positive breast cancers informs the prioritization of the combination anticancer treatments as anti-resistance interventions. 12, 256 0
- 28 Evaluation of the histological and immunohistochemical subtype of breast cancer patients from a referral hospital in the inland of the state of S \tilde{a} Paulo. 32, 0
- 27 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32 0
- 26 Ultrasound features for prediction of long-term outcomes of women with primary breast cancer <20 mm. 13, 0
- 25 Synthesis and biological evaluation of theranostic Trastuzumab α N38 conjugate for Near-IR fluorescence imaging and targeted therapy of HER2+ breast cancer. **2023**, 252, 115298 0
- 24 Special Studies. **2013**, 279-304 0
- 23 Cardiotoxicity of HER-2-targeted drugs when combined with other drugs: A systematic review and single-rate meta-analysis. 0
- 22 Basic Research. **2023**, 15-19 0
- 21 ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report. **2023**, 0
- 20 Emerging Targeted Therapies for HER2-Positive Breast Cancer. **2023**, 15, 1987 0
- 19 Comprehensive analysis of the expression and prognosis for RAI2: A promising biomarker in breast cancer. 13, 0
- 18 Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer. 0
- 17 Biochemistry of Human Bladder Tumor Invasion. **1991**, 25, 145-151 0
- 16 Mecanismos de resistencia al trastuzumab. **2023**, 17, 0
- 15 HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. 0
- 14 Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. **2023**, 15, 2278 0
- 13 Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach. 1-27 0

- 12 Electrochemical Cellulase-Linked ELASA for Rapid Liquid Biopsy Testing of Serum HER-2/neu. ○
- 11 Detailed curriculum vitae of HER2-targeted therapy. **2023**, 245, 108417 ○
- 10 High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database. 1-12 ○
- 9 Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. **2023**, ○
- 8 Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2. ○
- 7 Discordance of estrogen and progesterone receptors after neoadjuvant chemotherapy in locally advanced breast cancer. **2023**, 19, 0 ○
- 6 Research Progress of Targeted Combined Immunization in HER2 Positive Advanced Gastric Cancer: From Bench to Bedside. **2023**, 13, 5864-5871 ○
- 5 Advancing outcomes of metastatic HER2-positive breast cancer. **2023**, ○
- 4 ErbB2-upregulated HK1 and HK2 promote breast cancer cell proliferation, migration and invasion. **2023**, 40, ○
- 3 Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma. **2023**, ○
- 2 Pre-Operative MRI in HER-2 Receptor Positive and Her-2 Receptor Negative Breast Cancer: A Comparison. **2023**, 12, 51-61 ○
- 1 Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations. ○